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A B S T R A C T
Background
Critically ill people may lose fluid because of serious conditions, infections (e.g. sepsis), trauma, or burns, and need additional fluids
urgently to prevent dehydration or kidney failure. Colloid or crystalloid solutions may be used for this purpose. Crystalloids have small
molecules, are cheap, easy to use, and provide immediate fluid resuscitation, but may increase oedema. Colloids have larger molecules,
cost more, and may provide swifter volume expansion in the intravascular space, but may induce allergic reactions, blood clotting
disorders, and kidney failure. This is an update of a Cochrane Review last published in 2013.
Objectives
To assess the effect of using colloids versus crystalloids in critically ill people requiring fluid volume replacement on mortality, need for
blood transfusion or renal replacement therapy (RRT), and adverse events (specifically: allergic reactions, itching, rashes).
Search methods
We searched CENTRAL, MEDLINE, Embase and two other databases on 23 February 2018. We also searched clinical trials registers.
Selection criteria
We included randomised controlled trials (RCTs) and quasi-RCTs of critically ill people who required fluid volume replacement in
hospital or emergency out-of-hospital settings. Participants had trauma, burns, or medical conditions such as sepsis. We excluded
neonates, elective surgery and caesarean section. We compared a colloid (suspended in any crystalloid solution) versus a crystalloid
(isotonic or hypertonic).
Data collection and analysis
Independently, two review authors assessed studies for inclusion, extracted data, assessed risk of bias, and synthesised findings. We
assessed the certainty of evidence with GRADE.
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Main results
We included 69 studies (65 RCTs, 4 quasi-RCTs) with 30,020 participants. Twenty-eight studied starch solutions, 20 dextrans, seven
gelatins, and 22 albumin or fresh frozen plasma (FFP); each type of colloid was compared to crystalloids.
Participants had a range of conditions typical of critical illness. Ten studies were in out-of-hospital settings. We noted risk of selection
bias in some studies, and, asmost studies were not prospectively registered, risk of selective outcome reporting. Fourteen studies included
participants in the crystalloid group who received or may have received colloids, which might have influenced results.
We compared four types of colloid (i.e. starches; dextrans; gelatins; and albumin or FFP) versus crystalloids.
Starches versus crystalloids
We found moderate-certainty evidence that there is probably little or no difference between using starches or crystalloids in mortality
at: end of follow-up (risk ratio (RR) 0.97, 95% confidence interval (CI) 0.86 to 1.09; 11,177 participants; 24 studies); within 90
days (RR 1.01, 95% CI 0.90 to 1.14; 10,415 participants; 15 studies); or within 30 days (RR 0.99, 95% CI 0.90 to 1.09; 10,135
participants; 11 studies).
We found moderate-certainty evidence that starches probably slightly increase the need for blood transfusion (RR 1.19, 95% CI 1.02
to 1.39; 1917 participants; 8 studies), and RRT (RR 1.30, 95% CI 1.14 to 1.48; 8527 participants; 9 studies). Very low-certainty
evidence means we are uncertain whether either fluid affected adverse events: we found little or no difference in allergic reactions (RR
2.59, 95% CI 0.27 to 24.91; 7757 participants; 3 studies), fewer incidences of itching with crystalloids (RR 1.38, 95% CI 1.05 to
1.82; 6946 participants; 2 studies), and fewer incidences of rashes with crystalloids (RR 1.61, 95% CI 0.90 to 2.89; 7007 participants;
2 studies).
Dextrans versus crystalloids
We found moderate-certainty evidence that there is probably little or no difference between using dextrans or crystalloids in mortality
at: end of follow-up (RR 0.99, 95% CI 0.88 to 1.11; 4736 participants; 19 studies); or within 90 days or 30 days (RR 0.99, 95% CI
0.87 to 1.12; 3353 participants; 10 studies). We are uncertain whether dextrans or crystalloids reduce the need for blood transfusion, as
we found little or no difference in blood transfusions (RR 0.92, 95% CI 0.77 to 1.10; 1272 participants, 3 studies; very low-certainty
evidence). We found little or no difference in allergic reactions (RR 6.00, 95% CI 0.25 to 144.93; 739 participants; 4 studies; very
low-certainty evidence). No studies measured RRT.
Gelatins versus crystalloids
We found low-certainty evidence that there may be little or no difference between gelatins or crystalloids in mortality: at end of follow-
up (RR 0.89, 95% CI 0.74 to 1.08; 1698 participants; 6 studies); within 90 days (RR 0.89, 95% CI 0.73 to 1.09; 1388 participants;
1 study); or within 30 days (RR 0.92, 95% CI 0.74 to 1.16; 1388 participants; 1 study). Evidence for blood transfusion was very low
certainty (3 studies), with a low event rate or data not reported by intervention. Data for RRT were not reported separately for gelatins
(1 study). We found little or no difference between groups in allergic reactions (very low-certainty evidence).
Albumin or FFP versus crystalloids
We found moderate-certainty evidence that there is probably little or no difference between using albumin or FFP or using crystalloids
in mortality at: end of follow-up (RR 0.98, 95% CI 0.92 to 1.06; 13,047 participants; 20 studies); within 90 days (RR 0.98, 95% CI
0.92 to 1.04; 12,492 participants; 10 studies); or within 30 days (RR 0.99, 95% CI 0.93 to 1.06; 12,506 participants; 10 studies). We
are uncertain whether either fluid type reduces need for blood transfusion (RR 1.31, 95% CI 0.95 to 1.80; 290 participants; 3 studies;
very low-certainty evidence). Using albumin or FFP versus crystalloids may make little or no difference to the need for RRT (RR 1.11,
95% CI 0.96 to 1.27; 3028 participants; 2 studies; very low-certainty evidence), or in allergic reactions (RR 0.75, 95% CI 0.17 to
3.33; 2097 participants, 1 study; very low-certainty evidence).
Authors’ conclusions
Using starches, dextrans, albumin or FFP (moderate-certainty evidence), or gelatins (low-certainty evidence), versus crystalloids probably
makes little or no difference tomortality. Starches probably slightly increase the need for blood transfusion and RRT (moderate-certainty
evidence), and albumin or FFP may make little or no difference to the need for renal replacement therapy (low-certainty evidence).
Evidence for blood transfusions for dextrans, and albumin or FFP, is uncertain. Similarly, evidence for adverse events is uncertain.
Certainty of evidence may improve with inclusion of three ongoing studies and seven studies awaiting classification, in future updates.
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P L A I N L A N G U A G E S U M M A R Y
Colloids or crystalloids for fluid replacement in critically people
Background
Critically ill people may lose large amounts of blood (because of trauma or burns), or have serious conditions or infections (e.g. sepsis);
they require additional fluids urgently to prevent dehydration or kidney failure. Colloids and crystalloids are types of fluids that are
used for fluid replacement, often intravenously (via a tube straight into the blood).
Crystalloids are low-cost salt solutions (e.g. saline) with small molecules, which can move around easily when injected into the body.
Colloids can be man-made (e.g. starches, dextrans, or gelatins), or naturally occurring (e.g. albumin or fresh frozen plasma (FFP)),
and have bigger molecules, so stay in the blood for longer before passing to other parts of the body. Colloids are more expensive than
crystalloids. We are uncertain whether they are better than crystalloids at reducing death, need for blood transfusion or need for renal
replacement therapy (filtering the blood, with or without dialysis machines, if kidneys fail) when given to critically ill people who need
fluid replacement.
Study characteristics
The evidence is current to February 2018. We searched the medical literature and identified 69 relevant studies with 30,020 critically
ill participants who were given fluid replacement in hospital or in an emergency out-of-hospital setting. Studies compared colloids
(starches; dextrans; gelatins; or albumin or FFP) with crystalloids.
Key results
We found moderate-certainty evidence that using colloids (starches; dextrans; or albumin or FFP) compared to crystalloids for fluid
replacement probably makes little or no difference to the number of critically ill people who die within 30 or 90 days, or by the end of
study follow-up. We also found low-certainty evidence that using gelatins or crystalloids may make little or no difference to the number
of deaths within each of these time points.
We found moderate-certainty evidence that using starches probably slightly increases the need for blood transfusion. However, we are
uncertain whether using other types of colloids, compared to crystalloids, makes a difference to whether people need a blood transfusion
because the certainty of the evidence is very low.
We foundmoderate-certainty evidence that using starches for fluid replacement probably slightly increases the need for renal replacement
therapy. Using albumin or FFP compared to crystalloids may make little or no difference to the need for renal replacement therapy.
One study comparing gelatins did not report results for renal replacement therapy according to the type of fluid given, and no studies
comparing dextrans assessed renal replacement therapy.
Few studies reported adverse events (specifically, allergic reactions, itching, or rashes), so we are uncertain whether either fluid type
causes fewer adverse events (very low-certainty evidence). We found little or no difference between starches or crystalloids in allergic
reactions, but fewer participants given crystalloids reported itching or rashes. We found little or no difference in allergic reactions for
the use of dextrans (four studies), gelatins (one study), and albumin or FFP (one study).
Certainty of the evidence
Some study authors did not report study methods clearly and many did not register their studies before they started, so we could not
be certain whether the study outcomes were decided before or after they saw the results. Also, we found that some people who were
given crystalloids may also have had colloids, which might have affected the results. For some outcomes, we had very few studies, which
reduced our confidence in the evidence.
Conclusions
Using colloids (starches; dextrans; or albumin or FFP) compared to crystalloids for fluid replacement probably makes little or no
difference to the number of critically ill people who die. It may make little or no difference to the number of people who die if gelatins
or crystalloids are used for fluid replacement.
Starches probably increase the need for blood transfusion and renal replacement therapy slightly. Using albumin or FFP may make little
or no difference to the need for renal replacement therapy. We are uncertain whether using dextrans, albumin or FFP, or crystalloids
affects the need for blood transfusion. Similarly, we are uncertain if colloids or crystalloids increase the number of adverse events.
Results from ongoing studies may increase our confidence in the evidence in future.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Starches compared to crystalloid for fluid resuscitation in critically ill patients
Participants: crit ically ill people requiring f luid resuscitat ion
Setting: in hospital, in Algeria, Argent ina, Belgium, Brazil, Canada, China, France, Germany, India, the Netherlands, Phillipines, South Af rica, Switzerland, Tunisia, the UK, USA
and Vietnam
Intervention: starches to include hydroxyethyl starch, hetastarch, and pentastarch
Comparison: crystalloids to include normal saline, hypertonic saline, Ringer’s lactate and Ringer’s acetate
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1 study included dif fer-
ent types of colloids
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min). We did not in-
clude this in analysis
because study authors
did not report data for
only starches; we noted
lit t le or no dif ference
between groups in need
for renal replacement
therapy in this study
82 per 1000 106 per 1000
(93 to 121)
Adverse events Allergic react ion ⊕©©©
Very lowc
Study populat ion RR 2.59 (0.27 to 24.91) 7757 (3 studies)
0 per 1000 0 per 1000
(0 to 0)
Itching
Study populat ion RR 1.38 (1.05 to 1.82) 6946 (2 studies)




































































































Study populat ion RR 1.61 (0.90 to 2.89) 7007 (2 studies)
5 per 1000 9 per 1000
(5 to 15)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aWe downgraded by one level for study lim itat ions; some included studies had unclear risk of select ion bias, one small study
had a high risk of select ion bias, and we were of ten unable to assess risk of select ive report ing bias because many included
studies did not have prospect ive clinical trials registrat ion.
bWe downgraded by one level for study lim itat ions; some included studies had unclear risk of select ion bias, and we were
of ten unable to assess risk of select ive report ing bias because many included studies did not have prospect ive clinical trials
registrat ion.
cWe downgraded by one level for study lim itat ions; some included studies had unclear risk of select ion bias, and we were
unable to assess risk of select ive report ing bias in some studies because they did not have prospect ive clinical trials


































































































B A C K G R O U N D
Description of the condition
Critically ill people may experience excessive fluid loss, and hypo-
volaemia, because of haemorrhage from serious injury or burns,
or because of critical illnesses, which lead to dehydration, vomit-
ing, or diarrhoea. Fluid loss may lead to mortality and morbidity,
for example, haemorrhage accounts for almost half of deaths in
the first 24 hours after traumatic injury (Geeraedts 2009; Kauvar
2006), and, worldwide, traumatic injury is a leading cause of death
(Peden 2002). Changes in body fluid balance may also lead to
acute kidney injury or failure.
Description of the intervention
Fluid resuscitation is one of the most important strategies for early
management of critically ill people (Rhodes 2016; Rossaint 2016).
Fluids used for this purpose are crystalloids or colloids.
Crystalloids, such as saline and Ringer’s lactate, are solutions of
salt, water and minerals, and are commonly used in the clinical
setting. They have small molecules, and, when used intravenously,
they are effective as volume expanders. They may have an isotonic
or hypertonic composition, which could affect the distribution
of fluid in the body; for example, because hypertonic crystalloids
lower plasma osmolality they cause water movement from the in-
travascular to the extravascular space, and a lower volume may be
required for fluid resuscitation (Coppola 2014). They are cheap
and easy to use, with few side effects. However, because they move
more easily into the extravascular space, their use may increase
oedema (Coppola 2014). The composition of the crystalloid may
not affect clinical outcomes; recent reviews have examined the pos-
sible effect of hypertonic solutions (Shrum 2016), and compared
buffered with non-buffered fluids (Bampoe 2017), but have not
found important clinical differences.
Colloids, which are suspended in crystalloid solutions, are simi-
larly given for the purpose of volume expansion. Different types
of colloids may be grouped as synthetic or semi-synthetic, for ex-
ample: starches, dextrans, gelatins; or naturally occurring, such as
human albumin or fresh frozen plasma (FFP). These colloid so-
lutions have different pharmacokinetic properties that may affect
plasma expansion in different ways (Orbegozo 2015). All colloids
have a larger molecular weight than crystalloids and do not cross
the endothelium into the interstitial fluid easily. This means that
they stay in the intervascular space for longer than crystalloids,
provide the benefit of rapid plasma expansion, and can correct col-
loidal osmotic pressure (McClelland 1998). Colloids are a more
expensive fluid replacement option, and they may have adverse
effects such as allergic reactions, blood clotting disorders, and kid-
ney failure (Bailey 2010).
Why it is important to do this review
This is an update of a Cochrane Review that was first published in
1997 and has been updated several times since. The most recent
published version of this Cochrane Review looked at the effect
of colloids and crystalloids on mortality at the end of study fol-
low-up (Perel 2013). Meta-analysis demonstrated no evidence of
a difference in mortality when participants were given dextrans,
gelatins, albumin or FFP, versus crystalloids. However, the review
found evidence of an increase in mortality with the use of starches.
Whilst some advise against using starches as a first line of resusci-
tation (Reinhart 2012), this is not consistent with findings from
large randomised trials (Myburgh 2012; Perner 2012), nor with
some other systematic reviews (He 2015; Qureshi 2016).
It is possible that results from Perel 2013 could have been con-
founded by the inclusion of a wider variety of participants in need
of fluid resuscitation. In this review, we have sought to reduce
heterogeneity in a critically ill population as much as possible by
excluding participants who were scheduled for elective surgery;
whilst these participants may require fluid replacement during pe-
rioperative management to reduce the risk of hypovolaemia, they
are less likely to be critically ill at the point of randomisation -
even elderly people undergoing semi-urgent surgery can seldom
be seen as critically ill (Lewis 2016).
Also, our aim was to explore other effects of colloids or crystalloids
on resuscitation. In particular we aimed to consider whether col-
loids or crystalloids affect the number of people who require blood
transfusion, and the effect on renal function by assessing whether
more or fewer critically ill people are likely to need renal replace-
ment therapy after fluid resuscitation interventions, because evi-
dence suggests that use of some types of fluids may increase these
risks (Zarychanski 2013). In addition, we considered the effect of
type of fluids on adverse events (allergic reactions, itching or pru-
ritis, and rashes) that have been reported in trials (e.g. inMyburgh
2012).
O B J E C T I V E S
To assess the effect of using colloids versus crystalloids in critically
ill people requiring fluid volume replacement on mortality, need
for blood transfusion or renal replacement therapy, and adverse
events (specifically: allergic reactions, itching, rashes).
M E T H O D S
Criteria for considering studies for this review
Types of studies
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We included parallel-design randomised controlled trials (RCTs),
and quasi-randomised studies (e.g. studies in which the method of
assignment is based on alternation, date of birth or medical record
number). We excluded randomised cross-over trials. We excluded
study reports that had been retracted after publication.
Types of participants
We included participants who required fluid volume replacement
in hospital or in an emergency out-of-hospital setting. We in-
cluded participants who were described as critically ill, and partici-
pants who required fluid volume replacement as a result of trauma,
burns, or medical conditions such as sepsis.
We excluded studies of participants undergoing elective surgical
procedures. We excluded neonates, and women undergoing cae-
sarean section.
See Differences between protocol and review.
Types of interventions
We included studies that compared a colloid (suspended in any
crystalloid solution) versus a crystalloid. We excluded studies in
which a colloid was given in both groups of participants.
We included the following colloids: starches; dextrans; gelatins;
albumin or fresh frozen plasma (FFP). We included crystalloids of
different electrolyte compositions (isotonic or hypertonic).
We considered each colloid type as a separate comparison group.
Therefore, we compared:
• starches versus crystalloids;
• dextrans versus crystalloids;
• gelatins versus crystalloids;
• albumin or FFP versus crystalloids.
We excluded studies in which the colloid was given to replace a
known nutritional deficiency (for example, given for hypoalbu-
minaemia), or was given as a preloading solution before surgery.
We excluded studies in which fluids were given to people with
head injury to control intracranial pressure.
See Differences between protocol and review.
Types of outcome measures
We did not exclude studies that did not measure or report review
outcomes.
We collected outcome data for mortality from any cause at end-
of-study follow-up; we included data for this outcome for which
the time point was not reported, and for which the time point
was reported as ’before hospital discharge’, ’within the ICU’, or
within 30 days, 60 days, or 90 days. In addition, we collected
mortality data that were clearly reported within 90 days, or within
30 days. Our secondary outcomes assessed the effectiveness of the
resuscitation fluids and included need for transfusion of any blood
product, and need for renal replacement therapy. In addition, we
collected data for outcomes of adverse events, specifically: allergic
reactions, itching/pruritis, and rashes.
Primary outcomes
• All-cause mortality (at end of follow-up)
• All-cause mortality (within 90 days)
• All-cause mortality (within 30 days)
Secondary outcomes
• Transfusion of blood products
• Renal replacement therapy
• Adverse events (allergic reactions, itching, and rashes)
Search methods for identification of studies
Electronic searches
We developed subject-specific search strategies in consultation
with the Cochrane Injuries Group Information Specialist. We
identified RCTs through literature searching of the following elec-
tronic databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2018, Issue 2) (which contains the Cochrane
Injuries Trials Register) in the Cochrane Library (searched 23
February 2018) (Appendix 1);
• MEDLINE Ovid (1946 to 23 February 2018) (Appendix
2);
• Embase Ovid (1974 to 23 February 2018) (Appendix 3);
• PubMed (1948 to 23 February 2018) (Appendix 4);
• Web of Science (Core Collection, 1970 to 23 February
2018) (Appendix 5);
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov; searched 13 April
2018) (Appendix 6);
• World Health Organization ( WHO) International Clinical
Trials Registry Platform ( ICTRP) ( www.who.int/ictrp; searched
13 April 2018) (Appendix 7)
• OpenGrey ( System for Information on Grey Literature in
Europe) ( www.opengrey.eu; searched 12 April 2018) (Appendix
8).
This review was an update of a previous Cochrane Review (Perel
2013).However, because wemade changes to the inclusion criteria
and increased the outcome measures, we ran all the searches from
database inception.
Searching other resources
We conducted citation searching of identified included stud-
ies published from 2013 onwards in Web of Science (
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apps.webofknowledge.com) (12 April 2018). We scanned refer-
ence lists of relevant systematic reviews (identified during database
searches) to search for additional trials.
Data collection and analysis
Two review authors (Sharon Lewis (SL) and either: Michael
Pritchard (MP), Andrew Butler (AB), or David Evans (DE)) inde-
pendently completed all data collection and analyses before com-
paring results and reaching consensus.We consulted a third review
author (Andrew Smith (AS)) to resolve conflicts if necessary.
Selection of studies
Weused Endnote referencemanagement software to collate the re-
sults of the searches and to remove duplicates. We used Covidence
software to screen titles and abstracts and identify potentially rel-
evant studies. We sourced the full texts of all potentially relevant
studies and assessed whether the studies met the review inclusion
criteria (see Criteria for considering studies for this review). We
reviewed abstracts at this stage and included these in the review
only if they provided sufficient information to assess eligibility.
We reassessed eligibility of studies included in the last versionof the
review (Perel 2013), because of changes made to review inclusion
criteria.
We recorded the number of papers retrieved at each stage and
reported this in aPRISMAflowchart (Liberati 2009; Figure 1).We
reported in the review brief details of closely related but excluded
papers.
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Figure 1. Study flow diagram
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Data extraction and management
We used Covidence software to extract data from individual stud-
ies. A basic template for data extraction forms is available at
www.covidence.org. We adapted this template to include the fol-
lowing information.
• Methods - type of study design; setting; country; dates of
study; funding sources
• Participants - number of participants randomised to each
group, number of lost participants, and number of analysed
participants, participant condition or reason for fluid
resuscitation. Baseline characteristics to include: age, gender,
weight or body mass index, blood pressure, prognostic or illness
severity scores (American Society of Anaesthesiologists (ASA),
Acute Physiology and Chronic Health Evaluation (APACHE) I
or II, Simplified Acute Physiology Score (SAPS), Sequential
Organ Failure Assessment (SOFA), Glasgow Coma Scale (GCS))
• Interventions - details of colloid and crystalloid
(concentration of solution, volume, and rate of administration),
additional relevant patient management
• Outcomes - all outcomes reported by study authors,
relevant outcomes (including time of measurement for mortality)
• Outcome data - results of outcome data
Because of changes in reporting expectations in Cochrane Reviews
- the Methodological Expectations of Cochrane Intervention Re-
views (MECIR) (Higgins 2016) - since the last version of the re-
view (Perel 2013), we also used Covidence to re-conduct data ex-
traction on studies included in the last version of the review.
We considered the applicability of information from individual
studies and the generalisability of data to our intended study pop-
ulation (i.e. the potential for indirectness in the review). If we
found associated publications from the same study, we created a
composite data set based on all eligible publications.
Assessment of risk of bias in included studies
Two review authors (SL and MP, AB, or DE) independently as-
sessed study quality, study limitations, and the extent of potential
bias using the Cochrane ’Risk of bias’ tool (Higgins 2017). We
completed ’Risk of bias’ assessment only for studies that reported
the review outcomes.
We assessed the following domains.
• Sequence generation (selection bias)
• Allocation concealment (selection bias)
• Blinding of participants, personnel, and outcome assessors
(performance bias and detection bias)
• Incomplete outcome data (attrition bias)
• Selective outcome reporting (reporting bias)
• Baseline characteristics
• Other bias
We made separate judgements for performance and detection bias
formortality and for blood transfusion/renal replacement therapy/
adverse events.
For each domain, we judged whether study authors had made
sufficient attempts tominimise bias in their study design.Wemade
judgements using three measures, high, low and unclear risk of
bias. We recorded this decision in ’Risk of bias’ tables and present
a ’Risk of bias’ graph and summary figure (Figure 2; Figure 3).
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies. We did not make judgements for studies that did not report outcomes
of interest in the review, which are indicated by blank spaces
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study. We did not make judgements for studies that did not report outcomes of interest in the review, which
are indicated by blank spaces
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Because of changes in reporting expectations in Cochrane Reviews
(MECIR; Higgins 2016) since the last version of the review, we
also completed a ’Risk of bias’ assessment on all studies included
in Perel 2013.
Measures of treatment effect
We collected dichotomous data for each outcome measure (the
number of participants who had died, the number of participants
who required transfusion of blood products, the number of par-
ticipants who required renal replacement therapy, and the number
of participants who had adverse events).
Unit of analysis issues
We reported data separately according to type of colloid (starches;
dextrans; gelatins; albumin or FFP).
For multi-arm studies that included more than one of the same
type of study fluid (e.g. two groups of starches combined with
an isotonic or a hypertonic crystalloid), we combined data from
study groups in the same analysis only when it was appropriate
and when it did not include double-counting of participants.
In subgroup analysis, in which studies were grouped by different
types of crystalloid solution, it was not always appropriate to com-
bine data frommulti-arm study groups. If we had included multi-
arm studies in subgroup analysis, we planned to use the halving
method to avoid unit of analysis issues (Deeks 2017).
Dealing with missing data
We assessed whether all measured outcomes had been reported
by study authors by comparing, when possible, published reports
with protocols or clinical trials register documents that had been
prospectively published.
We assessed whether all randomised participants had been in-
cluded in outcome data. In the absence of an explanation for loss
of data, we used the ’Risk of bias’ tool to judge whether a study
was at high risk of attrition bias.
Assessment of heterogeneity
We assessed whether evidence of inconsistency was apparent in
our results by considering heterogeneity. We assessed clinical and
methodological heterogeneity by comparing similarities in our in-
cluded studies between study designs, participants, and interven-
tions, using data collected during data extraction (Data extraction
and management). We assessed statistical heterogeneity by calcu-
lating the Chi² test and I² statistic (Higgins 2003), and judged
any heterogeneity using values of I² greater than 60% and Chi² P
value of 0.05 or less to indicate moderate to substantial statistical
heterogeneity (Deeks 2017).
As well as looking at statistical results, we considered point esti-
mates and overlap of confidence intervals (CIs). If CIs overlap,
then results are more consistent. Combined studies may show a
large consistent effect but with significant heterogeneity. There-
fore, we planned to interpret heterogeneity with caution (Guyatt
2011a).
Assessment of reporting biases
We attempted to source published protocols for each of our in-
cluded studies by using clinical trials registers. We compared pro-
tocols or clinical trials register documents that had been prospec-
tively published with study results to assess the risk of selective
reporting. We generated a funnel plot to assess risk of publication
bias in the review, for outcomes in which we identified more than
10 studies (Sterne 2017). An asymmetrical funnel plot may sug-
gest publication of only positive results (Egger 1997).We included
funnel plot figures for the primary outcome: all-cause mortality
(at the end of follow-up) (Figure 4; Figure 5; Figure 6).
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Figure 4. Funnel plot of comparison 1. Starches vs crystalloid, outcome: 1.1 mortality at end of follow-up
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Figure 5. Funnel plot of comparison 2. Dextrans vs crystalloid, outcome: 2.1 mortality at end of follow-up
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Figure 6. Funnel plot of comparison 4. Albumin and FFP vs crystalloid, outcome: 4.1 mortality at end of
follow-up
Data synthesis
We completed meta-analysis of outcomes in which we had com-
parable effect measures for more than one study, and when mea-
sures of clinical and methodological heterogeneity indicated that
pooling was appropriate.
We presented results according to type of colloid (starches; dex-
trans; gelatins; albumin or FFP) as four separate comparisons (see
Types of interventions).
We used the statistical calculator in Review Manager 5 (RevMan
5) to calculate risk ratios (RR) using the Mantel-Haenszel model
(Review Manager 2014). We used a random-effects statistical
model that accounted for the variation amongst participant groups
in the review. We calculated CIs at 95% and used a P value of 0.05
or less to judge whether a result was statistically significant. We
considered imprecision in the results of analyses by assessing the
CI around an effect measure; a wide CI would suggest a higher
level of imprecision in our results. A small number of identified
studies may also reduce precision (Guyatt 2011b).
Subgroup analysis and investigation of heterogeneity
We explored potential differences in the tonicity of crystalloid so-
lutions that had been used with colloids or used as the compar-
ative crystalloid. This was an a priori subgroup analysis included
in the previous version of the review (Perel 2013). We used the
calculator in RevMan 5 to perform subgroup analysis, comparing
the Chi² and P value for the test for subgroup differences; we in-
terpreted a P value of less than 0.05 as being indicative of a differ-
ence between subgroups. We conducted subgroup analysis when
data were available for more than 10 studies (Deeks 2017). We
considered subgroup analysis only for the primary outcome (all-
cause mortality (at end of follow-up)) for each of our comparisons
(starches; dextrans; gelatins; albumin or FFP). Subgroups were as
follows.
• Tonicity of crystalloid solution:
◦ colloid + isotonic crystalloid versus isotonic crystalloid;
◦ colloid + hypertonic crystalloid versus isotonic
crystalloid;
◦ colloid + isotonic crystalloid versus hypertonic
crystalloid;
◦ colloid + hypertonic crystalloid versus hypertonic
crystalloid.
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Sensitivity analysis
We explored the potential effects of decisions made as part of the
review process as follows.
• We excluded all studies that we judged to be at high or
unclear risk of selection bias.
• We excluded studies in which we noted that some
participants in the crystalloid group were given, or may have
been given, additional colloids.
• We conducted meta-analysis using the alternative meta-
analytical effects model (fixed-effect).
• We used alternative data for individual studies in which we
noted discrepancies in reported data.
We conducted sensitivity analysis on the primary outcome: all-
cause mortality (at end of follow-up).
’Summary of findings’ table and GRADE
We used the GRADE system to assess the certainty of the body of
evidence associated with the following outcomes (Guyatt 2008).
• All-cause mortality (at end of follow-up)
• All-cause mortality (within 90 days)
• All-cause mortality (within 30 days)
• Transfusion of blood products
• Renal replacement therapy
• Adverse events (allergic reactions, itching, rashes)
The GRADE approach appraises the certainty of a body of evi-
dence based on the extent to which one can be confident that an
estimate of effect or association reflects the item being assessed.
Evaluation of the certainty of a body of evidence considers within-
study risk of bias, directness of the evidence, heterogeneity of the
data, precision of effect estimates, and risk of publication bias.
We constructed four ’Summary of findings’ tables using the
GRADEpro GDT software to create ’Summary of findings’ tables
for the following comparisons in this review (GRADEpro GDT
2015).
• Starches versus crystalloids
• Dextrans versus crystalloids
• Gelatins versus crystalloids
• Albumin or FFP versus crystalloids
One review author (SL) completed the table in consultation with
a second author (MP).
R E S U L T S
Description of studies
Results of the search
We screened 7920 titles and abstracts from database searches, for-
ward and backward citation searches, and clinical trials register
searches.We assessed 248 full-text reports for eligibility. See Figure
1.
Included studies
See Characteristics of included studies.
We included 69 studies; 42 of these had been included in the
previous version of the review (Perel 2013), and 27 were included
for the first time in this update.
These 69 studies comprised a total of 114 publications, and in-
cluded 30,020 participants (Alpar 2004; Annane 2013; Baker
2009; Bechir 2013; Bentsen 2006; Brunkhorst 2008; Bulger
2008; Bulger 2010; Bulger 2011; Caironi 2014; Chavez-Negrete
1991; Cifra 2003; Cooper 2006; Du 2011; Dubin 2010; Dung
1999; Ernest 1999; Evans 1996; Finfer 2004; Goodwin 1983;
Grba-Bujevic 2012; Guidet 2012; Hall 1978; Heradstveit 2010;
James 2011; Jelenko 1979; Jie 2015; Kumar 2017; Li 2008; Lowe
1977; Lu 2012; Lucas 1978; Mahrous 2013; Maitland 2005;
Maitland 2011; Martin 2005; Masoumi 2016; Mattox 1991;
McIntyre 2008; McIntyre 2012; Metildi 1984; Modig 1986;
Morrison 2011; Myburgh 2012; Nagy 1993; Ngo 2001; O’Mara
2005;Oliveira2002; Park2015; Perner 2012; Philips 2015; Pockaj
1994; Quinlan 2004; Rackow 1983; Shah 1977; Upadhyay 2005;
Van der Heijden 2009; Vassar 1990; Vassar 1991; Vassar 1993a;
Vassar 1993b; Vlachou 2010;Wills 2005;Wu2001; Younes 1992;
Younes 1997; Younes 1998; Zhao 2013; Zhu 2011).
Four studies were quasi-randomised (Alpar 2004; Cifra 2003;
Lucas 1978; Modig 1986), and the remaining studies were RCTs.
We included three studies for which we could only source the
abstract (Mahrous 2013; Park 2015; Philips 2015); we sourced
the full text of all remaining studies.
Study population
Participants had a wide variety of diagnoses for which fluid volume
resuscitation was required, including: trauma, burns, and medical
conditions such as sepsis and hypovolaemic shock. We have listed
each study with the primary participant conditions in Table 1.
Seven studies recruited only children (Cifra 2003; Dung 1999;
Maitland 2005;Maitland 2011;Ngo 2001;Upadhyay 2005;Wills
2005), and two studies recruited children and adults (Hall 1978;
Wu 2001). We noted that some studies reported an inclusion
criteria of over 15 years of age (Bulger 2010; Bulger 2011), over
16 years of age (Baker 2009; Bechir 2013; Evans 1996; Masoumi
2016; Mattox 1991; Morrison 2011), or over 17 years of age (
Bulger 2008); using mean ages reported by study authors, most
participants in these studies were adults over 18 years of age. All
remaining studies included only adult participants.
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Study setting
Nineteen studies were multicentre studies (Annane 2013; Baker
2009; Brunkhorst 2008; Bulger 2010; Bulger 2011; Caironi 2014;
Cooper 2006; Dubin 2010; Finfer 2004; Guidet 2012; Maitland
2011; Martin 2005; Mattox 1991; McIntyre 2008; McIntyre
2012; Morrison 2011; Myburgh 2012; Perner 2012; Quinlan
2004); the remaining studies were single-centre studies.
Ten studies were based in an out-of-hospital setting before tran-
sition to an emergency or trauma department within a hos-
pital (Baker 2009; Bulger 2008; Bulger 2010; Caironi 2014;
Grba-Bujevic 2012; Mattox 1991; Morrison 2011; Vassar 1991;
Vassar 1993a; Vassar 1993b); the remaining studies were based in
a hospital.
Most single- or multicentre studies were conducted in one of
the following countries: the USA (Bulger 2008; Goodwin 1983;
Jelenko 1979; Lowe 1977; Lucas 1978; Martin 2005; Mattox
1991; Metildi 1984; Nagy 1993; O’Mara 2005; Pockaj 1994;
Quinlan 2004; Rackow 1983; Shah 1977; Vassar 1990; Vassar
1991; Vassar 1993a; Vassar 1993b); Canada (Baker 2009; Cooper
2006; Ernest 1999; McIntyre 2008; McIntyre 2012; Morrison
2011); China (Du 2011; Jie 2015; Li 2008; Lu 2012; Zhao
2013; Zhu 2011); Brazil (Oliveira 2002; Park 2015; Younes
1992; Younes 1997; Younes 1998); India (Kumar 2017; Philips
2015; Upadhyay 2005); Vietnam (Dung 1999; Ngo 2001; Wills
2005); Norway (Bentsen 2006; Heradstveit 2010); South Africa
(Evans 1996; James 2011); the UK (Alpar 2004; Vlachou 2010);
Argentina (Dubin 2010); Croatia (Grba-Bujevic 2012); Den-
mark (Hall 1978); Germany (Brunkhorst 2008); Iran (Masoumi
2016); Italy (Caironi 2014); Kenya (Maitland 2005); Mexico
(Chavez-Negrete 1991); theNetherlands (Van derHeijden 2009);
the Philippines (Cifra 2003); Saudi Arabia (Mahrous 2013); Swe-
den (Modig 1986); Switzerland (Bechir 2013); Taiwan (Wu2001).
Eight multicentre studies were conducted in more than one coun-
try (Annane 2013: France, Belgium, Canada, Algeria and Tunisia;
Perner 2012: Denmark, Finland, Iceland and Norway; Maitland
2011: Kenya, Tanzania and Uganda; Bulger 2010 and Bulger
2011: USA and Canada; Finfer 2004 and Myburgh 2012: Aus-
tralia and New Zealand; Guidet 2012: France and Germany).
Interventions and comparison
Nine studies were multi-arm studies that included more than one
colloid solution ormore than one crystalloid solution ormore than
one of each type of solution (Dung 1999; Li 2008; Ngo 2001;
Rackow 1983; Van der Heijden 2009; Vassar 1993b; Wills 2005;
Zhao 2013; Zhu 2011). One study compared colloids with crys-
talloids and the type of colloid or crystalloid was at the discretion
of the physician (Annane 2013); types of colloids in this study
were starches, gelatins, and albumin.
Colloids
Twenty-eight studies used a starch solution (hydroxyethyl starch,
hetastarch, or pentastarch) for fluid resuscitation (Annane 2013;
Bechir 2013; Bentsen 2006; Brunkhorst 2008; Cifra 2003; Du
2011;Dubin 2010;Grba-Bujevic 2012;Guidet 2012;Heradstveit
2010; James 2011; Jie 2015; Kumar 2017; Li 2008; Lu 2012;
Mahrous 2013; Masoumi 2016; McIntyre 2008; Myburgh 2012;
Nagy 1993; Perner 2012; Rackow 1983; Van der Heijden 2009;
Vlachou 2010; Wills 2005; Younes 1998; Zhao 2013; Zhu 2011).
Of these, sixteen studies did not describe what they used as a sus-
pension solution (Annane 2013; Cifra 2003; Dubin 2010; James
2011; Jie 2015; Li 2008; Lu 2012; Mahrous 2013; Nagy 1993;
Perner 2012;Rackow 1983;Van derHeijden 2009;Vlachou2010;
Younes 1998; Zhao 2013; Zhu 2011). Five studies used a starch so-
lution combined with an isotonic crystalloid solution, which was
normal saline (Brunkhorst 2008;Masoumi 2016;McIntyre 2008;
Myburgh 2012; Wills 2005), and seven studies used a starch solu-
tion combined with a hypertonic crystalloid solution, which was
hypertonic saline (Bentsen 2006; Grba-Bujevic 2012; Heradstveit
2010; Li 2008; Zhu 2011), or Ringer’s lactate (Bechir 2013; Du
2011). Two studies did not specify the type of crystalloid solution
that was combined with a starch (Guidet 2012; Kumar 2017),
and one multi-arm study also included a starch combined with
glutamine (Zhao 2013).
Twenty studies used dextrans for fluid resuscitation (Alpar 2004;
Baker 2009; Bulger 2008; Bulger 2010; Bulger 2011; Chavez-
Negrete 1991;Dung 1999;Hall 1978;Mattox 1991;Modig 1986;
Morrison 2011; Ngo 2001; Oliveira 2002; Vassar 1990; Vassar
1991; Vassar 1993a; Vassar 1993b; Wills 2005; Younes 1992;
Younes 1997). Two studies did not describe what they used as
a suspension solution in dextran 70 (Modig 1986; Ngo 2001);
Ngo 2001 gave Ringer’s lactate to all participants after an initial
infusion of dextran 70. Three studies used dextran 70 (which has
relative molecular mass of 70,000) combined with an isotonic
crystalloid solution which was normal saline (Dung 1999; Hall
1978; Wills 2005). Eleven studies used hypertonic saline with 6%
dextran 70 solution (HSD 6%) (Baker 2009; Bulger 2008; Bulger
2010; Bulger 2011; Mattox 1991; Morrison 2011; Vassar 1990;
Vassar 1993a; Vassar 1993b; Younes 1992; Younes 1997). Three
studies used hypertonic saline with dextran 70; Vassar 1993b used
it at 12%, while Alpar 2004 used it at 4.2% and Oliveira 2002
used it at 8%. One study used hypertonic saline with dextran 60
(a relative molecular mass of 60,000 (HSD 6%)) (Chavez-Negrete
1991).One study changed concentrationofHSDduring the study
period; participants were initially given HSD 4.2% with dextran
70 before a protocol change to HSD 6% with dextran 70 (Vassar
1991).
Seven studies used a succinylated gelatin solution (of an isotonic
composition) for fluid resuscitation (Annane 2013; Dung 1999;
Evans 1996; Ngo 2001 Upadhyay 2005; Van der Heijden 2009;
Wu 2001).
Twenty-two studies used albumin or FFP for fluid resuscitation.
Thirteen studies used albumin (Annane 2013; Caironi 2014;
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Ernest 1999; Finfer 2004; Lucas 1978; Maitland 2005; Maitland
2011; Martin 2005; McIntyre 2012; Park 2015; Philips 2015;
Quinlan 2004; Rackow 1983). Three studies used albumin com-
bined with an isotonic crystalloid, which was normal saline
(Cooper 2006; Pockaj 1994; Van derHeijden 2009), and five stud-
ies used albumin combined with a hypertonic crystalloid, which
was hypertonic saline (Jelenko1979), or Ringer’s lactate (Goodwin
1983; Lowe 1977; Metildi 1984; Shah 1977). One study used
FFP with Ringer’s lactate (O’Mara 2005).
Individual study protocols for the concentration, quantity, and
timing of administration of each type of study colloid varied. We
were not able to establish volume ratios of colloid solutions to
crystalloid solutions in most studies; we found that study authors
often reported that fluids were provided by the pharmacist and
manufacturers in pre-packaged bags, which we assumed contained
fluids in clinically appropriate volume ratios.
Crystalloids
Thirty-four studies used isotonic solutions as the comparative crys-
talloid fluid, which was normal saline (Annane 2013; Baker 2009;
Bentsen 2006; Bulger 2010; Bulger 2011; Dubin 2010; Dung
1999; Ernest 1999; Finfer 2004;Grba-Bujevic 2012;Guidet 2012;
James 2011; Jie 2015; Maitland 2005; Maitland 2011; Martin
2005; Masoumi 2016; McIntyre 2008; McIntyre 2012; Morrison
2011; Myburgh 2012; Ngo 2001; Oliveira 2002; Philips 2015;
Pockaj 1994; Quinlan 2004; Rackow 1983; Upadhyay 2005; Van
der Heijden 2009; Vassar 1993a; Younes 1992; Younes 1997;
Younes 1998; Zhao 2013).
Forty-one studies used a hypertonic solution, which was Ringer’s
lactate (Alpar 2004; Annane 2013; Bechir 2013; Brunkhorst 2008;
Bulger 2008; Chavez-Negrete 1991; Cifra 2003; Cooper 2006;
Du 2011; Dung 1999; Evans 1996; Goodwin 1983; Hall 1978;
Jelenko 1979; Jie 2015; Kumar 2017; Lowe 1977; Lu 2012;
Mahrous 2013; Metildi 1984; Nagy 1993; Ngo 2001; O’Mara
2005; Park 2015; Shah 1977; Vassar 1990; Vassar 1991; Vassar
1993b; Vlachou 2010;Wills 2005;Wu 2001; Zhu 2011), Ringer’s
acetate (Modig 1986; Perner 2012), or hypertonic saline (Bulger
2010; Bulger 2011; Jelenko 1979; Li 2008; Vassar 1993a; Vassar
1993b; Younes 1992).
One study used Ringer’s acetate and normal saline (Heradstveit
2010), and three studies did not specify the type of crystalloid
(Caironi 2014; Lucas 1978; Mattox 1991).
Individual study protocols for the quantity and timing of admin-
istration of each type of study crystalloid varied.
Outcomes
Only five studies did not report mortality data (Bentsen 2006;
Dung 1999; Ernest 1999; Grba-Bujevic 2012; Masoumi 2016);
these five studies did not report any of our review outcomes.
Fourteen studies reported number of participants who required
transfusion of blood products (Annane 2013; Brunkhorst 2008;
Bulger 2011; Cifra 2003; Cooper 2006;Guidet 2012; Lowe 1977;
McIntyre 2008; Nagy 1993; Ngo 2001; Perner 2012; Pockaj
1994; Vlachou 2010; Wills 2005). Thirteen studies reported
number of participants who required renal replacement therapy
(Annane 2013; Bechir 2013; Brunkhorst 2008; Caironi 2014;
Finfer 2004; Guidet 2012; James 2011; Mahrous 2013; McIntyre
2008; Myburgh 2012; Park 2015; Perner 2012; Vlachou 2010).
Nine studies reported data for adverse events (Bulger 2008;Guidet
2012; Mattox 1991; Myburgh 2012; Ngo 2001; Perner 2012;
Vassar 1990; Vassar 1991; Wills 2005); seven reported incidences
of allergic reaction (Bulger 2008; Mattox 1991; Myburgh 2012;
Ngo 2001; Perner 2012; Vassar 1990; Vassar 1991), two reported
incidences of itching (Guidet 2012; Myburgh 2012), and two
reported incidences of rashes (Myburgh 2012; Wills 2005).
Funding sources
Thirty-nine studies reported funding from departments or other
sources that we judged to be independent (Annane 2013; Baker
2009; Brunkhorst 2008; Bulger 2008; Bulger 2010; Bulger 2011;
Caironi 2014; Du 2011; Dubin 2010; Dung 1999; Evans 1996;
Finfer 2004; Goodwin 1983; Hall 1978; Heradstveit 2010;
James 2011; Jelenko 1979; Lowe 1977; Lucas 1978; Maitland
2005; Maitland 2011; Martin 2005; McIntyre 2012; Metildi
1984; Modig 1986; Morrison 2011; Myburgh 2012; Nagy 1993;
Oliveira 2002; Perner 2012; Quinlan 2004; Rackow 1983; Shah
1977; Van der Heijden 2009; Vassar 1990; Vassar 1991; Vassar
1993a; Wills 2005; Zhao 2013). Nineteen studies reported fund-
ing from pharmaceutical companies, which may have supplied
study fluids (Bechir 2013; Brunkhorst 2008; Cooper 2006; Dung
1999; James 2011; Guidet 2012; Maitland 2011; Martin 2005;
Mattox 1991; McIntyre 2008; Morrison 2011; Myburgh 2012;
Ngo 2001; Perner 2012; Van der Heijden 2009; Vassar 1991;
Vassar 1993a; Vassar 1993b; Younes 1992). We noted that one
study with pharmaceutical funding reported that funders were in-
volved in the study design, analysis and preparation of the report
(Guidet 2012).
The remaining studies did not report funding sources or declare
conflicts of interest.
Excluded studies
See Characteristics of excluded studies.
We excluded 127 studies following consideration of the full-text
reports. Ninety-three reports were of an ineligible study design
(studies that were not RCTs, or were commentaries or editorial
reports), nine studies had an ineligible participant group, and 25
studies used ineligible interventions (did not compare a colloid
versus crystalloid, or fluids given at the wrong time). See Figure 1.
We have not included references and details of all 127 studies
excluded during full-text review, only the 31 that we considered
to be key excluded studies (Higgins 2011).
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Because of changes to the criteria for considering studies since the
last version of the review (Perel 2013), we excluded 31 studies that
were previously included and have listed these in the review. Rea-
sons for excluding these studies were: in 28 studies fluid resuscita-
tion was given as part of perioperative management of people un-
dergoing elective surgery (Boutros 1979; Dawidson 1991; Dehne
2001; Eleftheriadis 1995; Evans 2003; Fries 2004;Gallagher1985;
Guo 2003; Hartmann 1993; Hondebrink 1997; Karanko 1987;
Lee 2011; Ley 1990;Mazher 1998;McNulty 1993;Moretti 2003;
Nielsen 1985; Prien 1990; Shires 1983; Sirieix 1999; Skillman
1975; Tollusfrud 1995; Tollusfrud 1998; Verheij 2006; Virgilio
1979; Wahba 1996; Zetterstorm 1981a; Zetterstorm 1981b); two
studieswere notRCTs (Bowser-Wallace 1986;Grundmann 1982);
and one study was an abstract of a study protocol where the full
study was never published (Rocha e Silva 1994). In addition, we
excluded five studies because the publications have been retracted;
we have not listed references for these retracted publications.
See Criteria for considering studies for this review and Differences
between protocol and review.
Studies awaiting classification
Seven studies are awaiting classification (Halim 2016; Bulanov
2004; Charpentier 2011; NCT00890383; NCT01337934;
NCT02064075; Protsenko 2009).
We found three studies during the searches of clinical trials reg-
isters (NCT00890383; NCT01337934; NCT02064075). These
studies were described as completed but study results were not
available; we await publication of the full reports to assess their eli-
gibility for inclusion in the review.One study compared tetrastarch
versus an unspecified crystalloid for fluid resuscitation following
trauma (NCT00890383); one study compared albumin versus
Ringer’s lactate for fluid resuscitation for sepsis and septic shock
(NCT01337934); and one study compared hydroxyethyl starch
versus Ringer’s lactate for fluid resuscitation following subarach-
noid haemorrhage (NCT02064075). Two studies were published
only as abstracts with insufficient information; one compared
gelatin versus normal saline for fluid resuscitation for sepsis and
septic shock (Halim 2016), and one compared albumin versus
normal saline for fluid resuscitation for septic shock (Charpentier
2011). Two studies were published in Russian and require trans-
lation to assess eligibility: one compared starches with normal
saline (Bulanov 2004), and no details are known about the other
study (Protsenko 2009). See Characteristics of studies awaiting
classification.
Ongoing studies
We found three ongoing studies during searches of clinical trial reg-
isters (NCT01763853; NCT02721238; NCT02782819). One
study compares 4% albumin versus an unspecified crystalloid in
people with acute respiratory distress syndrome (NCT01763853);
one study compares 20% albumin versus plasmalyte in people
with cirrhosis- and sepsis-induced hypotension (NCT02721238);
and the last study compares 5% albumin or gelatin versus Ringer’s
lactate or normal saline for treatment of shock (NCT02782819).
See Characteristics of ongoing studies.
Risk of bias in included studies
See Figure 2 and Figure 3.
We did not complete ’Risk of bias’ assessments for studies that
reported none of our review outcomes (Bentsen 2006;Dung 1999;
Ernest 1999; Grba-Bujevic 2012; Masoumi 2016).
We did not seek translation of studies that were published in Chi-
nese (Jie 2015; Li 2008; Lu 2012; Zhu 2011). We made ’Risk of
bias’ assessments from details available in the English abstracts,
and from the baseline characteristics tables.
Allocation
All studies were described as randomised. Thirty studies reported
adequate methods of randomisation and we judged these to have
a low risk of bias for random sequence generation (Annane 2013;
Baker 2009; Bechir 2013; Bulger 2008; Bulger 2010; Bulger 2011;
Caironi 2014; Cooper 2006; Du 2011; Finfer 2004; Goodwin
1983; Guidet 2012; James 2011; Kumar 2017; Maitland 2011;
Martin 2005; Mattox 1991; McIntyre 2008; Morrison 2011;
Myburgh 2012; Ngo 2001; O’Mara 2005; Oliveira 2002; Perner
2012; Upadhyay 2005; Vassar 1991; Vassar 1993a; Vassar 1993b;
Vlachou 2010; Wills 2005). Twenty-four studies reported ade-
quate methods of allocation concealment and we judged these to
have a low risk of bias (Annane 2013; Baker 2009; Bechir 2013;
Bulger 2008; Bulger 2010; Bulger 2011; Caironi 2014; Cooper
2006; Finfer 2004; Guidet 2012; James 2011; Maitland 2011;
Martin 2005;Mattox 1991;McIntyre 2008;Morrison 2011; Ngo
2001; Perner 2012;Upadhyay 2005;VanderHeijden 2009;Vassar
1991; Vassar 1993a; Vassar 1993b; Wills 2005).
Four studies were quasi-randomised studies, and we believed that
methods for random sequence generation and random allocation
concealment were at high risk of selection bias (Alpar 2004; Cifra
2003; Lucas 1978; Modig 1986). Two studies were described as
randomised but because of differences noted in the baseline char-
acteristics table (Jelenko 1979), and unexplained differences in
participant numbers (Lowe 1977), we judged them to be at high
risk of bias for random sequence generation. One study described
“use of lots” to allocate participants to groups and, without ad-
ditional details, we were uncertain whether this method was ade-
quate and so assessed risk of bias of random sequence generation
as unclear (Hall 1978).
The remaining studies reported insufficient details of random
sequence generation (Brunkhorst 2008; Chavez-Negrete 1991;
Dubin 2010; Evans 1996; Hall 1978; Heradstveit 2010; Jie 2015;
Li 2008; Lu 2012; Mahrous 2013; Maitland 2005; McIntyre
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2012; Metildi 1984; Nagy 1993; Park 2015; Philips 2015; Pockaj
1994; Quinlan 2004; Rackow 1983; Shah 1977; Van der Heijden
2009; Vassar 1990; Wu 2001; Younes 1992; Younes 1997; Younes
1998; Zhao 2013; Zhu 2011), and random allocation conceal-
ment (Brunkhorst 2008; Chavez-Negrete 1991; Du 2011; Dubin
2010; Evans 1996; Goodwin 1983; Hall 1978; Heradstveit 2010;
Jelenko 1979; Jie 2015; Kumar 2017; Li 2008; Lowe 1977; Lu
2012; Mahrous 2013; Maitland 2005; McIntyre 2012; Metildi
1984; Myburgh 2012; Nagy 1993; O’Mara 2005; Oliveira 2002;
Park 2015; Philips 2015; Pockaj 1994; Quinlan 2004; Rackow
1983; Shah 1977; Vassar 1990; Vlachou 2010; Wu 2001; Younes
1992; Younes 1997; Younes 1998; Zhao 2013; Zhu 2011), and
we judged these to have an unclear risk of selection bias.
Blinding
For the mortality outcome, we believed that lack of blinding was
unlikely to influence performance, or influence outcome assess-
ment, therefore, we judged all studies that reported mortality data
as having a low risk of performance bias and a low risk of detection
bias for mortality.
For the remaining outcomes (transfusion of blood products, re-
nal replacement therapy, and adverse events), we assessed whether
methods had been used to disguise fluid types from clinicians, and
from outcome assessors. Nine studies reported sufficient methods
of blinding and we judged these to have low risk of performance
bias (Bechir 2013; Bulger 2011; Guidet 2012; Finfer 2004; James
2011; McIntyre 2008; Ngo 2001; Perner 2012; Wills 2005). Two
studies described methods of fluid administration as open-label,
in which differences between study fluids would be apparent to
personnel; we judged these to have a high risk of performance bias
(Brunkhorst 2008; Cooper 2006). Study authors in Annane 2013
reported that clinicians were not blinded because of the immediate
need for resuscitation; we judged this study to have a high risk of
performance bias. We judged the remaining studies as having an
unclear risk of performance bias because methods of blinding were
not described (Caironi 2014; Cifra 2003; Lowe 1977; Mahrous
2013; Nagy 1993; Pockaj 1994; Vlachou 2010).
Six studies reported sufficient methods of blinding of outcome
assessors and we judged these to have a low risk of detection bias
(Bechir 2013; Bulger 2011; Guidet 2012; McIntyre 2008; Perner
2012; Wills 2005). We judged the remaining studies to have an
unclear risk of detection bias because study authors reported in-
sufficient methods of blinding of outcome assessors (Brunkhorst
2008; Caironi 2014; Cifra 2003; Cooper 2006; Finfer 2004; James
2011; Lowe 1977; Mahrous 2013; Nagy 1993; Ngo 2001; Pockaj
1994; Vlachou 2010).
Incomplete outcome data
Two studies, published only as abstracts, appeared to have some
discrepancies in mortality data and we could not be certain
whether this was because of loss of participant data; we judged
these studies to have unclear risk of attrition bias (Mahrous 2013;
Park 2015).
One study had an apparent loss of analysed participants for mor-
tality, but not for transfusion of blood products, and we could
not explain this difference in loss; we judged this study to have a
high risk of attrition bias (Pockaj 1994). One study excluded three
participants because of protocol deviations; because the study was
small this represented a high loss and we judged the study to have
an unclear risk of attrition bias (Vlachou 2010). One study noted
that approximately 10% of participants did not meet eligibility
criteria after randomisation, however these were included in an
intention-to-treat (ITT) analysis; we judged this study to have an
unclear risk of attrition bias because this was a large number of
participants in an ITT analysis (Bulger 2008).
The remaining studies had no losses, or few losses that were ex-
plained, and we judged them all to have low risk of attrition bias.
Selective reporting
We found prospective clinical trials registration reports for nine
studies (Annane 2013; Bechir 2013; Bulger 2008; Bulger 2010;
Caironi 2014; Finfer 2004; Guidet 2012; Myburgh 2012; Perner
2012). Outcomes were reported according to these trial registra-
tion documents in six studies andwe judged these to have a low risk
of selective reporting bias (Annane 2013; Bulger 2010; Caironi
2014; Finfer 2004; Myburgh 2012; Perner 2012). In one study,
we noted that outcomes were added to the trials register docu-
ments after the start of the study, and we could not be certain
whether selective reporting bias was introduced because of this
(Bulger 2008). In two studies, we noted that outcomes in the study
report were not listed as outcomes in the clinical trials registration
documents, and we judged these studies to have a high risk of
selective reporting bias (Bechir 2013; Guidet 2012).
Three studies were registered retrospectively with clinical trials
registers (Dubin 2010; James 2011; Maitland 2011); it was not
feasible to use information from these clinical trials documents to
assess risk of selective reporting bias.
We could not be certain whether Philips 2015 was prospectively
registered because the available abstract report included the clinical
trials register identification number but not the study dates; we
judged this to have an unclear risk of selective reporting bias.
All other studies did not provide clinical trials registration infor-
mation, or references for published study protocols, and we were
unable to assess risk of selective reporting bias for these studies.
Baseline characteristics
Wenoted no differences in baseline characteristics that we believed
could introduce bias in 46 studies, and we judged these studies to
have a low risk of bias (Annane 2013; Baker 2009; Bechir 2013;
Brunkhorst 2008; Bulger 2010; Bulger 2011; Chavez-Negrete
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1991; Cifra 2003; Du 2011; Dubin 2010; Evans 1996; Goodwin
1983; Guidet 2012; Hall 1978; Jie 2015; Li 2008; Lowe 1977; Lu
2012; Lucas 1978; Maitland 2011; Martin 2005; Metildi 1984;
Modig 1986; Morrison 2011; Myburgh 2012; Nagy 1993; Ngo
2001; O’Mara 2005; Perner 2012; Philips 2015; Pockaj 1994;
Rackow 1983; Shah 1977; Upadhyay 2005; Van der Heijden
2009; Vassar 1990; Vassar 1991; Vassar 1993a; Vassar 1993b;
Vlachou 2010;Wills 2005;Wu 2001; Younes 1992; Younes 1997;
Younes 1998; Zhu 2011).
We noted an imbalance in some baseline characteristics in eleven
studies (Alpar 2004; Bulger 2008; Caironi 2014; Cooper 2006;
Finfer 2004; James 2011; Kumar 2017; Maitland 2005; McIntyre
2008; Oliveira 2002; Quinlan 2004). We could not be certain
whether these imbalances could influence results and we judged
these studies to have an unclear risk of bias. We noted differences
in several baseline characteristics in one study and judged this to
have a high risk of bias (Jelenko 1979).
We could not assess comparability of baseline characteristics in
four studies because these were either not reported or not reported
by group (Mattox 1991; Mahrous 2013; McIntyre 2012; Park
2015).
Other potential sources of bias
We noted that in 14 studies some participants were given, or may
have been given, additional colloids in the crystalloid arm either
before or during the study (Annane 2013; Baker 2009; Brunkhorst
2008; Bulger 2011; Chavez-Negrete 1991; Cifra 2003; Du 2011;
Finfer 2004; Goodwin 1983; Myburgh 2012; Ngo 2001; Perner
2012; Vassar 1991; Wills 2005); we judged all these studies to
have a high risk of other bias.
We noted that one studywas published by a single author, and time
between completion of the study and publication of the report
was longer than expected (Kumar 2017). We could not be certain
whether this study was a primary publication, or a secondary pub-
lication of an existing or unknown study, and we judged it to have
a high risk of bias. We noted differences in the reported number
of deaths in Lucas 1978 according to different study reports, and
these differences were unexplained; we judged this study to have
a high risk of other bias.
We could not be certain of other risks of bias in theChinese studies
for which we did not seek translation (Jie 2015; Li 2008; Lu 2012;
Zhu 2011), nor in studies that were published only as abstracts
(Mahrous 2013; Park 2015; Philips 2015); and we assessed these
studies to have an unclear risk of other bias.
We noted no other sources of bias in the remaining studies, and
judged these all to have a low risk of other bias.
Effects of interventions
See: Summary of findings for the main comparison Starches
compared to crystalloid for fluid resuscitation in critically
ill patients; Summary of findings 2 Dextrans compared to
crystalloid for fluid resuscitation in critically ill patients; Summary
of findings 3 Gelatins compared to crystalloid for fluid
resuscitation in critically ill patients; Summary of findings 4
Albumin and fresh frozen plasma compared to crystalloid for fluid
resuscitation in critically ill patients
1. Starches versus crystalloids
All-cause mortality at end of follow-up
Twenty-five studies measured mortality (Annane 2013; Bechir
2013; Brunkhorst 2008; Cifra 2003; Du 2011; Dubin 2010;
Guidet 2012; Heradstveit 2010; James 2011; Jie 2015; Kumar
2017; Li 2008; Lu 2012; Mahrous 2013; McIntyre 2008;
Myburgh 2012; Nagy 1993; Perner 2012; Rackow 1983; Van der
Heijden 2009; Vlachou 2010; Wills 2005; Younes 1998; Zhao
2013; Zhu 2011).
We included24 in this analysis, inwhich the time of the assessment
point was: within 24 hours (Dubin 2010; Rackow 1983; Younes
1998); within the ICU or hospital stay (Du 2011; Van derHeijden
2009; Vlachou 2010); up to 30 days from hospital discharge (
Kumar 2017); within 28 or 30 days (Guidet 2012; Li 2008;
McIntyre 2008); within 60 days (Zhao 2013); within 90 days
(Annane 2013; Bechir 2013; Brunkhorst 2008; Myburgh 2012;
Perner 2012); at 12 months (Heradstveit 2010); and studies in
which the time point was unknown (Cifra 2003; James 2011; Jie
2015; Lu 2012; Nagy 1993; Wills 2005; Zhu 2011). We did not
include mortality data reported in Mahrous 2013, the data were
reported as percentages in the abstract and we could not be certain
whether the data were for all randomised participants or whether
some participant data were lost.
Three studies were multi-arm studies. We combined data for both
colloid groups in two studies (Zhao 2013; Zhu 2011); and for
both colloid groups and both crystalloid groups in Li 2008. One
study, which allowed type of colloid or crystalloid to be at the
discretion of the clinician, reported mortality outcome data for
participants who received only one type of fluid (Annane 2013);
we included data for participants who received only hydroxyethyl
starch in the colloid group, and combined data for two crystalloid
groups (isotonic saline, and Ringer’s lactate).
We found little or no difference in the number of participants who
died at the end of follow-up according to whether fluid resuscita-
tion was with a starch or with a crystalloid (RR 0.97 95% CI 0.86
to 1.09; 11,177 participants; 24 studies; I² = 34%; Analysis 1.1).
We generated a funnel plot to assess risk of publication bias and
did not interpret this to indicate high risk (Figure 4).
We used GRADE, and assessed the level of certainty of the evi-
dence for this outcome as moderate.We downgraded the evidence
by one level for study limitations because some studies had an
unclear risk of selection bias, one small study had a high risk of
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selection bias, and because, for many studies, we were unable to
assess risk of selective reporting bias due to lack of prospective
clinical trials registration. See Summary of findings for the main
comparison.
All-cause mortality within 90 days
Sixteen studies measured mortality within 90 days (Annane 2013;
Bechir 2013; Brunkhorst 2008;Dubin 2010;Guidet 2012;Kumar
2017; Li 2008; Mahrous 2013; McIntyre 2008; Myburgh 2012;
Perner 2012;Rackow 1983;Van derHeijden 2009;Vlachou2010;
Younes 1998; Zhao 2013).
We included mortality data in this analysis in which the time
point was: within 24 hours (Dubin 2010; Rackow 1983; Younes
1998); within the ICU or hospital stay (Van der Heijden 2009;
Vlachou 2010); up to 30 days from hospital discharge (Kumar
2017); within 28 or 30 days (Guidet 2012; Li 2008; McIntyre
2008); within 60 days (Zhao 2013); or within 90 days (Annane
2013; Bechir 2013; Brunkhorst 2008; Myburgh 2012; Perner
2012).We did not include themortality data reported inMahrous
2013, as the data were not clearly reported in the abstract.
Two studies were multi-arm studies. We combined data for both
colloid groups in Zhao 2013, and for both colloid groups and both
crystalloid groups in Li 2008. One study, which allowed type of
colloid or crystalloid to be at the discretion of the clinician, re-
ported mortality outcome data for participants who received only
one type of fluid (Annane 2013). We included data for partici-
pants who received only hydroxyethyl starch in the colloid group,
and combined data for two crystalloid groups (isotonic saline, and
Ringer’s lactate).
We found little or no difference in the number of participants who
died within 90 days according to whether fluid resuscitation was
with a starch or with a crystalloid (RR 1.01, 95% CI 0.90 to 1.14;
10,415 participants; 15 studies; I² = 36%; Analysis 1.2).
We generated a funnel plot to assess risk of publication bias and
did not interpret this as indicating high risk.
We used GRADE, and assessed the level of certainty of the evi-
dence for this outcome as moderate.We downgraded the evidence
by one level for study limitations because some studies had an
unclear risk of selection bias and because, for many studies, we
were unable to assess risk of selective reporting bias due to lack
of prospective clinical trials registration. See Summary of findings
for the main comparison.
All-cause mortality within 30 days
Twelve studies measured mortality within 30 days (Annane 2013;
Bechir 2013; Brunkhorst 2008; Dubin 2010; Guidet 2012; Li
2008; Mahrous 2013; McIntyre 2008; Myburgh 2012; Perner
2012; Rackow 1983; Younes 1998). We did not include mortal-
ity data reported in Mahrous 2013, as the data were not clearly
reported in the abstract.
One study was a multi-arm study (Li 2008); we combined data
for both colloid groups and both crystalloid groups in this study.
We includedmortality data in this analysis in which the time point
was: within 24 hours (Dubin 2010; Rackow 1983; Younes 1998);
and within 28 or 30 days (Annane 2013; Bechir 2013; Brunkhorst
2008; Guidet 2012; Li 2008; McIntyre 2008; Myburgh 2012;
Perner 2012).
We found little or no difference in the number of participants who
died within 30 days according to whether fluid resuscitation was
with a starch or with a crystalloid (RR 0.99, 95% CI 0.90 to 1.09;
10,135 participants; 11 studies; I² = 12%; Analysis 1.3).
We generated a funnel plot to assess risk of publication bias and
did not interpret this as indicating high risk.
We used GRADE, and assessed the level of certainty of the evi-
dence for this outcome as moderate.We downgraded the evidence
by one level for study limitations because some studies had unclear
risk of selection bias and because, for many studies, wewere unable
to assess risk of selective reporting bias due to lack of prospective
clinical trials registration. See Summary of findings for the main
comparison.
Transfusion of blood products
Nine studies reported the number of participants who required
transfusion of blood products (Annane 2013; Brunkhorst 2008;
Cifra 2003; Guidet 2012; McIntyre 2008; Nagy 1993; Perner
2012; Vlachou 2010; Wills 2005).
One study, which allowed type of colloid or crystalloid to be at
the discretion of the clinician, combined data for all types of col-
loids (hydroxyethyl starch, gelatins, or albumin), and we could
not include these data in the analysis of starches (Annane 2013).
We reported data for transfusion of blood products for this study
in Table 2; we noted little or no difference between groups in the
need for blood products according to type of fluid.
For the remaining eight studies, we found that more participants
required a transfusion of blood product when starches were given
(RR 1.19, 95% CI 1.02 to 1.39; 1917 participants; 8 studies; I²
= 14%; Analysis 1.4).
We used GRADE, and assessed the level of certainty of the evi-
dence for this outcome as moderate.We downgraded the evidence
by one level for study limitations because some studies had unclear
risk of selection bias, one small study had a high risk of selection
bias, and because, for many studies, we were unable to assess risk
of selective reporting bias due to lack of prospective clinical trials
registration. See Summary of findings for the main comparison.
Renal replacement therapy
Ten studies reported the number of participants who required
renal replacement therapy or dialysis (Annane 2013; Bechir 2013;
Brunkhorst 2008; Guidet 2012; James 2011; Mahrous 2013;
McIntyre 2008; Myburgh 2012; Perner 2012; Vlachou 2010).
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One study, which allowed type of colloid or crystalloid to be at
the discretion of the clinician, combined data for all types of col-
loids (hydroxyethyl starch, gelatins, or albumin), and we could
not include these data in analysis of starches (Annane 2013). We
reported data for renal replacement therapy for this study in Table
2; we noted little or no difference between groups in the need for
renal replacement therapy according to type of fluid.
We found that fewer participants were given renal replacement
therapy when fluid resuscitation was with a crystalloid (RR 1.30,
95% CI 1.14 to 1.48; 8527 participants; 9 studies; I² = 0%;
Analysis 1.5).
We used GRADE, and assessed the level of certainty of the evi-
dence for this outcome as moderate.We downgraded the evidence
by one level for study limitations because some studies had unclear
risk of selection bias and because, for many studies, wewere unable
to assess risk of selective reporting bias due to lack of prospective
clinical trials registration. See Summary of findings for the main
comparison.
Adverse events (allergic reaction, itching, rashes)
Six studies reported adverse event data for allergic reaction, itching,
or rashes (Bulger 2008; Guidet 2012; Myburgh 2012; Ngo 2001;
Perner 2012; Wills 2005).
Allergic reaction
We found little or no difference in allergic reaction according to
whether starches or crystalloids were used (RR 2.59, 95% CI 0.27
to 24.91; 7757 participants; 3 studies; I² = 0%; Analysis 1.6).
Itching
We found fewer incidences of itchingwhen participants were given
crystalloids (RR 1.38, 95% CI 1.05 to 1.82; 6946 participants; 2
studies; I² = 0%; Analysis 1.7).
Rashes
We found little or no difference in incidences of rashes (RR 1.61,
95% CI 0.90 to 2.89; 7007 participants; 2 studies; I² = 0%;
Analysis 1.8).
We used GRADE, and assessed the level of certainty of the ev-
idence for adverse events as very low. We downgraded the evi-
dence by one level for study limitations because some studies had
unclear risk of selection bias, and because, for many studies, we
were unable to assess risk of selective reporting bias due to lack
of prospective clinical trials registration. We downgraded the ev-
idence by two levels for imprecision because few of our included
studies reported data for these outcomes. See Summary of findings
for the main comparison.
Subgroup analysis
Tonicity of crystalloid solution
We found that many studies did not report the solution in which
the colloid was suspended. Two studies compared a starch and iso-
tonic crystalloid versus an isotonic crystalloid and reported mor-
tality outcome data (McIntyre 2008; Myburgh 2012), two stud-
ies compared a starch and isotonic crystalloid versus a hypertonic
crystalloid (Brunkhorst 2008;Wills 2005), and three studies com-
pared a starch and hypertonic crystalloid versus a hypertonic crys-
talloid (Bechir 2013; Du 2011; Heradstveit 2010). We did not
perform subgroup analysis on all-cause mortality (at end of follow-
up) for this comparison because we had insufficient studies to do
so meaningfully.
Sensitivity analysis
Studies at high or unclear risk of selection bias
We excluded 10 studies that we judged to have unclear risk of
selection bias (Brunkhorst 2008; Du 2011; Dubin 2010; Jie 2015;
Li 2008; Lu 2012; Nagy 1993; Van der Heijden 2009; Younes
1998; Zhu 2011), and one study that we judged to have high
risk of selection bias from analysis of the primary outcome (Cifra
2003). This did not alter interpretation of the effect, with little
or no difference between groups in all-cause mortality (at end of
follow-up) when these studies were excluded (RR 1.03, 95% CI
0.91 to 1.17; 10,139 participants; 13 studies; I² = 34%).
Studies in which some participants in the crystalloid group
were given, or may have been given, additional colloids
Some studies were at risk of bias because some participants in the
crystalloid group were given, or may have been given, additional
colloids. We excluded seven studies from analysis of the primary
outcome (Annane 2013; Brunkhorst 2008; Cifra 2003; Du 2011;
Myburgh 2012; Perner 2012; Wills 2005). Although excluding
these studies did not alter interpretation of the effect for analysis
of all-cause mortality (at end of follow-up), we noted that without
these studies statistical heterogeneity was reduced from 34% to
0% (RR 0.84, 95%CI 0.70 to 1.01; 1115 participants; 17 studies;
I² = 0%).
Alternative meta-analytical effects model (fixed-effect)
Using the alternative meta-analytical effects model (fixed-effect),
we found no difference in interpretation of the effect, with little
or no difference between groups in all-cause mortality (at end of
follow-up) (RR 1.01, 95% CI 0.95 to 1.08; 11,177 participants;
24 studies; I² = 34%).
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Studies with discrepancies in data
In one study we noted discrepancies in mortality data within the
study report (Dubin 2010). We removed this study from analysis
and found that itmade no difference to interpretation of the effect,
with little or no difference between groups in all-cause mortality
(at end of follow-up) (RR 0.98, 95% CI 0.87 to 1.10; 11,152
participants; 23 studies; I² = 33%).
2. Dextrans versus crystalloids
All-cause mortality at end of follow-up
Nineteen studies measured outcome data for mortality (Alpar
2004; Baker 2009; Bulger 2008; Bulger 2010; Bulger 2011;
Chavez-Negrete 1991; Hall 1978; Mattox 1991; Modig 1986;
Morrison 2011; Ngo 2001; Oliveira 2002; Vassar 1990; Vassar
1991; Vassar 1993a; Vassar 1993b; Wills 2005; Younes 1992;
Younes 1997).
Six studies were multi-arm studies. We combined data in analysis
for both crystalloid groups in Bulger 2010, Bulger 2011, Ngo
2001, Vassar 1993b, and Younes 1992, and we combined data
in analysis for both colloid groups and both crystalloid groups in
Vassar 1993a.
We included mortality data in this analysis in which the time
point was: within 24 hours (Chavez-Negrete 1991); within 48
hours (Hall 1978); until hospital discharge (Vassar 1991; Vassar
1993a; Vassar 1993b; Younes 1992); or was unknown (Alpar
2004; Modig 1986; Ngo 2001; Oliveira 2002; Wills 2005). The
remaining studies reported data at 28 or 30 days (Baker 2009;
Bulger 2008; Bulger 2010; Bulger 2011; Mattox 1991; Morrison
2011; Vassar 1990; Younes 1997).
We found little or no difference in the number of participants who
died at end of follow-up according to whether fluid resuscitation
was with dextran or with a crystalloid (RR 0.99, 95% CI 0.88 to
1.11; 4736 participants; 19 studies; I² = 7%; Analysis 2.1).
We generated a funnel plot to assess risk of publication bias. One
study was an outlier in this plot, which we could not explain, but,
because the only outlier was a small study from 1991 (Chavez-
Negrete 1991), we did not believe this was evidence of a high risk
of publication bias. See Figure 5.
We used GRADE, and assessed the level of certainty of the evi-
dence for this outcome as moderate.We downgraded the evidence
by one level for study limitations because some studies had unclear
risk of selection bias and because, for many studies, wewere unable
to assess risk of selective reporting bias due to lack of prospective
clinical trials registration. See Summary of findings 2.
All-cause mortality within 90 days and within 30 days
Ten studies measured mortality within 30 days (Baker 2009;
Bulger 2008; Bulger 2010; Bulger 2011; Chavez-Negrete 1991;
Hall 1978; Mattox 1991; Morrison 2011; Vassar 1990; Younes
1997). No studies reported mortality within 90 days, and we in-
cluded the same data for both outcome time points for this com-
parison.
Two studies were multi-arm studies (Bulger 2010; Bulger 2011).
We combined the data in analysis for both crystalloid groups.
We includedmortality data in this analysis in which the time point
was: within 24 hours (Chavez-Negrete 1991); within 48 hours
(Hall 1978); and within 28 or 30 days (Baker 2009; Bulger 2008;
Bulger 2010; Bulger 2011; Mattox 1991; Morrison 2011; Vassar
1990; Younes 1997).
We found little or no difference in the number of participants who
died within 90 days and within 30 days according to whether fluid
resuscitation was with dextran or with a crystalloid (RR 0.99, 95%
CI 0.87 to 1.12; 3353 participants; 10 studies; I² = 0%; Analysis
2.2).
We generated a funnel plot to assess risk of publication bias. One
study was an outlier in this plot, which we could not explain, but,
because the only outlier was a small study from 1991 (Chavez-
Negrete 1991), we did not believe this was evidence of a high risk
of publication bias.
We used GRADE, and assessed the level of certainty of the evi-
dence for this outcome as moderate.We downgraded the evidence
by one level for study limitations because some studies had unclear
risk of selection bias and because, for many studies, wewere unable
to assess risk of selective reporting bias due to lack of prospective
clinical trials registration. See Summary of findings 2.
Transfusion of blood products
Three studies reported the number of participants requiring a
blood transfusion (Bulger 2011; Ngo 2001; Wills 2005). Bulger
2011, a multi-arm study, reported blood transfusion of 9 units or
fewer of blood, and 10 units or fewer of blood. In analysis, we
combined data in the two crystalloids groups in Bulger 2011 for
9 units or fewer of blood.
We found little or no difference in participants requiring a trans-
fusion of blood products according to whether participants were
given dextran or a crystalloid (RR 0.92, 95% CI 0.77 to 1.10;
1272 participants; 3 studies; I² = 0%; Analysis 2.3).
We used GRADE, and assessed the level of certainty of the evi-
dence for this outcome as very low. We downgraded the evidence
by two levels for study limitations because we noted that in two
studies some participants were given additional colloids in the
crystalloid group, and in another study we could not be certain
whether some participants in the crystalloids groups had also re-
ceived up to 2000mL colloid resuscitation prior to randomisation.
In addition, we were unable to assess risk of selective reporting bias
because, for many studies there was a lack of prospective clinical
trials registration. See Summary of findings 2.
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Renal replacement therapy
No studies reported data for this outcome.
Adverse events (allergic reaction, itching, rashes)
Four studies reported allergic reactions (Mattox 1991; Ngo 2001;
Vassar 1990; Vassar 1991), with event data in only one study (Ngo
2001).
We found little or no difference between study fluids in cases of
allergic reaction (RR 6.00, 95% CI 0.25 to 144.93; 739 partici-
pants; 4 studies; Analysis 2.4).
We used the GRADE approach to downgrade the certainty of
the evidence for adverse events to very low. We downgraded by
one level for study limitations because one study had an unclear
risk of selection bias and we were unable to assess risk of selective
outcome reporting bias in all studies.We downgraded by two levels
for imprecision because evidence was from few studies with few
events.
Subgroup analysis
Tonicity of crystalloid solution
Eight studies used a dextran solutionwith hypertonic saline (HSD)
versus an isotonic crystalloid (which was normal saline) and re-
ported mortality outcome data (Baker 2009; Bulger 2010; Bulger
2011;Morrison 2011; Oliveira 2002; Vassar 1993a; Younes 1992;
Younes 1997); two studies used a dextran solution with an isotonic
crystalloid versus a hypertonic crystalloid (Ringer’s lactate) and
reported mortality outcome data (Hall 1978; Wills 2005); and
five studies used HSD versus Ringer’s lactate and reported mor-
tality outcome data (Alpar 2004; Bulger 2008; Chavez-Negrete
1991; Vassar 1990; Vassar 1991). One multi-arm study used two
concentrations of HSD that were appropriate to combine in sub-
group analysis versus two types of hypertonic crystalloid (hyper-
tonic saline and Ringer’s lactate), which were also appropriate to
combine in subgroup analysis (Vassar 1993b). We did not include
three studies in subgroup analysis because the type of crystalloid in
which the dextran was suspended was not reported (Modig 1986;
Ngo 2001), or a variety of crystalloids was used in the compari-
son group (Mattox 1991). We found no evidence of a difference
between studies in use of isotonic or hypertonic crystalloid solu-
tions for all-cause mortality (at end of follow-up) (P = 0.92). See
Analysis 5.1.
Sensitivity analysis
Studies at high or unclear risk of selection bias
We judged two studies to have high risk of selection bias (Alpar
2004; Modig 1986), and five studies to have unclear risk of selec-
tion bias (Chavez-Negrete 1991; Hall 1978; Vassar 1990; Younes
1992; Younes 1997), and excluded them from analysis of mor-
tality. This did not alter interpretation of the effect for all-cause
mortality (at the end of follow-up); there was little or no difference
between groups when these studies were excluded (RR 1.03, 95%
CI 0.91 to 1.16; 3940 participants; 12 studies; I² = 6%).
Studies in which some participants in the crystalloid group
were given, or may have been given, additional colloids
Some studies were at risk of bias because some participants in the
crystalloid group were given, or may have been given additional
colloids. We excluded six studies from analysis of mortality at end
of follow-up (Baker 2009; Bulger 2011; Chavez-Negrete 1991;
Ngo 2001; Vassar 1991; Wills 2005). This did not alter interpre-
tation of the effect on all-cause mortality (at end of follow-up);
there was little or no difference between groups when these studies
were excluded (RR 1.00, 95% CI 0.88 to 1.15; 3185 participants;
13 studies; I² = 11%).
Alternative meta-analytical effects model (fixed-effect)
Using the alternative meta-analytical effects model (fixed-effect),
did not alter interpretation of the effect on all-cause mortality (at
end of follow-up); there was little or no difference between groups
when we used the fixed-effect model (RR 0.99, 95% CI 0.89 to
1.10; 4570 participants; 18 studies; I² = 7%).
Studies with discrepancies in data
We included no studies with serious discrepancies in data.
3. Gelatins versus crystalloids
All-cause mortality at end of follow-up
Six studies reported outcome data for mortality (Annane 2013;
Evans 1996; Ngo 2001; Upadhyay 2005; Van der Heijden 2009;
Wu 2001). One study reported the time point as within the ICU
or hospital stay (Van der Heijden 2009), one study was at 90 days
(Annane 2013), and the remaining time points were unknown.
One study was a multi-arm study (Ngo 2001); we combined data
in analysis for both crystalloid groups.
One study, which allowed type of colloid or crystalloid to be at the
discretion of the clinician, reported mortality outcome data for
participants who received only one type of fluid (Annane 2013).
We included data for participants who received only gelatins in
the colloid group, and combined data for two crystalloid groups
(isotonic saline and Ringer’s lactate).
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We found little or no difference in the number of participants
who had died from any cause at the end of follow-up according to
whether fluid resuscitation was with gelatins or with a crystalloid
(RR 0.89, 95% CI 0.74 to 1.08; 1698 participants; 6 studies; I²
= 0%; Analysis 3.1).
We used GRADE, and assessed the level of certainty of the evi-
dence for this outcome as low. We downgraded the evidence by
one level for study limitations because risk of selection bias was
unclear in some studies and we were unable to assess risk of se-
lective outcome reporting bias in some studies that were not reg-
istered with clinical trials registers. We downgraded by one level
for imprecision because evidence was from few studies, and we
could not be certain of time points for data collection. Summary
of findings 3.
All-cause mortality within 90 days
One study reported mortality data at 90 days (Annane 2013).
This study allowed the type of colloid or crystalloid to be at the
discretion of the clinician and reported mortality outcome data
for participants who received only one type of fluid. We combined
data for the two crystalloid groups (normal saline and Ringer’s
lactate) and used RevMan 5 to calculate an effect estimate (Review
Manager 2014). Study data are reported in Table 2.
We found little or no difference in the number of participants who
died from any cause within 90 days according to whether fluid
resuscitation was with gelatins or with a crystalloid (RR 0.89, 95%
CI 0.73 to 1.09; 1388 participants; 1 study).
We used GRADE, and assessed the level of certainty of the evi-
dence for this outcome as low. We downgraded by two levels for
imprecision because evidence was from a single study.
All-cause mortality within 30 days
One study reportedmortality data at 28 days (Annane 2013). This
study allowed type of colloid or crystalloid to be at the discretion of
the clinician and reported mortality outcome data for participants
who received only one type of fluid.We combined data for the two
crystalloid groups (isotonic saline and Ringer’s lactate) and used
the RevMan 5 to calculate an effect estimate (Review Manager
2014). Study data are reported in Table 2.
We found little or no difference in the number of participants who
died from any cause within 30 days according to whether fluid
resuscitation was with gelatins or with a crystalloid (RR 0.92, 95%
CI 0.74 to 1.16; 1388 participants; 1 study).
We used GRADE, and assessed the level of certainty of the evi-
dence for this outcome as low. We downgraded by two levels for
imprecision because evidence was from a single study.
Transfusion of blood products
Three studies measured the number of participants who needed
a transfusion of blood products (Annane 2013; Ngo 2001; Wu
2001). However, we could not use the data in Wu 2001, because
it was not reported by group (five participants overall required
blood transfusion), and we could not report the data in Annane
2013, because it was not reported separately for participants who
received only gelatins (we noted little or no difference between
people receiving either hydroxyethyl starch, gelatins, or albumin;
Table 2).
The remaining study reported one participant in the gelatins group
who required a blood transfusion following a severe epistaxis (Ngo
2001). We used the calculator in RevMan 5 (Review Manager
2014), and found little or no difference between groups in need
for blood transfusion (RR 5.89, 95% CI 0.24 to 142.41; 167
participants; 1 study).
We used GRADE, and assessed the level of certainty of the evi-
dence for this outcome as very low. We downgraded by one level
for study limitations because we were unable to assess risk of selec-
tive outcome reporting bias due to lack of prospective clinical trials
registration, and some participants in the crystalloid groups also
received colloids. We downgraded two levels for imprecision be-
cause evidence was from a single small study with very few events.
Renal replacement therapy
One study, which allowed type of colloid or crystalloid to be at the
discretion of the clinician, reported number of participants who
required renal replacement therapy but did not report these data
according to type of colloid received (Annane 2013). We did not
include these data in our analysis of gelatins because the types of
colloid used were either hydroxyethyl starch, gelatins, or albumin.
We included data for renal replacement therapy for Annane 2013
in Table 2; we noted little or no difference between groups in the
need for renal replacement therapy according to whether a colloid
(hydroxyethyl starch, gelatins, or albumin) or a crystalloid was
used.
Adverse events (allergic reaction, itching, rashes)
One study reported that five participants in the gelatins group
had an allergic reaction (Ngo 2001). We used the calculator in
RevMan 5 (Review Manager 2014), and found little or no differ-
ence between groups in incidences of allergic reactions (RR 21.61,
95% CI 1.22 to 384.05; 167 participants; 1 study).
We used GRADE, and assessed the level of certainty of the evi-
dence for this outcome as very low. We downgraded by one level
for study limitations because we were unable to assess risk of se-
lective outcome reporting bias due to lack of prospective clinical
trials registration, and because some participants in the crystalloid
groups also received colloids. We downgraded two levels for im-
precision because evidence was from a single small study with very
few events.
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Subgroup analysis
Tonicity of crystalloid solution
We found insufficient studies to conduct meaningful subgroup
analysis. Of the six studies that reported mortality outcome data,
five studies reported using amodified gelatin solution suspended in
isotonic crystalloid solution. Two studies used Haemaccel (Evans
1996; Upadhyay 2005), two studies used Gelofusine (Van der
Heijden 2009; Wu 2001), and one study used Gelafundin (Ngo
2001). The remaining study, in which type of colloid solution
was at the discretion of the clinician, did not specify the gelatin
solution (Annane 2013).
Sensitivity analysis
Studies at high or unclear risk of selection bias
We excluded one study that we judged to have an unclear risk of
selection bias from analysis of mortality (Evans 1996). This did
not alter interpretation of the effect for all-cause mortality (at the
end of follow-up), with little or no difference between groups (RR
0.90, 95% CI 0.74 to 1.08; 1673 participants; 5 studies; I² = 0%).
Studies in which some participants in the crystalloid group
were given, or may have been given, additional colloids
Some studies were at risk of bias because some participants in the
crystalloid group were given, or may have been given additional
colloids. We excluded two studies from analysis of the primary
outcome (Annane 2013; Ngo 2001). This did not alter interpre-
tation of the effect for all-cause mortality (at the end of follow-
up), with little or no difference between groups (RR 0.94, 95%
CI 0.52 to 1.72; 143 participants; 4 studies; I² = 0%).
Alternative meta-analytical effects model (fixed-effect)
Using the alternative meta-analytical effects model (fixed-effect)
did not alter interpretation of the effect for all-cause mortality (at
the end of follow-up), with little or no difference between groups
(RR 0.89, 95% CI 0.74 to 1.08; 1689 participants; 6 studies; I²
= 0%).
Studies with discrepancies in data
We included no studies with serious discrepancies in data.
4. Albumin or FFP versus crystalloids
All-cause mortality at end of follow-up
Twenty-one studies reported mortality (Annane 2013; Caironi
2014; Cooper 2006; Finfer 2004; Goodwin 1983; Jelenko 1979;
Lowe 1977; Lucas 1978; Maitland 2005; Maitland 2011; Martin
2005; McIntyre 2012; Metildi 1984; O’Mara 2005; Park 2015;
Philips 2015; Pockaj 1994; Quinlan 2004; Rackow 1983; Shah
1977; Van der Heijden 2009). One study was a multi-arm study
and we combined data in analysis for both crystalloid groups (
Jelenko 1979).
Wedidnot include outcomedata fromone study (McIntyre 2012),
as mortality data were reported overall, not by group (12 of 50
participants died).
We includedmortality data in this analysis in which the time point
was: within 24 hours (Rackow 1983); within seven days (Philips
2015); within the ICU or hospital stay (Van der Heijden 2009);
within 90 days (Annane 2013; Caironi 2014); or was unknown
(Goodwin 1983; Jelenko 1979; Lowe 1977; Lucas 1978;Maitland
2005;Metildi 1984;O’Mara 2005; Pockaj 1994; Shah 1977). The
remaining studies reported data at 28 or 30 days.
We found little or no difference in the number of participants
who had died from any cause at the end of follow-up according to
whether fluid resuscitation was with albumin or FFP compared to
a crystalloid (RR 0.98, 95% CI 0.92 to 1.06; 13,047 participants;
20 studies; I² = 7%; Analysis 4.1).
We generated a funnel plot to assess risk of publication bias. One
study was an outlier in this plot, which we could not explain, but,
because the only outlier was a small study from 1978, we did not
believe this was evidence of a high risk of publication bias. See
Figure 6.
We used GRADE, and assessed the level of certainty of the ev-
idence for this outcome as moderate. We downgraded the evi-
dence by one level for study limitations because some studies had
unclear risk of selection bias, and because, for many studies, we
were unable to assess risk of selective reporting bias due to lack of
prospective clinical trials registration. See Summary of findings 4.
All-cause mortality within 90 days
Eleven studies measured mortality within 90 days (Annane 2013;
Caironi 2014; Cooper 2006; Finfer 2004; Maitland 2011;Martin
2005; McIntyre 2012; Park 2015; Philips 2015; Quinlan 2004;
Rackow 1983). We did not include outcome data from one study
(McIntyre 2012), as mortality data were reported overall, not by
group (12 of 50 participants died).
We includedmortality data in this analysis in which the time point
was: within 24 hours (Rackow 1983); within seven days (Philips
2015); within 30 days (Cooper 2006; Finfer 2004;Maitland 2011;
Martin 2005; Park 2015; Quinlan 2004); and within 90 days
(Annane 2013; Caironi 2014).
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We found little or no difference in the number of participants who
died from any cause within 90 days according to whether fluid
resuscitation was with albumin or FFP compared to a crystalloid
(RR 0.98, 95% CI 0.92 to 1.04; 12,492 participants; 10 studies;
I² = 0%; Analysis 4.2).
We generated a funnel plot to assess risk of publication bias. One
study was an outlier in this plot, which we could not explain; we
could not be certain whether this indicated risk of publication
bias.
We used GRADE, and assessed the level of certainty of the ev-
idence for this outcome as moderate. We downgraded the evi-
dence by one level for study limitations because some studies had
unclear risk of selection bias, and because, for many studies, we
were unable to assess risk of selective reporting bias due to lack of
prospective clinical trials registration. See Summary of findings 4.
All-cause mortality within 30 days
Eleven studies measured mortality within 30 days (Annane 2013;
Caironi 2014; Cooper 2006; Finfer 2004; Maitland 2011;Martin
2005; McIntyre 2012; Park 2015; Philips 2015; Quinlan 2004;
Rackow 1983). We did not include outcome data from one study
(McIntyre 2012), as mortality data were reported overall, not by
group (12 of 50 participants died).
We includedmortality data in this analysis in which the time point
was: within 24 hours (Rackow 1983); within seven days (Philips
2015); or within 28 or 30 days (Annane 2013; Caironi 2014;
Cooper 2006; Finfer 2004; Maitland 2011; Martin 2005; Park
2015; Quinlan 2004).
We found little or no difference in the number of participants who
died from any cause within 30 days according to whether fluid
resuscitation was with albumin or FFP compared to a crystalloid
(RR 0.99, 95% CI 0.93 to 1.06; 12,506 participants; 10 studies;
I² = 0%; Analysis 4.3).
We generated a funnel plot to assess risk of publication bias. One
study was an outlier in this plot, which we could not explain; we
could not be certain whether this indicated risk of publication
bias.
We used GRADE, and assessed the level of certainty of the ev-
idence for this outcome as moderate. We downgraded the evi-
dence by one level for study limitations because some studies had
unclear risk of selection bias, and because, for many studies, we
were unable to assess risk of selective reporting bias due to lack of
prospective clinical trials registration. See Summary of findings 4.
Transfusion of blood products
Four studies reported outcome data for transfusion of blood prod-
ucts (Annane 2013; Cooper 2006; Lowe 1977; Pockaj 1994).
One study, which allowed type of colloid or crystalloid to be at
the discretion of the clinician, reported the number of participants
who received a blood product, but these data were not reported ac-
cording to type of colloid received (Annane 2013). We did not in-
clude these data in analysis of albumin or FFP because the types of
colloid used were either hydroxyethyl starch, gelatins, or albumin.
We included data for transfusion of blood products for Annane
2013 in Table 2; we noted little or no difference between groups
in the need for blood products according to whether participants
were given a colloid (hydroxyethyl starch, gelatins, or albumin) or
a crystalloid.
We found little or no difference in the number of participants
who had transfusion of blood products according to whether fluid
resuscitation was with albumin or FFP compared to a crystalloid
(RR 1.31, 95% CI 0.95 to 1.80; 290 participants; 3 studies; I² =
0%; Analysis 4.4).
We used GRADE, and assessed the level of certainty of the evi-
dence for this outcome as very low. We downgraded the evidence
by two levels for study limitations because some studies had un-
clear risk of selection bias, and we noted baseline imbalances in
one study. We downgraded by one level for imprecision because
analysis included few studies with few participants. See Summary
of findings 4.
Renal replacement therapy
Four studies collected outcome data related to renal replacement
therapy (Annane 2013; Caironi 2014; Finfer 2004; Park 2015).
One study, which allowed type of colloid or crystalloid to be at
the discretion of the clinician, reported the number of participants
who required renal replacement therapy, but these data were not
reported according to type of colloid received (Annane 2013). We
did not include these data in analysis of albumin or FFP because
the types of colloid used were either hydroxyethyl starch, gelatins,
or albumin. We included data for renal replacement therapy for
Annane 2013 in Table 2; we noted little or no difference between
groups in the need for renal replacement therapy according to
type of fluid. The study report for Park 2015 was an abstract that
stated that renal replacement therapy was a secondary outcome,
but outcome data were not reported in the abstract. Data in Finfer
2004 were reported for a smaller subgroup of participants who
had severe sepsis; we included these data in the analysis.
We noted little or no difference according to type of fluid resus-
citation in the number of participants who received renal replace-
ment therapy (RR 1.11, 95% CI 0.96 to 1.27; 3028 participants;
2 studies; I² = 0%; Analysis 4.5).
We used GRADE, and assessed the level of certainty of the evi-
dence for this outcome as low. We downgraded the evidence by
two levels for study limitations because we noted baseline imbal-
ances and because we could not be certain whether participants
in the crystalloids group in one study may have received colloids.
See Summary of findings 4.
Adverse events (allergic reaction, itching, rashes)
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One study reported incidences of allergic reaction (Maitland
2011). We used RevMan 5 to calculate an effect estimate (Review
Manager 2014); we noted little or no difference between groups
in allergic reactions (RR 0.75, 95% CI 0.17 to 3.33; 2097 partic-
ipants; 1 study; Table 2).
We used the GRADE approach to downgrade the certainty of
the evidence to very low. We downgraded by one level for study
limitations because we were unable to assess the risk of selective
outcome reporting bias since the study authors did not report
clinical trials registration. We downgraded by two levels because
evidence was from one study with few events. See Summary of
findings 4.
Subgroup analysis
Tonicity of crystalloid solution
We found that many studies did not report the solution in which
the colloid was suspended. One study used albumin with an iso-
tonic crystalloid (suspended in normal saline) versus an isotonic
crystalloid (normal saline) (Pockaj 1994), and one study used al-
bumin with an isotonic crystalloid (normal saline) versus a hyper-
tonic crystalloid (Ringer’s lactate) (Cooper 2006). One study used
albumin with a hypertonic crystalloid (hypertonic saline) versus a
hypertonic crystalloid (Ringer’s lactate) (Jelenko 1979), and five
studies used albumin with a hypertonic crystalloid (Ringer’s lac-
tate) versus a hypertonic crystalloid (Ringer’s lactate) (Goodwin
1983; Lowe 1977; Metildi 1984; O’Mara 2005; Shah 1977). We
found insufficient studies to conduct meaningful subgroup anal-
ysis.
Sensitivity analysis
Studies at high or unclear risk of selection bias
We excluded two studies that we judged to have high risk of se-
lection bias (Lowe 1977; Lucas 1978), and nine studies that we
judged to have unclear risk of selection bias from analysis of mor-
tality (Goodwin 1983; Maitland 2005; Metildi 1984; Park 2015;
Philips 2015; Pockaj 1994; Quinlan 2004; Rackow 1983; Shah
1977). This did not alter interpretation of the effect for all-cause
mortality (at end of follow-up), with little or no difference between
groups (RR 0.98, 95% CI 0.91 to 1.04; 12,111 participants; 9
studies; I² = 0%).
Studies in which some participants in the crystalloid group
were given, or may have been given, additional colloids
Some studies were at risk of bias because some participants in the
crystalloid group were given, or may have been given, additional
colloids. We excluded three studies from analysis of mortality (
Annane 2013; Finfer 2004; Goodwin 1983). This did not alter
interpretation of the effect for all-cause mortality (at end of follow-
up), with little or no difference between groups (RR 0.96, 95%
CI 0.88 to 1.04; 4970 participants; 17 studies; I² = 0%).
Alternative meta-analytical effects model (fixed-effect)
Using the alternative meta-analytical effects model (fixed-effect)
did not alter interpretation of the effect for all-cause mortality (at
end of follow-up), with little or no difference between groups (RR
0.99, 95% CI 0.93 to 1.05; 13,047 participants; 20 studies; I² =
7%).
Studies with discrepancies in data
We noted a discrepancy in mortality outcome data in different
published reports for Lucas 1978. In sensitivity analysis, we used
alternative data reported in a later publication, Lucas 1980, which
is cited as part of Lucas 1978. This did not alter interpretation of
the effect for all-cause mortality (at end of follow-up), with little
or no difference between groups (RR 0.98, 95% CI 0.92 to 1.04;
13,047 participants; 20 studies; I² = 0%).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Dextrans compared to crystalloid for fluid resuscitation in critically ill patients
Participants: crit ically ill people requiring f luid resuscitat ion
Setting: in hospital, or out of hospital, in Brazil, Canada, Denmark, Mexico, Sweden, UK, USA and Vietnam
Intervention: dextrans
Comparison: crystalloids to include: normal saline, hypertonic saline, Ringer’s lactate, Ringer’s acetate, and unspecif ied types of crystalloids
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Itching
Study populat ion Not measured -
- -
Rashes
Study populat ion Not measured -
- -
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aWe downgraded by one level for study lim itat ions; some included studies had unclear risk of select ion bias and we were
of ten unable to assess risk of select ive report ing bias because many included studies did not have prospect ive clinical
trials registrat ion.
bWe downgraded by two levels for study lim itat ions; we noted in two studies that some part icipants were given addit ional
colloids in the crystalloid group, and in one study we could not be certain whether some part icipants in the crystalloids
groups also received up to 2000 mL colloid resuscitat ion prior to randomisat ion. In addit ion, we were unable to assess risk of
select ive report ing bias because of lack of prospect ive clinical trials registrat ion in each study. We downgraded by one level
for imprecision; evidence was f rom three studies.
cWe downgraded by one level for study lim itat ions; one study had an unclear risk of select ion bias and we were unable to
assess risk of select ive outcome report ing bias in all studies. We downgraded by two levels for imprecision because evidence

































































































Gelatins compared to crystalloid for fluid resuscitation in critically ill patients
Participants: crit ically ill people requiring f luid resuscitat ion
Setting: in hospital, in Algeria, France, Germany, India, South Af rica, Taiwan, Tunisia and Vietnam
Intervention: gelat ins
Comparison: crystalloids to include normal saline and Ringer’s lactate
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All-cause mortality (at
end of follow-up)
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aWe downgraded by one level for study lim itat ions; risk of select ion bias was unclear in some studies, and because we were
unable to assess risk of select ive outcome report ing bias in some studies. We downgraded by one level for imprecision;
evidence was f rom few studies, and we could not be certain of t ime points for data collect ion.
bWe downgraded by two levels for imprecision; evidence was f rom a single study.
cWe downgraded by one level for study lim itat ions; we were unable to assess risk of select ive outcome report ing bias due
to lack of prospect ive clinical trials registrat ion, and some part icipants in the crystalloid groups also received colloids. We



































































































Albumin and fresh frozen plasma compared to crystalloid for fluid resuscitation in critically ill patients
Participants: crit ically ill people requiring f luid resuscitat ion
Setting: in hospital and out of hospital, in Algeria, Brazil, Canada, France, Germany, Kenya, India, Italy, Tanzania, Tunisia, Uganda and USA
Intervention: albumin and f resh f rozen plasma
Comparison: crystalloids to include: normal saline, hypertonic saline, Ringer’s lactate, electrolytes, and unspecif ied types of crystalloids
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noted lit t le or no dif fer-
ence between groups in
need for transfusion of
blood products




201 per 1000 223 per 1000
(193 to 255)




One study stated that
renal replacement data
were measured but it
was not reported in the
study report (abstract)
1 study included dif fer-
ent types of colloids
(HES, gelat ins, or albu-
min). We did not include
this in analysis because
study authors did not
report data for only al-
bumin and FFP. We
noted lit t le or no dif fer-
ence between groups in
need for renal replace-
ment therapy
Adverse events Allergic react ions ⊕©©©
Very lowd
Study populat ion RR 0.75 (0.17 to 3.33) 2097
(1 study)
4 per 1000 3 per 1000
(1 to 13)
Itching




































































































- - - -
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; FFP: f resh f rozen plasma RR: Risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aWe downgraded by one level for study lim itat ions; some included studies had unclear risk of select ion bias, and we were
of ten unable to assess risk of select ive report ing bias because many included studies did not have prospect ive clinical
trials registrat ion.
bWe downgraded by two levels for study lim itat ions; some studies had unclear risk of select ion bias, and we noted baseline
imbalances in one study. We downgraded by one level for imprecision because analysis included few studies with few
part icipants.
cWe downgraded by two levels for study lim itat ions; we noted baseline imbalances and we could not be certain how many
part icipants in the crystalloids group may have received addit ional colloids.
dWe downgraded by one level for study lim itat ions; we were unable to assess risk of select ive report ing bias because the
included study did not appear to have prospect ive clinical trials registrat ion. We downgraded by two levels for imprecision;



































































































D I S C U S S I O N
Summary of main results
We included 69 studies comparing colloids (suspended in any so-
lution) versus crystalloids (isotonic or hypertonic) in critically ill
people who required fluid resuscitation. In addition, we identi-
fied seven studies that are awaiting classification (two studies were
published only as abstracts with insufficient information, three
completed studies are listed on clinical trials register sites with-
out publication of full reports, and two studies require translation
from Russian), and three ongoing studies.
We reported four comparisons for each type of colloid (starches;
dextrans; gelatins; and albumin or FFP) versus crystalloids. We
collected outcome data for all-cause mortality at end of follow-up,
within 90 days, and within 30 days; need for transfusion of blood
products; need for renal replacement therapy; and adverse events
(allergic reaction, itching, and rashes).
We found moderate-certainty evidence that there is probably little
or no difference in all-cause mortality at the end of follow-up,
within 90 days, or within 30 days between colloids (which are:
starches; dextrans; or albumin or FFP) or crystalloids for fluid
resuscitation. We found low-certainty evidence that there may be
little or no difference in all-cause mortality at the end of follow-up,
within 90 days, or within 30 days between gelatins or crystalloids
for fluid resuscitation.
We found moderate-certainty evidence that using starches proba-
bly slightly increases the need for transfusion of blood products.
Studies comparing dextrans, gelatins, and albumin or FFP to crys-
talloids, found little or no difference in the need for transfusion
of blood products but certainty of this evidence was very low.
We found moderate-certainty evidence that using starches proba-
bly slightly increases the need for renal replacement therapy. We
found low-certainty evidence from two studies that albumin or
FFP versus crystalloids may make little or no difference to the
need for renal replacement therapy. We could not use data from
renal replacement therapy from one study of gelatins because data
were not reported by type of colloid solution, and no studies of
dextrans measured this outcome.
Evidence for adverse events (allergic reactions, itching, or rashes) is
very low certainty because studies often did not report events. For
starches, we found little or no difference between either fluid group
in allergic reactions in three studies, but we found more incidences
of itching and rashes in two studies. For dextrans, gelatins, and for
albumin or FFP, we found little or no difference between groups
in allergic reactions.
Overall completeness and applicability of
evidence
We identified 69 studies with 30,020 participants who were un-
dergoing fluid resuscitation for conditions that indicated that they
were critically ill. The conditions being managed with fluid resus-
citation varied, and settings also varied; 10 studies were based in
an out-of-hospital setting.
All studies compared colloids versus crystalloids. We found 28
studies using starch solutions, 20 studies using dextran solutions,
seven studies using gelatins, and 22 studies using albumin or FFP.
Some study authors did not report the specific nature of the so-
lution the colloid was suspended in, and other studies reported
the use of either an isotonic or hypertonic crystalloid suspension
solution. Because of the different use of crystalloid solutions for
this purpose, and the different compositions of the comparative
crystalloids, we could not be certain whether comparisons by type
of colloid were always equivalent. We were unable to perform
meaningful subgroup analysis for most types of colloids because
of limitations in reporting of suspension solutions. Also, individ-
ual study protocols for the concentration, quantity, and timing of
administration of fluids varied.
We also noted that studies ranged in date of publication from1977
to 2016, and, while we did not consider the potential influence
of date on our results, it is possible that changes in management
of critically ill people may mean that some study data may not be
generalisable to the current clinical context.
Quality of the evidence
Weused GRADE to consider the effect of study limitations on our
outcomes. We found many studies did not report adequate meth-
ods of randomisation or allocation concealment, and we could
not be certain of the risk of selection bias. We noted that some
studies did not report whether clinicians were blinded to the type
of study fluids they were giving to participants, or whether out-
come assessors were blinded. However, we did not consider risk
of performance or detection bias to be likely for mortality, and
we did not believe lack of performance or detection bias for our
remaining outcomes (transfusion of blood products, renal replace-
ment therapy, or adverse events) were important reasons to down-
grade the evidence for this review. We noted that few studies were
registered prospectively with clinical trials registers, and although
many studies predate the expectation of clinical trials registration,
we could not rule out the risk of selective outcome reporting in
this review. We included some studies in which some participants
in the crystalloid groups were given, or may have been given, ad-
ditional colloids. Because we could not be certain of the influ-
ence of this additional colloid use on the results, we judged these
studies to have a high risk of bias and downgraded the certainty
of the evidence accordingly. We downgraded the certainty of the
evidence for some of our outcomes because of imprecision; for
these outcomes, we found evidence from few studies.
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Potential biases in the review process
We conducted a thorough search and used two review authors
independently to assess study eligibility, extract data, and assess
risk of bias in included studies, and believe that this reduced po-
tential bias in the review process. However, we made a post hoc
decision to change criteria for considering studies in this review
update from the previous version of the review (Perel 2013). This
decision led to the exclusion of 36 previously included studies.
Our intention was to create a more focused review, with a more
comparable participant group, once we had excluded participants
scheduled for a wide range of elective surgical procedures; we ac-
knowledge that the exclusion of this large number of studies may
also have influenced a change in results since the previous review
publication.
We included a number of studies in the review in which partic-
ipants in the crystalloid group may have received additional col-
loids. It is possible that our decision to include these studies in
our primary analysis may have introduced clinical differences, or
bias, between studies, and subsequently influenced our results. We
assessed this decision during sensitivity analysis for our primary
outcome (all-cause mortality (at end of follow-up)) and found that
the interpretation of our effect estimates was the same regardless
of whether we included these studies. However, we noted that in
our comparison of starches versus crystalloids, inclusion of these
studies increased statistical heterogeneity (I² = 34%); we did not
explore this further in the review.
We included additional outcomes in this review; we intended to
explore other effects of colloids and crystalloids for fluid resusci-
tation. We limited these additional outcomes to need for blood
transfusion, need for renal replacement therapy, and three possi-
ble adverse events (allergic reactions, itching, and rashes). We ac-
knowledge that our review is limited to only eight outcomes in
four types of colloid solutions, and therefore does not explore all
the potential risks and benefits of using either colloids or crystal-
loids in the critically ill setting.
The review does not include seven studies that are awaiting
classification (Halim 2016; Bulanov 2004; Charpentier 2011;
NCT00890383; NCT01337934; NCT02064075; Protsenko
2009). We did not seek translation of the full study reports for
four studies that were reported in Chinese (Jie 2015; Li 2008; Lu
2012; Zhu 2011); our judgements and data were limited to infor-
mation available in the abstract, or the tables.
Agreements and disagreements with other
studies or reviews
The results of this review differ from those of the previous version
(Perel 2013), which found an increase in mortality when partic-
ipants were given starches rather than crystalloids for fluid resus-
citation. For this 2018 update, because of changes in the criteria
for considering studies in this review, we excluded studies of elec-
tive surgical patients. However, because of a decision to include
additional outcomes, we re-ran searches from database inception
and included 27 new studies in the review, 13 of which com-
pared starches to crystalloids. Our moderate-certainty evidence,
which demonstrates little or no difference in all-cause mortality
for starches, includes a large number of studies, but we cannot
be certain whether the difference in our results is because we ex-
cluded elective surgical patients. Results for mortality for dextrans,
gelatins, and albumin or FFP were the same as those in Perel 2013.
Whilst other systematic reviews may concentrate on particular
types of colloids, or particular participant groups, our findings for
mortality appear relatively comparable.He 2015 foundno increase
in mortality with hydroxyethyl starch for non-septic patients in
the intensive care unit, as did Haase 2013 for patients with sepsis.
However, Gattas 2013, which included participants undergoing
surgical procedures, reported a non-statistically significant increase
in mortality when starches were used. In reviews of other colloids,
de Crescenzo 2017 found no effect on mortality of trauma pa-
tients treated in a prehospital setting with dextrans; Qureshi 2016
found no increase in mortality of critically ill, trauma, and surgi-
cal patients with any type of colloid; and Eljaiek 2017 found no
difference in mortality of burn patients who were given albumin
for fluid replacement.
Also, we found some comparable results for renal replacement
and blood transfusion. Haase 2013 and Gattas 2013 found that
more participants given starches required renal replacement ther-
apy, whilst Haase 2013 also found this effect with starches for
transfusion of red blood cells. Similarly, Qureshi 2016 found an
increase in acute kidney failure requiring renal replacement that
was more pronounced for those who were given fluid resuscitation
with starches, but this result was not replicated by He 2015, who
found no difference in incidence of renal replacement therapywith
use of starches.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found moderate-certainty evidence that there is probably little
or no difference in all-causemortality at the end of follow-up, at 90
days, or at 30 days, between using colloids (starches; dextrans; or
albumin or FFP) or crystalloids for fluid resuscitation in critically
ill people.We found low-certainty evidence that theremay be little
or no difference in all-cause mortality at these time points between
gelatins or crystalloids for fluid resuscitation. Our evidence for all-
cause mortality at the end of follow-up came from 24 studies of
starch solutions, 19 studies of dextrans, six studies of gelatins, and
20 studies of albumin or FFP.
However, we found moderate-certainty evidence of a slight in-
crease in the need for blood transfusion or renal replacement ther-
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apy when starches were used for fluid resuscitation. Whilst evi-
dence for adverse events was very low because most studies did
not report these events, we found no evidence of a difference in
allergic reactions with starches from three studies, and two studies
reported more incidences of itching and rashes when starches were
used.
For other colloid solutions, we found little or no difference in the
need for blood transfusion for dextrans, gelatins, or for albumin or
FFP versus crystalloids but this was very low-certainty evidence.
We found low-certainty evidence from two studies that albumin
or FFP versus crystalloids may make little or no difference to the
need for renal replacement therapy. Similarly, evidence for adverse
events for dextrans, gelatins, or albumin or FFP was limited to few
studies and was very low certainty: we found little or no difference
in allergic reactions between dextrans, gelatins, or albumin or FFP
compared to crystalloids.
The previous version of this review found that starches might
increase mortality, and therefore, differs from the conclusion of
this review. However, evidence for this new 2018 version of the
review does not include participants who were undergoing elective
surgical procedures.
Implications for research
Whilst this review included a large body of evidence reporting
outcome data for mortality, we found that few studies reported the
number of participants that required transfusion of blood prod-
ucts, required renal replacement therapy, or experienced other ad-
verse events (allergic reactions, itching, and rashes). Consequently,
certainty in our evidence for some comparative colloids was lim-
ited because of few studies. We found three ongoing studies, and
seven studies awaiting classification (of which three are completed
studies without published reports). Inclusion of these studies in
future updates may contribute additional evidence to the review.
We would advise future studies of fluid resuscitation of colloids
versus crystalloids to consider blood transfusion and renal replace-
ment therapy as relevant outcomes for consideration, and to pro-
vide comprehensive reporting of possible adverse events.Wewould
also advise that studies are managed to avoid the risk of additional
colloid solutions being given to some participants in the crystal-
loids study arm. Improved reporting of suspension solutions when
colloids are given would allow for beneficial subgroup analysis for
the potential effect of isotonic or hypertonic crystalloids.
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Participants Total number of randomised participants: 180
Inclusion criteria: patients admitted to MIU
Exclusion criteria: no details
Participant condition: head, chest, abdominal injuries
Baseline characteristics
Colloids group
• Age, mean (range): 28 (21-60) years
• Gender, M:F: 81:9
• BP, mean (range): SBP: 95 (35-130); DBP: 49 (10-70) mmHg
Crystalloids group
• Age, mean (range): 27 (21-59) years
• Gender, M:F: 81:9




• Participants: n = 90; losses = 0; analysed = 90
• Details: 7.5% NaCl in 4.2% dextran 70; 4 mL/kg up to a maximum 250 mL
• Additional details: further fluid infusions continued with Hartmann’s or blood
transfusions, if required
Crystalloids group
• Participants: n = 90; losses = 0; analysed = 90
• Details: we have assumed that crystalloid solution was RL from other information
in the study report
• Additional details: further fluid infusions continued with Hartmann’s (RL) or
blood transfusions if required
Outcomes Outcomes measured/reported: haemodynamic analysis; urine outputs; recovery; LoS
Outcomes relevant to the review: mortality (time not reported)
Notes Funding/declarations of interest: none apparent
Study dates: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Alpar 2004 (Continued)
Random sequence generation (selection
bias)
High risk Alternate participants added to each group
based on odd/even numbers
Allocation concealment (selection bias) High risk Alternate allocation used and therefore un-
likely to be concealed
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce
bias for this outcome
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; not likely to intro-
duce bias for this outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration; not
feasible to assess risk of selective reporting
bias
Baseline characteristics Unclear risk The proportion of participants in each arm
with chest injuries differed. It is unclear
whether this influenced results





Participants Total number of randomised participants: 2857
Inclusion criteria: no prior fluid resuscitation in ICU; required fluid resuscitation for
acute hypovolaemia
Exclusion criteria: received fluid resuscitation in ICU; anaesthesia-related hypotension;
advanced chronic liver disease; acute anaphylactic reaction; inherited coagulation disor-
ders; do-not-resuscitate order; pregnant; burned > 20% of TBSA; allergy to study drug;
refused consent; dehydrated; brain death or organ donor; other (not specified)
Participant condition: acute hypovolaemia, sepsis, and trauma
Baseline characteristics
Colloids group
• Age, median (IQR): 63 (50-76) years
• Gender, M:F: 880:534
• Weight, median (IQR): 70 (60-81) kg
• BP, median (IQR): SBP: 92 (80-112) mmHg
• SAPS II, median (IQR): 48 (35-64)
Crystalloids group
• Age, median (IQR): 50 (36-65) years
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• Gender, M:F: 902:541
• Weight, median (IQR): 70 (61-81) kg
• BP, median (IQR): SBP: 94 (80-113) mmHg
• SAPS II, median (IQR): 50 (36-65)
Country: France, Belgium, Canada, Algeria, Tunisia
Setting: ICU
Interventions Colloids group
• Participants: n = 1414; losses = 0; analysed = 1414
• Details: colloids, any type from 4% gelatin, 5% albumin, dextrans, HES, 20% or
25% albumin; at discretion of local investigators; not > 30 mL/kg/d; median in first 7
days 2000 mL (IQR, 1000 mL-3502 mlL; median 2 d duration
• Additional details: participants received colloids or crystalloids prior to ICU
Crystalloids group
• Participants: n = 1443; losses = 0; analysed = 1443
• Details: crystalloids, any type; at discretion of local investigator; median for first 7
days 3000 mL (IQR, 500 mL-5200 mL); median 2 d duration
• Additional details: isotonic saline or HS, any buffered solutions; participants
received colloids or crystalloids prior to ICU
Outcomes Outcomes measured/reported: mortality at 28 days; mortality at 90 days and at ICU
and hospital discharge; number of days alive and not receiving renal replacement therapy,
mechanical ventilation or vasopressor therapy; days not in ICU or hospital; days without
organ failure
Outcomes relevant to the review: mortality (at 28 days, 90 days, and at end of follow-
up); renal replacement therapy; requiring blood transfusion
Notes Funding/declarations of interest: funded by FrenchMinistry of Health. Study sponsors
not involved in design and conduct of study
Study dates: Febuary 2003-November 2012
Note: study was stopped early because study authors noted no difference in 28-day
mortality rates
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated sequence
Allocation concealment (selection bias) Low risk Sealed envelopes were used at the bedside to allow
randomisation of eligible participants without any
delay and was done blinded to block size
Blinding of participants and personnel
(performance bias): mortality
Low risk Clinicians were not blinded because of immediate
need for resuscitation; unlikely to introduce bias for
this outcome
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Blinding of participants and personnel
(performance bias): transfusion/renal re-
placement therapy/adverse events
High risk Clinicians were not blinded because of immediate
need for resuscitation; could introduce bias for this
outcome
Blinding of outcome assessment (detection
bias): mortality
Low risk Quote: “mortality end-points were collected and as-
sessed by study members blinded to treatment as-
signment.” Unlikely to introduce bias for this out-
come
Blinding of outcome assessment (detection
bias): transfusion/renal replacement ther-
apy/adverse events
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses
Selective reporting (reporting bias) Low risk Prospective
clinical trials registration (NCT00318942); all out-
comes listed on registration site were reported
Baseline characteristics Low risk Baseline characteristics appear comparable
Other bias High risk 47.5% of participants in the crystalloid group were
given colloids within 12 h before the start of the




Multicentre (2 x level 1 adult trauma centres)
Participants Total number of randomised participants: 64
Inclusion criteria: coma, with a loss of consciousness because of isolated blunt head
trauma or a GCS score ≤ 8
Exclusion criteria: primary penetrating injury; previous IV therapy ≥ 50 mL; time of
arrival at scene to IV access > 4 h; < 16 years of age; burn or amputation; presumed to
be pregnant; vital signs absent prior to randomisation
Participant condition: blunt trauma head injury
Baseline characteristics
Colloids group
• Age, mean (SD): 42.5 (± 20.9) years
• Gender, M:F: 18:13
• APACHE II, mean (SD): 13.2 (± 5.6)
Crystalloids group
• Age, mean (SD): 42.3 (± 20.7) years
• Gender, M:F: 23:10
• APACHE II, mean (SD): 14.4 (± 5.2)
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Country: Canada
Setting: ambulatory prior to adult-designated level 1 trauma centres
Interventions Colloids group
• Participants: n = 31; losses = 0; analysed = 31
• Details: 7.5% HS in 6% dextran 70; 250 mL
• Additional details: emergency medical service personnel administered the study
solution prehospital; after administration of study fluid participants were treated
according to ATLSG; participants received additional crystalloid for ongoing
resuscitation per existing protocols
Crystalloids group
• Participants: n = 33; losses = 0; analysed = 33
• Details: 0.9% isotonic NS; 250 mL
• Additional details: same as colloid group
Outcomes Outcomesmeasured/reported:neurological outcomes at hospital discharge (or 30 days)
using various scales; mortality; biomarkers
Outcomes relevant to the review: mortality (at 28 days)
Notes Funding/declarations of interest: funded by Defence Research and Development
Canada
Study dates: September 2004-January 2006
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated sequence
Allocation concealment (selection bias) Low risk Computer randomisation was used to as-
sign sequentially numbered identical IV
bags to the ambulance
Blinding of participants and personnel
(performance bias): mortality
Low risk Participants and personnel were blinded to
treatment allocation
Blinding of outcome assessment (detection
bias): mortality
Low risk Paramedics, physicians and study co-ordi-
nators were blinded to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration; not
feasible to assess risk of selective reporting
bias
Baseline characteristics Low risk Baseline characteristics appear comparable
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Other bias High risk Study authors report that participants
could receive additional fluid resuscitation
during standard care and this could influ-





Participants Total number of randomised participants: 48
Inclusion criteria: ≥ 16 years of age with second- or third-degree acute burn injuries
and > 15% of body surface area burned
Exclusion criteria: expected to die within 24-36 h (i.e. burn victims with whole body
burn trauma); in situations of palliative care; pregnancy; lack of informed consent;
known allergy to HES; contraindications for balanced 6% HES 130/0.04; intracerebral
bleeding; acute renal failure; severe hypernatraemia and other severe electrolyte disorders;
severe von Willebrand Syndrome; acute liver failure
Participant condition: burns; TBSA > 15%
Baseline characteristics
Colloids group
• Age, median (IQR): 49 (22-69) years
• Gender, M:F: 17:6
• Weight, median (IQR): 75 (70-83) kg
• BP, median (IQR): SBP: 109 (93-130); DBP: 60 (55-65) mmHg
• TBSA, median burned (IQR): 31% (21-47)
Crystalloids group
• Age, median (IQR): 47 (26-61) years
• Gender, M:F: 17:5
• Weight, median (IQR): 80 (70-80) kg
• BP, median (IQR): SBP: 123 (104-150) mmHg; DBP: 68 (59-76) mmHg
• TBSA, median burned (IQR): 32% (20%-50%)
Country: Switzerland
Setting: tertiary burns unit
Interventions Colloids group
• Participants: n = 24; losses = 0; analysed = 24
• Details: 6% HES 130/0.4; 500 mL; each participant first received 2 bags of
unblinded RL solution (500 mL each bag); after each bag of study solution, all
participants again received 2 bags of unblinded RL solution, before a next bag of study
solution from the blinded box was infused; maximum to be given as 50 mL/kg/24 h
• Additional details: fluid was administered until target variables were met; 2 bags
of unblinded RL (500 mL each bag); then 1 bag of HES; then 2 bags of unblinded RL
Crystalloids group
• Participants: n = 24; losses = 0; analysed = 24
• Details: RL solution; 500 mL; each participant first received 2 bags of unblinded
RL solution (500 mL each bag); after each bag of study solution, all participants again
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received 2 bags of unblinded RL solution, before a next bag of study solution from the
blinded box was infused
• Additional details: as for colloids group but given RL in blinded bags in between
unblinded bags
Outcomes Outcomes measured/reported: group difference in administration of fluid with 72 h;
creatinine levels; urine output; ARDS; LoS in ICU; LoS in hospital; in-hospital mortality
and at 28 days; post-hoc 90-day mortality; RRT
Outcomes relevant to the review: mortality (28 days; and 90 days); RRT (collected as
a 90-day post-hoc analysis)
Notes Funding/declarations of interest: funding from manufacturer of HES, which supplied
study fluids; 2 of the authors have vocationally beenmembers of advisory boardmeetings.
No competing interests declared. Funders reported as having no input in study design
and interpretation of results
Study dates: November 2009-January 2013
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation completed using minimisation
technique, conducted by a third party
Allocation concealment (selection bias) Low risk A third party not involved in conduction of study,
performed the randomisation process
Blinding of participants and personnel
(performance bias): mortality
Low risk All personnel blinded. Fluids prepared externally,
and concealed in bags of black plastic
Blinding of participants and personnel
(performance bias): transfusion/renal re-
placement therapy/adverse events
Low risk All personnel blinded. Fluids prepared externally,
and concealed in bags of black plastic
Blinding of outcome assessment (detection
bias): mortality
Low risk No details in study report. However, trial regis-
tration report states that outcome assessors were
blinded
Blinding of outcome assessment (detection
bias): transfusion/renal replacement ther-
apy/adverse events
Low risk No details in study report. However, trial regis-
tration report states that outcome assessors were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 participants were retrospectively excluded because
of meeting exclusion criteria. Data missing from
1 additional participant because of early discharge.
Overall, < 10% dropout/exclusion; data reported
for 45/48 randomised participants
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Selective reporting (reporting bias) High risk Prospective clinical
trials registration (NCT01012648). Only primary
outcome (fluid volume administered) was listed on
the trial registration site
Baseline characteristics Low risk Baseline characteristics comparable





Participants Total number of randomised participants: 22
Inclusion criteria: ICU patients with an acute, spontaneous subarachnoid haemorrhage, with stable ICP in the range
of 10 mmHg-20 mmHg; > 18 years of age; sedated; mechanically ventilated; stable haemodynamics; serum sodium
of < 160 mmol/L
Exclusion criteria: no details
Participant condition: spontaneous subarachnoid haemorrhage
Baseline characteristics
Colloids group
• Age, mean (SD): 50.1 (± 10.5) years
• Gender, M:F: 3:8
• SAPS II, mean (SD): 40.5 (± 11.1)
Crystalloids group
• Age, mean (SD): 55.2 (± 10.8) years
• Gender, M:F: 1:10




• Participants: n = 11; losses = 0; analysed = 11
• Details: 7.2% saline in 6% HES 200/0.5; 2 mL/kg over 30 min
• Additional details: participants monitored from 10 min before to 210 min after start of infusion; need for
rescue treatment was defined by treatment failure limits for ICP (> 20 mmHg) and CPP (< 60 mmHg). Otherwise,
no changes to study fluid regimen
Crystalloids group
• Participants: n = 11; losses = 0; analysed = 11
• Details: 0.9% saline solution; 2 mL/kg over 30 min
• Additional details: same as colloid group
Outcomes Outcomes measured/reported: ICP; CPP; extravascular lung water; serum sodium levels
Outcomes relevant to the review: none
59Colloids versus crystalloids for fluid resuscitation in critically ill people (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bentsen 2006 (Continued)
Notes Funding/declarations of interest: not reported
Study dates: April 2002-October 2004
Participant condition not reported by group; “A total of 21 patients had haemorrhaged because of a ruptured





Participants Total number of randomised participants: 537
Inclusion criteria: patients with severe sepsis or septic shock; ≥ 18 years of age; onset
of the syndrome < 24 h before admission to the ICU or < 12 h after admission if the
condition developed in the ICU
Exclusion criteria: treatment with > 1000 mL of HES within 24 h before study in-
clusion; pre-existing renal failure requiring dialysis or a serum creatinine level ≥ 320
µmoL/L (3.6 mg/dL); < 18 years of age; pregnancy; known allergy against HES; in-
tra-cerebral haemorrhage; heart failure with NYHA IV; requirement of an inspiratory
oxygen fraction of at least 0.7; immunosuppression from cytostatic chemotherapy; high
dosage of steroids or AIDS; participation in another interventional trial; moribund due
to coexisting disease; order to withhold or withdraw therapy
Participant condition: severe sepsis or septic shock
Baseline characteristics
Colloids group
• Age, mean (SD): 64.4 (± 13.3) years
• Gender, M:F: 158:104
• APACHE II, mean (SD): 20.1 (± 6.7)
Crystalloids group
• Age, mean (range): 64.9 (± 14.1) years
• Gender, M:F: 164:111
• APACHE II, mean (SD): 20.3 (± 6.7)
Country: Germany
Setting: ICU; 18 tertiary hospitals
Interventions Colloids group
• Participants: n = 262; losses = 0; analysed = 262
• Details: 10% pentastarch; HES 200/0.5 with 0.9% NS; to achieve CVP 8 mmHg,
MAP > 70 mmHG or central venous oxygen saturation > 70%; given for up to 96 h
• Additional details: participants to be excluded if they had received > 1000 mL
HES in 24 h prior to randomisation; all participants given different insulin therapies in
a 2 x 2 factorial design
Crystalloids group
• Participants: n = 275; losses = 0; analysed = 275
• Details: RL; to achieve CVP 8 mmHg, MAP > 70 mmHg or central venous
oxygen saturation > 70%; given for up to 96 h
• Additional details: same as colloids group
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Outcomes Outcomesmeasured/reported:mortality (at 28days and90days);morbidity (according
to SOFA scores); need for blood transfusion; renal failure (to include need for RRT)
; time to haemodynamic stabilisation; frequency of vasopressor therapy; need for red-
cell transfusion; duration of mechanical ventilation, LoS in the ICU; adverse events
(worsening of oxygenation, bleeding complications, allergic reaction, any event judged
to occur in relation to study fluid)
Outcomes relevant to the review: mortality (at 28 days and 90 days; need transfusion
of a blood product; need for renal replacement therapy
Notes Funding/declarations of interest: supported by a grant (01 KI 0106) from the German
Federal Ministry of Education and Research and by unrestricted grants from B Braun,
HemoCue and Novo Nordisk
Study dates: April 2003-June 2005
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias): mortality
Low risk Open-label design; unlikely to introduce bias for this
outcome
Blinding of participants and personnel
(performance bias): transfusion/renal re-
placement therapy/adverse events
High risk Open-label design; could introduce bias for this out-
come
Blinding of outcome assessment (detection
bias): mortality
Low risk No details; unlikely to introduce bias for this out-
come
Blinding of outcome assessment (detection
bias): transfusion/renal replacement ther-
apy/adverse events
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration; not feasible
to assess risk of selective reporting bias
Baseline characteristics Low risk Baseline characteristics appear comparable
Other bias High risk Note: 26.6% of participants in the crystalloid group
were given colloids during the study period and this
may have influenced study results
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Participants Total number of randomised participants: 209
Inclusion criteria: blunt trauma; > 17 years of age (or adult size if age was unknown)
; at least 1 prehospital SBP measurement ≤ 90 mmHg; transported directly to a single
level 1 trauma centre from the site of injury
Exclusion criteria: ongoing cardiopulmonary resuscitation; isolated penetrating trauma;
known or suspected pregnancy; receipt of > 2000 mL of crystalloid before availability of
study fluid
Participant condition: blunt trauma
Baseline characteristics
Colloids group
• Age, mean (SD): 41 (± 18) years
• Gender, M:F: 69:41
• BP, mean (SD): SBP: 71 (± 27) mmHg
Crystalloids group
• Age, mean (SD): 38 (± 19) years
• Gender, M:F: 68:31
• BP, mean (SD): SBP: 72 (± 25) mmHg
Country: USA
Setting: prehospital (ambulatory) prior to admission to a single level 1 trauma centre
Interventions Colloids group
• Participants: n = 110; losses = 0; analysed = 110
• Details: 7.5% HS and 6% dextran 70 (HSD); 250 mL; followed by additional RL
as necessary during transport
Crystalloids group
• Participants: n = 99; losses = 0; analysed = 99
• Details: 250 mL followed by additional RL as necessary during transport
Outcomes Outcomes measured/reported: incidence of ARDS; mortality; multiple organ failure
syndrome; nosocomial infections; length of hospital and ICU stay; ventilator-free days;
adverse events; non-infectious complications
Outcomes relevant to the review: mortality (28 days)
Notes Funding/declarations of interest: grant R01 HL073233-01 from the National Insti-
tutes of Health
Study dates: October 2003-August 2005
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
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Allocation concealment (selection bias) Low risk A random number (computer-generated by phar-
macist) was applied to each bag and kept by the
pharmacist. Ambulance crew did not have access to
allocation sequence
Blinding of participants and personnel
(performance bias): mortality
Low risk All contents of fluid bags were blinded by research
pharmacists. Therefore, personnel and participants
were blinded to treatment assignment
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality outcomes
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 21 participants did not meet eligibility criteria once
randomisation had taken place but remained in the
results using ITT analysis. Three participants lost to
follow-up, explanations reported by study authors
Selective reporting (reporting bias) Unclear risk Clinical trials registration ID: NCT01012648. All
outcomes specified on clinical trials registration site
were reported. However, we noted that the out-
comes were only added to the trials registration site
after the study start date
Baseline characteristics Unclear risk We noted higher injury severity scores for those in
the colloids group, and we could not be certain
whether this could influence outcome data





Participants Total number of randomised participants: 1331
Inclusion criteria: blunt mechanism of injury; ≥ 15 years of age; GCS score ≤ 8;
ineligibility for enrolment in the haemorrhagic shock cohort
Exclusion criteria: known or suspected pregnancy; < 15 years of age; out-of-hospital car-
diopulmonary resuscitation; administration of > 2000 mL of crystalloid or any amount
of colloid or blood products prior to enrolment; severe hypothermia (28 °C); drowning;
asphyxia because of hanging; burns on > 20% of TBSA; isolated penetrating head injury;
inability to obtain IV access; > 4 h between receipt of dispatch call to study intervention
Participant condition: traumatic brain injury
Baseline characteristics
Colloids group
• Age, mean (SD): 38.5 (± 18.6) years
• Gender, M:F: 86:273
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• BP, mean (SD): SBP: 141.2 (± 33.1) mmHg
Crystalloids group (NS)
• Age, mean (SD): 39.5 (± 19.2) years
• Gender, M:F: 156:426
• BP, mean (SD): SBP: 139.1 (± 33.1) mmHg
Crystalloids group (HS)
• Age, mean (SD): 38.6 (± 17.3) years
• Gender, M:F: 64:277
• BP, mean (SD): SBP: 136.9 (± 33.5) mmHg
Country: USA and Canada
Setting: 11 regional clinical centres
Interventions Colloids group
• Participants: n = 373; losses = 14 (5 did not meet inclusion criteria; 3 met an
exclusion criterion; 4 had no IV access; 1 fluid bag sterility broke; 1 EMS responder
unsure of inclusion/exclusion criteria); analysed = 359
• Details: 7.5% saline in 6% dextran 70; 250 mL
• Additional details: single bolus; all conducted out-of-hospital; participants may
have been given fluid before attendance of study personnel but must have only received
< 2 L of crystalloid and no colloid, mannitol or blood products
Crystalloids group (NS)
• Participants: n = 603; losses = 21 (8 did not meet inclusion criteria; 4 had
inadequate time to administer; 2 met an exclusion criterion; 4 had no IV access; 2 fluid
bag sterility broke; 1 EMS responder unsure of inclusion/exclusion criteria); analysed =
582
• Details: 0.9% saline; 250 mL
• Additional details: same as colloid group
Crystalloids group (HS)
• Participants: n = 355; losses = 14 (5 did not meet inclusion criteria; 1 met an
exclusion criterion; 6 had no IV access; 1 fluid bag sterility broke; 1 EMS responder
unsure of inclusion/exclusion criteria); analysed = 341
• Details: 7.5% saline; 250 mL
• Additional details: same as colloid group
Outcomes Outcomes measured/reported: 6-month neurologic status (Glasgow Outcome Score);
28-day survival; survival to discharge; ICP; interventions required tomanage intracranial
hypertension; fluid and bolus requirements in first 24 h; physiologic parameters of organ
dysfunction; 28-day ARDS-free survival; MODS; nosocomial infections
Outcomes relevant to the review: mortality (28 days)
Notes Funding/declarations of interest: National Heart, Lung and Blood Institute plus part-
ners
Study dates: May 2006-May 2009
Study terminated after futility criteria met at 6 months
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Randomly generated numeric code used at central
location
Allocation concealment (selection bias) Low risk Randomisation scheme conducted externally and all
personnel unaware of allocation
Blinding of participants and personnel
(performance bias): mortality
Low risk Quote: “Study fluids were provided in identical in-
travenous bags and shipped to a single distribution
center, where they were labelled with a randomly
generated numeric code”
Participants, caregivers, and outcome assessors were
blinded to treatment
Blinding of outcome assessment (detection
bias): mortality
Low risk Participants, caregivers, and outcome assessors were
blinded to treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Mortality data reported for 359/373 (HSD), 341/
355 (HS), and 582/603 (NS). < 5% dropout/loss in
each group
Selective reporting (reporting bias) Low risk Prospective clinical trials registration:
NCT00316004. All outcomes were prespecified
Baseline characteristics Low risk Baseline characteristics appear comparable





Participants Total number of randomised participants: 895
Inclusion criteria:≥ 15 years of age; in significant haemorrhagic shock (out-of-hospital
SBP ≤ 70 mmHg or 71-90 mmHg with concomitant HR ≤ 108 bpm)
Exclusion criteria: known or suspected pregnancy; < 15 years of age; out-of-hospital
cardiopulmonary resuscitation; administration of > 2000 mL crystalloid, colloid, or
blood products before enrolment; severe hypothermia (< 28 °C); drowning; asphyxia
because of hanging; burns > 20% TBSA; isolated penetrating head injury; inability to
obtain IV access; time of dispatch call received to study intervention > 4 h; known
prisoners
Participant condition: traumatic hypovolaemic shock
Baseline characteristics
Colloids group
• Age, mean (SD): 37.7 (± 17.3) years
• Gender, M:F: 170:50
• BP, mean (SD): SBP: 59.1 (± 35.5) mmHg
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• GCS, mean (SD): 10.0 (± 4.9)
Crystalloids group (NS)
• Age, mean (SD): 36.2 (± 16.4) years
• Gender, M:F: 291:85
• BP, mean (SD): SBP: 58.1 (± 32.2) mmHg
• GCS, mean (SD): 9.8 (± 5.0)
Crystalloids group (HS)
• Age, mean (SD): 36.8 (± 16.1) years
• Gender, M:F: 205:52
• BP, mean (SD): SBP: 54.1 (± 35.3) mmHg
• GCS, mean (SD): 10.0 (± 5.0)
Country: USA and Canada
Setting: out-of-hospital
Interventions Colloids group
• Participants: n = 231; losses = 0; analysed = 231
• Details: 7.5% saline in 6% dextran 70 (HSD); 250 mL bolus
• Additional details: bolus given in out-of-hospital setting; once study fluid had
been administered, additional fluids could be given as guided by local EMS protocols
Crystalloids group (NS)
• Participants: n = 395; losses = 0; analysed = 395
• Details: 0.9% NS; 250 mL bolus
• Additional details: same as colloid group
Crystalloids group (HS)
• Participants: n = 269; losses = 0; analysed = 269
• Details: 7.5% HS
• Additional details: same as colloid group
Outcomes Outcomes measured/reported: 28-day survival; physiologic parameters of organ dys-
function; ARDS criteria met in the first 28 days after injury; MODS; presence of noso-
comial infection
Outcomes relevant to the review: mortality (28 days); participants having transfusion
(0-9 units); participants having transfusion (> 10 units)
Notes Funding/declarations of interest:TheNationalHeart, Lung andBlood Institute. Study
authors declare no financial conflicts of interest
Study dates: May 2006-August 2008
Note: the previous version of this review did not include participants in the HS group
(Perel 2013). We have included outcome data for these participants, and in analysis we
have combined both crystalloid groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomly generated numeric code was ap-
plied to each bag and a randomization list kept by
the Data Co-ordinating Center”
Information taken from study protocol
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Allocation concealment (selection bias) Low risk Randomisation list kept by study investigators (taken
from study protocol)
Blinding of participants and personnel
(performance bias): mortality
Low risk Care providers, investigators, and participants were
blinded to treatment assignment, study fluids con-
cealed
Blinding of participants and personnel
(performance bias): transfusion/renal re-
placement therapy/adverse events
Low risk Care providers, investigators, and participants were
blinded to treatment assignment, study fluids con-
cealed
Blinding of outcome assessment (detection
bias): mortality
Low risk All personnel were blinded
Blinding of outcome assessment (detection
bias): transfusion/renal replacement ther-
apy/adverse events
Low risk All personnel were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 42/895participantswere not included in analysis but
reasons were clearly provided (most of these losses
were because of inclusion/exclusion criteria)
Selective reporting (reporting bias) Unclear risk A protocol was published for this study; publication
of protocol was retrospective and it was not feasible
to use this to assess risk of selective reporting bias
Baseline characteristics Low risk Baseline characteristics appear comparable
Other bias High risk We noted that participants may have received up to
2000 mL of crystalloid or colloid before randomi-
sation (as part of exclusion criteria). Study authors
did not report how many participants received fluid
resuscitation before randomisation, or which fluid






Participants Total number of randomised participants: 1810
Inclusion criteria: ≥ 18 years of age; severe sepsis within previous 24 h
Exclusion criteria: < 18 years of age; terminal state; known adverse reaction to albu-
min administration; severe sepsis or septic shock after proved or suspected head injury;
clinically active; congestive heart failure (NYHA class 3 or 4); pathological conditions
in which albumin administration was clinically indicated (hepatic cirrhosis with ascites,
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intestinal malabsorption syndrome, nephrotic syndrome, burns); > 24 h since inclusion
criteria were met; religious objection to the administration of human blood products;
inclusion in other experimental studies
Participant condition: severe sepsis
Baseline characteristics
Colloids group
• Age, median (IQR): 70 (57-77) years
• Gender, M:F: 543:360
• SAPS II, median (IQR): 48 (37-59)
Crystalloids group
• Age, median (IQR): 69 (59-77) years
• Gender, M:F: 550:357




• Participants: n = 903; losses = 0; analysed = 903
• Details: 20% albumin; 300 mL; fluids administered according to the “early-goal
directed therapy” protocol; administered from day 1 until day 28 or ICU discharge to
maintain serum concentration ≥ 30 g/L; given crystalloids whenever clinically
indicated by attending physician
• Additional details: all conducted out-of-hospital. Participants may have been
given fluid before attendance of study personnel, but had to have received < 2 L of
crystalloid and no colloid, mannitol or blood products
Crystalloids group
• Participants: n = 907; losses = 0; analysed = 907
• Details: no details of crystalloid solution or administration
• Additional details: same as colloid group
Outcomes Outcomes measured/reported: death from any cause (28 days); death from any cause
(90 days); number of participants with organ dysfunction; length of ICU and hospital
stay
Outcomes relevant to the review: mortality (at 28 days, and at 90 days); RRT
Notes Funding/declarations of interest: Italian Medicines Agency
Study dates: Aug 2008-Feb 2012
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed centrally,
with the use of the computer-generated and blinded
assignment sequence. Randomization was stratified
according to the participating ICU and the interval
between the time that the patient met the clinical
criteria for severe sepsis and randomization”
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Allocation concealment (selection bias) Low risk Central allocation, blinded
Blinding of participants and personnel
(performance bias): mortality
Low risk Open-label study; lack of blinding unlikely to intro-
duce bias for this outcome
Blinding of participants and personnel
(performance bias): transfusion/renal re-
placement therapy/adverse events
Unclear risk No details
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias for
this outcome
Blinding of outcome assessment (detection
bias): transfusion/renal replacement ther-
apy/adverse events
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk Few losses; unlikely to affect analysis
Selective reporting (reporting bias) Low risk Prospective clinical trials registration
(NCT00707122). All outcomes listed were reported
Baseline characteristics Unclear risk Quote: “Baseline characteristics were similar be-
tween the two study groups, except for a slight im-
balance in the number of patients with organ dys-
function and values of central venous oxygen satu-
ration”
It was not reported if these differences between
groups were at a level of statistical significance. We
were uncertain whether these differences might in-
fluence the results





Participants Total number of randomised participants: 49
Inclusion criteria: SBP ≤ 90 mmHg for < 1 h; normal ECG; written consent by
participant or first-degree relative
Exclusion criteria: pregnancy; renal, cardiac, or neurological diseases
Participant condition: haemorrhagic shock
Baseline characteristics
Colloids group
• Age, mean (range): 42 (22-76) years
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• Gender, M:F: 18:8
• BP, mean (SD): SBP: 64 (± 21); DBP: 32 (± 14) mmHg
Crystalloids group
• Age, mean (range): 42 (52-58 [sic]) years
• Gender, M:F: 14:9




• Participants: n = 26; losses = 0; analysed = 26
• Details: 7.5% NaCl in 6% dextran 60; 250 mL
• Additional details: all solutions were administered as soon as possible; 16
participants by peripheral vein; 10 participants via the intraosseous route;
supplementary isotonic saline fluid given to achieve SBP > 100 mmHg
Crystalloids group
• Participants: n = 23; losses = 0; analysed = 23
• Details: conventional RL
• Additional details: by peripheral vein; supplementary isotonic saline fluid given to
achieve SBP > 100 mmHg; dextran 40 given if necessary according to medical
judgement
Outcomes Outcomes measured/reported: haemodynamic variables; urinary output; GCS; mor-
tality (within 24 h)
Outcomes relevant to the review: mortality
Notes Funding/declarations of interest: none reported
Study dates: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were assigned to groups using random
numbers but no Additional details provided
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for this outcome
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for this outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
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Selective reporting (reporting bias) Unclear risk No details of clinical trials registration; not feasible
to assess risk of selective reporting bias
Baseline characteristics Low risk Baseline characteristics appear comparable
Other bias High risk Quote: “Dextran 40 was administered to the con-
trol group if necessary according to medical judge-
ment.” Study authors did not report the number of
participants in the crystalloid group who received
additional colloids and this may influence outcome





Participants Total number of randomised participants: 26
Inclusion criteria: admitted to a children’s medical centre; fever lasting 2-7 days; haem-
orrhagic manifestations; evidence of consumptive coagulopathy, a fall in platelet count,
prolonged bleeding, prolonged prothrombin time, or prolonged partial thromboplastin
time; evidence of plasma leakage; evidence of circulatory failure
Exclusion criteria: severe infection other than dengue haemorrhagic fever; protein-




• Age, mean (SD): 56.2 (± 22.86) months
• Gender, M:F: 6:5
Crystalloids group
• Age, mean (SD): 73.88 (± 28.66) months




• Participants: n = 11; losses = 1 (withdrawn from study because different fluid
management was required); analysed = 11 for mortality data; 10 for blood transfusion
data
• Details: 6% Haes-Steril given in doses of 10 mL/kg-20 mL/kg; doses repeated ≥
2-3 times until vital signs were restored to normal
• Additional details: once vital signs were restored, participants were given fluids
according to hospital ICU hydration protocol
Crystalloids group
• Participants: n = 16 ; losses = 3 (withdrawn from study because different fluid
management was required); analysed = 16 for mortality data; 13 for blood transfusion
data
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• Details: RL given in doses of 10 mL/kg-20 mL/kg; doses repeated ≥ 2-3 times
until vital signs were restored to normal
• Additional details: once vital signs were restored, participants were given fluids
according to hospital ICU hydration protocol
Outcomes Outcomes measured/reported: duration of control of shock, haematocrit level, length
of ICU stay, transfusion of blood products, frequency of recurrence of shock, mortality
Outcomes relevant to the review: mortality (time point not reported); transfusion of
blood products (FFP or packed red blood cells)
Notes Funding/declarations of interest: not reported
Study dates: June 2001-July 2001
Note: 3 out of 16 participants in the crystalloid group (18.75%) also received colloids
during the study period and this may have influenced study results
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomised method to allocate par-
ticipants, using alternating allocation to each
group
Allocation concealment (selection bias) High risk Not possible to conceal allocation because of
methods used to allocate participants
Blinding of participants and personnel
(performance bias): mortality
Low risk Personnel were not blinded; however, un-
likely to introduce bias for this outcome
Blinding of participants and personnel
(performance bias): transfusion/renal re-
placement therapy/adverse events
Unclear risk No details
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce
bias for this outcome
Blinding of outcome assessment (detection
bias): transfusion/renal replacement ther-
apy/adverse events
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk Four participants were excluded from some
analysis. Because mortality data were re-
ported for these participants we included
these in analysis
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration; not
feasible to assess risk of selective reporting
bias
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Baseline characteristics Low risk Baseline characteristics appear comparable
Other bias High risk 3 out of 16 participants in the crystalloid
group (18.75%) also received colloids dur-






Participants Total number of randomised participants: 42
Inclusion criteria: thermal burn of ≥ 20% TBSA; time elapsed since injury ≤ 12 h;
written informed consent from the participant or a suitable substitute decision maker;
availability of data regarding fluids administered before arrival at the study centre
Exclusion criteria:unlikely survival, defined as APACHE II score > 30 or predictedmor-
tality ≥ 90%; ventricular fibrillation; ventricular tachycardia; unstable angina; known
congestive heart failure or myocardial infarction within themonth before thermal injury;




• Age, median (95% CI): 36 (24-45) years
• Gender, M:F: 15:4
• Weight, median (95% CI): 80 (70-100) kg
• APACHE II, median (95% CI): 15 (11-27)
Crystalloids group
• Age, median (95% CI): 31 (25-39) years
• Gender, M:F: 21:2
• Weight, median (95% CI): 82 (75-90) kg




• Participants: n = 19; losses = 0; analysed = 19
• Details: 5% albumin; participants initially given basal rate of saline using
calculation; then given stabilisation rate (2 mL × body weight × TBSA%)/24 mL/h;
within first 24 h, followed by stabilisation phase for > 24 h until wound closure
• Additional details: participants received fluids through two independently
controlled infusions (BR and AFR) over two periods: not > 24 h after injury
(resuscitation phase) and > 24 h and injury (stabilisation phase); the use of synthetic
colloid starches for volume resuscitation was not permitted; conservative red cell and
blood product transfusion strategies were also recommended
Crystalloids group
• Participants: n = 23; losses = 0; analysed = 23
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• Details: RL as BR = (2 mL × body weight × TBSA%) − TFV/24 mL/h; and as
additional flow rate (2 mL x body weight x TBSA%)/24 mL/h; within first 24 h,
followed by stabilisation phase for > 24 h until wound closure
• Additional details: same as colloid group
Outcomes Outcomes measured/reported:MODS; mortality; duration of mechanical ventilation;
LoS in ICU; local infection events; systemic infection events; percentage of graft take;
oxygenation failure (PaO2-to-FiO2 ratio) (all evaluated up to and including Day 28)
Outcomes relevant to the review: mortality (28 days); blood transfusion
Notes Funding/declarations of interest: funded by Bayer Biologics, Canada
Study dates: June 1999-June 2001
Trial stopped early due to slow enrolment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list
Allocation concealment (selection bias) Low risk Sequentially numbered, sealed, opaque envelopes
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias for
this outcome
Blinding of participants and personnel
(performance bias): transfusion/renal re-
placement therapy/adverse events
High risk Quote: “Treatment fluid was given in an open label
fashion owing to differences in the physical proper-
ties (color, tendency to bubble) and medium of de-
livery (glass vials vs. polymer bags)”
Could introduce bias for blood transfusion outcome
Blinding of outcome assessment (detection
bias): mortality
Low risk Nodetails; lack of blinding unlikely to influence data
for mortality
Blinding of outcome assessment (detection
bias): transfusion/renal replacement ther-
apy/adverse events
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration; not feasible
to assess risk of selective reporting bias
Baseline characteristics Unclear risk Baseline characteristics and demographics were com-
parable between groups except for predicted mortal-
ity, which was greater in the colloid group (18.6%)
compared with the crystalloid group (9.4%)
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Cooper 2006 (Continued)





Participants Total number of randomised participants: 41
Inclusion criteria: adults; male and female; with hospital diagnosis of severe acute
pancreatitis
Exclusion criteria: history of allergy to HES; history of cardiac dysfunction or renal
insufficiency; pregnancy, malignancy or immunoinsufficiency; other colloids within 24
h; serum albumin < 25 g/L; likely death within 48 h. Also excluded those who died
within 72 h; received surgery during treatment period; severe adverse effects to HES
Participant condition: severe acute pancreatitis
Baseline characteristics
Colloids group
• Age, mean (SD): 45.6 (± 10.8) years
• Gender, M:F: 12:8
• APACHE II, mean (SD): 12.1 (± 10.8)
• BP, mean (SD): SBP: 134.9 (± 12.8) mmHg
Crystalloids group
• Age, mean (SD): 45.7 (± 11.1) years
• Gender, M:F: 12:9
• APACHE II, mean (SD): 10.7 (± 4.1)




• Participants: n = 20; losses = 0; analysed = 20
• Details: 6% HES 130/0.4, plus RL; RL given to both groups at 1 mL/kg/h-2 mL/
kg/h; HES infused at volume ratio of 1:3 compared with saline solution
• Additional details: rate and volume given to maintain haemodynamic stability
Crystalloids group
• Participants: n = 21; losses = 0; analysed = 21
• Details: RL; given at 1 mL/kg/h-2 mL/kg/h
• Additional details: same as colloid group
Outcomes Outcomes measured/reported: mortality (within-hospital stay); intra-abdominal pres-
sure; fluid balance; major organ complications; use of respirator; APACHE II score;
serum levels of inflammatory mediators
Outcomes relevant to the review: mortality (within-hospital stay)
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Du 2011 (Continued)
Notes Funding/declarations of interest: supported by Sichuan Province of Science and Tech-
nology Department Technology Support Project
Study dates: January 2008-November 2009
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-derived random number table
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for this outcome
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for this outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk We have included 1 participant that was excluded
from the study as this participant died therefore
providing relevant data for this review
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration; not feasible
to assess risk of selective reporting bias
Baseline characteristics Low risk Baseline characteristics appear comparable
Other bias High risk 57.1% of participants in the crystalloid group were
given colloids during the study period and we noted





Participants Total number of randomised participants: 25
Inclusion criteria:≥ 18 years of age; confirmed or suspected infection plus≥ 2 signs of
the systemic inflammatory response syndrome (definition of sepsis by American College
of Chest Physicians/Society of Critical Care Medicine criteria), and tissue hypoperfusion
(MAP < 65 mmHg despite a crystalloid fluid challenge of 20 mL/kg or blood lactate
concentration of ≥ 4 mmol/L)
Exclusion criteria: impossible to perform sublingual video-microscopy; < 18 years of
age; pregnancy; stroke; acute coronary syndrome; hydrostatic pulmonary oedema; sta-
tus asthmaticus; cardiac arrhythmias (as a main diagnosis); contraindication for central
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Dubin 2010 (Continued)
venous catheterisation; active gastrointestinal haemorrhage; seizures; drug intoxications;
burns; trauma; need of immediate surgery; terminal cancer; immunosuppression (organ
transplant or systemic illness); no resuscitation order; delayed admission to the intensive





• Age, mean (SD): 62 (± 21) years
• Gender, M:F: 8:4
Crystalloids group
• Age, mean (SD): 65 (± 12) years
• Gender, M:F: 7:6
Country: Argentina
Setting: 2 teaching ICUs
Interventions Colloids group
• Participants: n = 12; losses = 0; analysed = 12
• Details: 6% HES 130/0.4 (Voluven); early goal-directed therapy; administered to
achieve CVP 8-12 mmHg, MAP > 65 mmHg, and ScV02 ≥ 70%
• Additional details: up to 1500 mL fluids permitted
Crystalloids group
• Participants: n = 13; losses = 0; analysed = 13
• Details: 0.9% saline; early goal directed therapy: administered to achieve CVP 8-
12 mmHg, MAP > 65 mmHg, and ScV02 ≥ 70%
• Additional details: same as colloid group
Outcomes Outcomes measured/reported: heart rate; MAP; CVP; central venous gases and oxygen
saturations; microcirculatory variables; mortality
Outcomes relevant to the review: mortality (time point not reported)
Notes Funding/declarations of interest: supported by the grant PICT-2007-00912, Agencia
Nacional de Promoción Científica y Tecnológica, Argentina
Study dates: January 2006-August 2009
Note: data for mortality were not clearly reported in the study report. We have included
deaths of participants within 24 h and combined these with deaths reported in the study
report outcome table. The previous version of this review did not include mortality
outcome data (Perel 2013).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Simple randomization by the use of sealed
envelopes”
Insufficient details to allow judgement
Allocation concealment (selection bias) Unclear risk Sealed envelopes, but no mention of opaqueness, or
whether they were numbered sequentially
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Dubin 2010 (Continued)
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias for
this outcome
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias for
this outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk Study authors reported a small number of losses be-
cause of death. We included these as data for the
mortality outcome
Selective reporting (reporting bias) Unclear risk Clinical trials registration occurred after the start of
the study (NCT00799916); not feasible to assess risk
of selective outcome reporting bias
Baseline characteristics Low risk Baseline characteristics appear comparable





Participants Total number of randomised participants: 50
Inclusion criteria: 5-15 years of age; DSS; had not received IV fluid therapy during their current illness




• No baseline characteristics reported
Colloids group (gelatin)
• No baseline characteristics reported
Crystalloids group (RL)
• No baseline characteristics reported
Crystalloids group (NS)
• No baseline characteristics reported
Country: Vietnam
Setting: hospital
Interventions Colloids group (dextran)
• Participants: n = 12; losses = 0; analysed = 12
• Details: dextran 70 (60 g dextran in 0.9% saline); 20 mL/kg for first hour; 10 mL/kg for next hour; IV; in
packs of 500 mL; study fluids only given for 2 h then subsequent fluid given according to physician preference and
WHO guidelines
Colloids group (gelatin)
• Participants: n = 13; losses = 0; analysed = 13
• Details: Gelafundin, 35,000 Da; 20 mL/kg for first hour; 10 mL/kg for next h; IV; in packs of 500 mL; study
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Dung 1999 (Continued)
fluids only given for 2 h then subsequent fluid given according to physician preference and WHO guidelines
Crystalloids group (RL)
• Participants: n = 13; losses = 0; analysed = 13
• Details: RL solution; 20 mL/kg for first hour; 10 mL/kg for next h; IV; in packs of 500 mL; study fluids only
given for 2 h then subsequent fluid given according to physician preference and WHO guidelines
Crystalloids group (NS)
• Participants: n = 12; losses = 0; analysed = 12
• Details: 0.9% w/v saline and chloride; 20 mL/kg for first hour; 10 mL/kg for next h; IV; in packs of 500 mL;
study fluids only given for 2 h then subsequent fluid given according to physician preference and WHO guidelines
Outcomes Outcomes measured/reported: recovery from shock; duration of shock and number of episodes of shock; improve-
ments in cardiac output and haematocrit values; requirements for further fluid resuscitation
Outcomes relevant to the review: none
Notes Funding/declarations of interest: B Braun provided the fluids used in this study. Financial support from The
Wellcome Trust of Great Britain





Participants Total number of randomised participants: 18
Inclusion criteria: septic; critically ill; fluid infusion clinically indicated; pulmonary catheter already in place; patient
not overtly bleeding




• Age, mean (SD): 51 (± 21) years
• Gender, M:F: 5:4
• APACHE II, mean (SD): 19 (± 8)
Crystalloids group
• Age, mean (SD): 55 (± 17) years
• Gender, M:F: 6:3




• Participants: n = 9; losses = 0; analysed = 9
• Details: 5% albumin; fluid infusion to meet PAOP determined by clinician, which was mostly 15 mmHg
Crystalloids group
• Participants: n = 9; losses = 0; analysed = 9
• Details: NS; fluid infusion to meet PAOP determined by clinician, which was mostly 15 mmHg
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Ernest 1999 (Continued)
Outcomes Outcomes measured/reported:MAP, PAOP, cardiac index, arterial oxygen content, plasma albumin concentration,
PV and ECFV
Outcomes relevant to the review: none
Notes Funding/declarations of interest: none reported





Participants Total number of randomised participants: 25
Inclusion criteria: > 16 years of age; blunt or penetrating trauma; requiring IV fluid
resuscitation; arrival at trauma unit within 2 h of injury; RL as the only prehospital
infusion; no underlying illness or medication that would affect the patient’s coagulating
system




• Age, median (IQR): 30 (29-38) years
• Gender, M:F: 9:2
Crystalloids group
• Age, median (IQR): 30 (25-39) years




• Participants: n = 11; losses = 0; analysed = 11
• Details: Haemaccel; given fluid until fully resuscitated, with end point as stable
vital signs
Crystalloids group
• Participants: n = 14; losses = 0; analysed = 14
• Details: RL; given fluid until fully resuscitated, with end point as stable vital signs
Outcomes Outcomes measured/reported: bleeding times, prothrombin, thrombin, partial throm-
boplastin times, platelet count, secondary resuscitation
Outcomes relevant to the review: mortality (data from personal communication with
study authors; time point unknown)
Notes Funding/declarations of interest: “Hoechst SA for their independent grant and spon-
sorship for this research project”
Study dates: not reported
Note: we used mortality data reported in the previous version of this review (Perel 2013)
. These data were collected from personal communication with the study authors
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Evans 1996 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised but no further details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for this outcome
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for this outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration; not feasible
to assess risk of selective reporting bias
Baseline characteristics Low risk Baseline characteristics appear comparable





Participants Total number of randomised participants: 6997
Inclusion criteria: ≥ 18 years of age; treating clinician judged to require fluid admin-
istration to maintain or increase intravascular volume
Exclusion criteria: people admitted to ICU after cardiac surgery; liver transplantation;
treatment of burns
Participant condition: various ICU admissions (to include trauma, sepsis, ARDS)
Baseline characteristics
Colloids group
• Age, mean (SD): 58.6 (± 19.1) years
• Gender, M:F: 2073:1424
• APACHE II, mean (SD): 18.7 (± 7.9)
Crystalloids group
• Age, mean (SD): 58.5 (± 18.7) years
• Gender, M:F: 2124:1376
• APACHE II, mean (SD): 19.0 (± 8.0)
Country: Australia and New Zealand
Setting: hospital - 16 ICUs
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Finfer 2004 (Continued)
Interventions Colloids group
• Participants: n = 3497; losses = study authors reported loss of 26 participants
mostly because of withdrawal of surrogate consent; analysed = 3473
• Details: 4% albumin; volume determined by treating clinicians
• Additional details: until discharge, death or 28 days from randomisation
Crystalloids group
• Participants: n = 3500; losses = study authors reported loss of 41 participants
mostly because of withdrawal of surrogate consent; analysed = 3460
• Details: 0.9% NaCl; volume determined by treating clinicians
• Additional details: until discharge, death or 28 days from randomisation
Outcomes Outcomes measured/reported: all-cause mortality within 28 days, survival time during
first 28 days, proportion of participants with organ failure, duration of mechanical
ventilation, duration of renal-replacement therapy, duration of ICU and hospital stay
Outcomes relevant to the review: mortality (28 days), RRT (for subgroup of partici-
pants with severe sepsis)
Notes Funding/declarations of interest: Auckland District Health Board and the Health
Research Council of New Zealand
Study dates: November 2001-June 2003
Note: in the previous version of the review (Perel 2013), this study was called SAFE
2004.
This study reports a subgroup of participants who had severe sepsis (1218 participants;
603 in the albumin group, and 615 in the saline group). Data were available for RRT
for these participants and we have included this subgroup of participants in analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was carried out centrally with the
use of a minimisation algorithm; service accessed
through a secure website
Allocation concealment (selection bias) Low risk Used central randomisation by a third party
Blinding of participants and personnel
(performance bias): mortality
Low risk Blinding was maintained by use of identical 500 mL
bottles and cartons designed to mask fluid type and
administration sets
Blinding of participants and personnel
(performance bias): transfusion/renal re-
placement therapy/adverse events
Low risk Blinding was maintained by use of identical 500 mL
bottles and cartons designed to mask fluid type and
administration sets
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding provided; unlikely to intro-
duce bias for this outcome
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Finfer 2004 (Continued)
Blinding of outcome assessment (detection
bias): transfusion/renal replacement ther-
apy/adverse events
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data (on vital status) were missing for 1% of ran-
domised participants at 28 days, which is acceptable.
Some discrepancies with reported numbers of par-
ticipants analysed, but not significant
Selective reporting (reporting bias) Low risk Prospective clinical trials regis-
tration (ISRCTN76588266); all outcomes listed on
registration site were reported
Baseline characteristics Unclear risk We noted that the albumin group had a higher CVP
at baseline; we could not be certain whether this
imbalance might influence results. No other baseline
imbalances were noted
Other bias High risk Study authors reported that 3.9% of participants in
the saline group were given albumin in the previous
72 h; this represents few participants and it is not
likely to have introduced significant bias. However,
some participants were given additional resuscitation
fluids during the study period according to clinician
preference, and numbers for this were not reported.





Participants Total number of randomised participants: 79
Inclusion criteria: control of resuscitation obtained within 4 h of injury; all participants
admitted within 12 h of injury




• Age, mean (SD): 28 (± 7) years
Crystalloids group
• Age, mean (SD): 28 (± 8) years
Country: USA
Setting: Brooke Army Medical Center
83Colloids versus crystalloids for fluid resuscitation in critically ill people (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Goodwin 1983 (Continued)
Interventions Colloids group
• Participants: n = 40; losses = 0; analysed = 40
• Details: 2.5% albumin RL; during the first 24 h, fluid was administered at a rate
sufficient to stabilise vital signs and to produce a urinary output of 30 mL/h-50 mL/h
• Additional details: plasma volume was replaced on the second postburn day by
colloid equivalent to plasma in a dosage of 0.3 mL/kg body weight/% TBSA to 0.5
mL/kg body weight/% TBSA
Crystalloids group
• Participants: n = 39; losses = 0; analysed = 39
• Details: RL
• Additional details: same as colloids group
Outcomes Outcomes measured/reported: haemodynamic responses; mortality at end of follow-
up
Outcomes relevant to the review: mortality at end of follow-up
Notes Funding/declarations of interest: study authors state, “the opinions or assertions con-
tained herein are the private views of the authors and are not to be construed as official
or as reflecting the views of the Department of the Army or the Department of Defense”
Study dates: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants randomised using random numbers ta-
ble
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for this outcome
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for this outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses reported
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration; not feasible
to assess risk of selective reporting bias
Baseline characteristics Low risk Baseline characteristics are comparable
Other bias High risk All participants in the crystalloid group received
colloids after 24 h and this may have influenced
study results
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Participants Total number of randomised participants: 50
Inclusion criteria: trauma patients who met the criteria for haemorrhagic-hypovolaemic shock, with definitive signs
of external or internal haemorrhage in a prehospital setting; aged 18-60 years
Exclusion criteria: no details
Participant condition: haemorrhagic-hypovolaemic shock
Baseline characteristics
Colloids group
• No baseline characteristics reported
Crystalloids group




• Participants: n = 25; losses = 0; analysed = 25
• Details: 10% HES plus 7.5% NaCl solution; 4 mL/kg 7.5% NaCl followed by 500 mL HES
Crystalloids group
• Participants: n = 25; losses = 0; analysed = 25
• Details: 0.9% NaCl solution; 2000 mL 0.9% NaCl
Outcomes Outcomes measured/reported: BP, pulse rate, peripheral oxygen saturation, and respiration rate
Outcomes relevant to the review: none
Notes Funding/declarations of interest: none reported





Participants Total number of randomised participants: 196
Inclusion criteria: ≥ 18 years of age; required fluid resuscitation; clinically defined
severe sepsis
Exclusion criteria: serum creatinine > 300 µmol/L; chronic renal failure; anuria lasting
> 4 h; requirement for renal support
Participant condition: severe sepsis
Baseline characteristics
Colloids group
• Age, mean (SD): 65.8 (± 15.4) years
• Gender, M:F: 64:36
• SOFA, mean: 7.9
Crystalloids group
• Age, mean (SD): 65.9 (± 14.7) years
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Guidet 2012 (Continued)
• Gender, M:F: 57:39
• SOFA, mean: 9.1
Country: France and Germany
Setting: hospital
Interventions Colloids group
• Participants: n = 100; losses = 0; analysed = 100
• Details: 6% HES 130/0.4; maximum dose 50 mL/kg/day on day 1, then 25 mL/
kg/day from day 2-day 4; to ensure sufficient hydration, additional crystalloid
infusions given in ratio of 1:2
Crystalloids group
• Participants: n = 96; losses = 1; analysed mortality = 95; analysed RRT = 96
• Details: 0.9% NaCl; maximum dose 50 mL/kg/day on day 1, then 25 mL/kg/day
from day 2-day 4; to ensure sufficient hydration, additional crystalloid infusions given
in ratio of 1:2
Outcomes Outcomes measured/reported: amount of study drug to achieve haemodynamic sta-
bilisation; time to achieve initial haemodynamic stabilisation; quantity of study drug
infused over 4 consecutive days; LoS in ICU and hospital; SOFA scores; kidney injury
(RIFLE and AKIN scores); mortality (28 days and 90 days); blood transfusion; adverse
events (itching)
Outcomes relevant to the review: mortality (28 days); blood transfusion (red blood
cells); RRT (score of 3 using AKIN); adverse events (itching)
Notes Funding/declarations of interest: supported by grant from Fresenius Kabi, Germany.
The pharmaceutical company was involved in the study design, analysis and preparation
of the report
Study dates: not reported
Note: the previous version of this review (Perel 2013) used mortality data at 90 days; in
this review we have analysed mortality data at 28 days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Refers to reference from Myburgh 2012 to describe
randomisation technique. Used external web-based
randomisation
Allocation concealment (selection bias) Low risk Use ofweb-based system ensured that allocation code
was kept concealed
Blinding of participants and personnel
(performance bias): mortality
Low risk Participants and personnel were blinded. Study
drugs were kept in identical packaging
Blinding of participants and personnel
(performance bias): transfusion/renal re-
placement therapy/adverse events
Low risk Participants and personnel were blinded. Study
drugs were kept in identical packaging
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Blinding of outcome assessment (detection
bias): mortality
Low risk Reference fromMyburgh 2012 suggests that all per-
sonnel were blinded, including outcome assessors
Blinding of outcome assessment (detection
bias): transfusion/renal replacement ther-
apy/adverse events
Low risk Reference fromMyburgh 2012 suggests that all per-
sonnel were blinded, including outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk One participant was unaccounted for in saline group
for mortality outcome only, unlikely to influence
outcome data overall
Selective reporting (reporting bias) High risk Prospective clinical trials
registration (NCT00464204). Clinical trials regis-
tration documents do not list mortality, transfusion
of blood products, or RRT as study outcomes. Clin-
ical trials registration documents title of the study is
“Effects of voluven on hemodynamics and tolerabil-
ity of enteral nutrition in patients with severe sepsis”
and some outcomes relate to assessment of caloric
intake
Baseline characteristics Low risk Baseline characteristics appear comparable





Participants Total number of randomised participants: 172
Inclusion criteria: admitted during acute phase, with burns for which treatment for
shock was indicated; adults and children




• Age, median (5% and 95% percentiles): 20 (1 and 71) years
• Weight, median (5% and 95% percentiles): 54 (10 and 85) kg
Crystalloids group
• Age, median (5% and 95% percentiles): 24 (1 and 66) years
• Weight, median (5% and 95% percentiles): 65 (11 and 90) kg
Country: Denmark
Setting: hospital
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Hall 1978 (Continued)
Interventions Colloids group
• Participants: n = 86; losses = 0; analysed = 86
• Details: 6% dextran 70 in 0.9% NaCl; 120 mL/% TBSA; in first 48 h
• Additional details: plus metabolic water requirements (orally or IV); participants
could drink freely during the shock phase
Crystalloids group
• Participants: n = 86; losses = 0; analysed = 86
• Details: RL; 4 mL RL/% TBSA/kg body weight in first 24 h; during next 24 h,
indicator formula for fluid administration was 10% of body weight before the burn
• Additional details: same as colloid group
Outcomes Outcomes measured/reported: fluid input and output, haemoglobin levels, mortality
Outcomes relevant to the review: mortality (48 h)
Notes Funding/declarations of interest: supported by grant from Danish Medical Research
Council
Study dates: not reported, the last participant was recruited in December 1975
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were stratified according to burn sever-
ity and type and then lots were used to determine
which treatment the first participant in each stra-
tum received
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for this outcome
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for this outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data are reported for all randomised participants
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or pre-pub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Low risk Baseline characteristics appear comparable
Other bias Low risk No other sources of bias identified
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Participants Total number of randomised participants: 19
Inclusion criteria: witnessed cardiac arrest with probable cardiac cause; advanced med-
ical life support within 15 min; return of spontaneous circulation within 60 min; co-
matose when admitted to the hospital; aged 18-80 years
Exclusion criteria: terminal illness; strongly in need of nursing; primary coagulopathy;
prehospital fluid load > 2000 mL
Participant condition: postcardiac arrest
Baseline characteristics
Colloids group
• Age, median (range): 60 (48-74) years
• Gender, M:F: 8:2
Crystalloids group
• Age, median (range): 60 (22-75) years




• Participants: n = 10; losses = 0; analysed = 10
• Details: hypertonic colloid 7.2% NaCl with 6% HES 200/0.5 (volume ratios not
reported); fluid given to achieve standardised treatment parameters
• Additional details: HS with HES limited to 500 mL/24 h (20 mL/h); further
needs for fluid were met by Ringer’s acetate/saline 9 mg/mL; all participants who
returned to spontaneous circulation and remained unconscious were cooled to 33 °C
using a Coolgard catheter.
Crystalloids group
• Participants: n = 9; losses = 0; analysed = 9
• Details: Ringer’s acetate and saline 9 mg/mL; fluid given to achieve standardised
treatment parameters
• Additional details: further needs for fluid were met by Ringer’s acetate/saline 9
mg/mL; all participants who returned to spontaneous circulation and remained
unconscious were cooled to 33 °C using a Coolgard catheter.
Outcomes Outcomes measured/reported: fluid volume required to achieve treatment goals;
oedema; haemodynamics; adverse events (to include renal failure); survival after 1 year
Outcomes relevant to the review: survival after 1 year
Notes Funding/declarations of interest: supported by grant from the Regional Centre for
EmergencyMedical Research andDevelopment andDevelopment and Section of Emer-
gency Medicine, Dept of Anaesthesia and Intensive Care, Haukeland University Hospi-
tal
Study dates: September 2005-March 2007
Risk of bias
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Heradstveit 2010 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study authors report use of stratified randomisa-
tion, with allocation generated by study authors.
We could not be certain whether this method was
sufficient
Allocation concealment (selection bias) Unclear risk Numbered envelopes were distributed and opened
by a physician after participant enrolment. Study
authors donot reportwhether envelopeswere sealed
or opaque
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding of physician; unlikely to in-
troduce bias for this outcome
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for this outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration; not feasible
to assess risk of selective reporting bias
Baseline characteristics Low risk Baseline characteristics are comparable





Participants Total number of randomised participants: 115
Inclusion criteria: penetrating or blunt trauma; requiring > 3 L of volume resuscitation;
18-60 years of age
Exlusion criteria: fluid overload pulmonary oedema; known allergy to HES; known
pre-existing renal failure with oliguria or anuria; receiving dialysis treatment before the
injury; severe hypernatraemia or hyperchloraemia on admission; severe head injury from
which recovery was unlikely; severe intracranial bleeding; severe crush injury; arterial
pressure unresponsive to 2 L IV fluid loading which could not be recorded; clinically
obvious cardiac tamponade; neurogenic shock (high spinal cord injury); known AIDS
or AIDS-related complex; admitted > 6 h after injury; people who had already received
any colloid before randomisation; taking part in another clinical trial at the same time;
refused consent
Participant condition: penetrating or blunt trauma
Baseline characteristics
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Colloids group (penetrating trauma HES)
• Age, mean (range): 27.6 (18-49) years
• Gender, M:F: 33:3
• Weight, mean (SD): 72.2 (± 7.6) kg
Crystalloids group (penetrating trauma saline)
• Age, mean (range): 32.6 (21-56) years
• Gender, M:F: 27:4
• Weight, mean (SD): 77.4 (± 13.7) kg
Colloids group (blunt trauma HES)
• Age, mean (range): 33 (18-50) years
• Gender, M:F: 15:5
• Weight, mean (SD): 76.8 (± 14.4) kg
Crystalloids group (blunt trauma saline)
• Age, mean (range): 35.7 (20-58) years
• Gender, M:F: 15:7
• Weight, mean (SD): 78.8 (± 13.6) kg
Country: South Africa
Setting: hospital, level 1 trauma centre
Interventions Colloids group (penetrating trauma HES + blunt trauma HES)
• Participants: randomised = 58; losses = 2 (prior colloids = 1; severe head injury = 1
(died)); analysed for mortality = 58; analysed for RRT = 56
• Details: 6% HES 130/0.4; given according to predetermined algorithm;
resuscitation complete when haemodynamic and renal targets achieved and sustained
• Additional details: severely injured participants received a maximum of 2 L of
crystalloids before randomisation; participants given adrenaline (epinephrine) for
vasoactive support if required
Crystalloids group (penetrating trauma saline + blunt trauma saline)
• Participants: randomised = 57; losses = 4 (under age = 2; protocol violation = 1;
unresponsive BP = 1 (died)); analysed for mortality = 57; analysed for RRT = 53
• Details: 0.9% NS; given according to predetermined algorithm; resuscitation
complete when haemodynamic and renal targets achieved and sustained
• Additional details: same as colloid group
Outcomes Outcomes measured/reported: volumes of study fluid in first 24 h; number of partic-
ipants achieving normal gastrointestinal function by day 5; mortality; serious adverse
events; acute renal injury; dialysis; use of blood products; biochemical abnormalities;
days in ICU; days on ventilator support, SOFA scores, TEGmeasurements, skin itching
Outcomes relevant to the review: mortality (time point unknown), dialysis
Notes Funding/declarations of interest: funding from Fresenius-Kabi, who also supplied
study fluids. Funders had no input into study design, analysis, interpretation etc. Also
funds from TEG and laboratory investigations derived from Dept of Anaesthesia, UCT,
research funds
Study dates: not reported
Study authors stratified data according to whether participants had penetrating or blunt
trauma injuries. We have combined both types of injuries in analysis
Note: we used mortality data reported in the previous version of this review (Perel 2013)
. These data were collected from personal communication with the study authors
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used random numbers in blocks of 8 for each cat-
egory of trauma
Allocation concealment (selection bias) Low risk Fluids prepacked by pharmacy, and we have as-
sumed that, therefore, allocation was concealed
from personnel
Blinding of participants and personnel
(performance bias): mortality
Low risk Study fluids were presented in identical black bags
Blinding of participants and personnel
(performance bias): transfusion/renal re-
placement therapy/adverse events
Low risk Study fluids were presented in identical black bags
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for this outcome
Blinding of outcome assessment (detection
bias): transfusion/renal replacement ther-
apy/adverse events
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk Few losses, and reasons were reported by study au-
thors
Selective reporting (reporting bias) Unclear risk Retrospective clinical trials registration (ISRCTN
42061860); so not feasible to assess risk of selective
reporting bias from these documents
Baseline characteristics Unclear risk Injury severity scores were higher in the colloids
group. We could not be certain whether this could
influence outcome data





Participants Total number of randomised participants: 19
Inclusion criteria: 20%-98% TBSA; selected when, within 15 min, precise time of
burn injury and intake and output experienced by patient from time of injury to time
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of admission was known




• Age, mean (SE): 47 (± 5.6) years
• Weight, mean (SE): 97 (± 7.4) kg
Crystalloids group (RL)
• Age, mean (SE): 34 (± 5.3) years
• Weight, mean (SE): 83 (± 1.4) kg
Crystalloids group (HS)
• Age, mean (SE): 52 (± 12.7) years




• Participants: n = 7; losses = 0; analysed = 7
• Details: hypertonic solution with albumin; hypertonic solution - 240 mEq
sodium and 120 mEq each of chloride and lactate; 12.5 g albumin added to each litre;
to maintain MAP ≥ 60 to ≤ 110 mmHg with a urine flow of 30 mL/h-50 mL/h
• Additional details: resuscitation complete when MAP stable at 70 mmHg-110
mmHg; urine output stable at 40 mL/h-50 mL/h; lactic acid was ≤ 2 mg or fluid needs
could be met by mouth; absolute BP and pulse rate were not criteria of concern for this
group
Crystalloids group (RL)
• Participants: n = 7; losses = 0; analysed = 7
• Details: RL; to maintain MAP ≥ 60 to ≤ 110 mmHg with a urine flow of 30
mL/h-50 mL/h
• Additional details: resuscitation complete when urine flow of at least 40 mL/h;
pulse rate ≤ 110/min and elevation of SBP and DBP into premorbid normal range for
participant
Crystalloids group (HS)
• Participants: n = 5; losses = 0; analysed = 5
• Details: 240 mEq Na 120 mEq Cl; to maintain MAP ≥ 60 mmHg to ≤ 110
mmHg with a urine flow of 30 mL/h-50 mL/h
• Additional details: resuscitation complete when MAP stable at 70 mmHg-110
mmHg; urine output stable at 40 mL/h-50 mL/h; lactic acid was ≤ 2 mg or fluid needs
could be met by mouth
Outcomes Outcomes measured/reported: fluid volume; clinical results; laboratory results; urine
variables (including renal failure); serum osmolality; sodium and potassium levels; car-
diorespiratory and haemodynamic variables
Outcomes relevant to the review: mortality (time point not reported)
Notes Funding/declarations of interest: supported in part by National Institutes of Health
Grant
Study dates: January 1977-March 1978
In the previous version of the review (Perel 2013), the study ID was Jelenko 1978
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Described as randomised. No additional details but
significant details in baseline demographics which
would suggest an insufficient method of randomi-
sation
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias): mortality
Low risk No details; lack of blinding unlikely to influence
data for this outcome
Blinding of outcome assessment (detection
bias): mortality
Low risk No details; lack of blinding unlikely to influence
data for this outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics High risk Statistically significant differences between groups
for baseline characteristics





Participants Total number of randomised participants: 84
Inclusion criteria: 18-85 years of age; meet criteria for septic shock; resuscitation within
6 h with crystalloid or HES≥ 30 mL/kg; within 24 h no packed red blood cells, plasma
or other blood products that would affect coagulation and fibrinolysis significantly; no
unauthorised drugs; no previous coagulation disorders
Exclusion criteria: severe heart failure; bleeding occurring during resuscitation and
requiring the use of blood products; serious renal insufficiency
Participant condition: septic shock
Baseline characteristics
Colloids group
• Age, mean (SD): 65.7 (± 15.1) years
• Gender, M:F: 16:28
• Weight, mean (SD): 65.9 (±12.0) kg
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• APACHE II, mean (SD): 27.9 (± 5.9)
Crystalloids group
• Age, mean (SD): 64.7 (± 13.7) years
• Gender, M:F: 14:26
• Weight, mean (SD): 66.6 (± 11.3) kg




• Participants: randomised = 44; losses = 0; analysed = 44
• Details: HES 130/0.4
Crystalloids group
• Participants: randomised = 40; losses = 0; analysed = 40
• Details: RL
Outcomes Outcomes measured/reported: prothrombin time, tissue factor, tissue factor pathway
inhibitor, active protein C, LoS in ICU, mortality
Outcomes relevant to the review: mortality (time point unknown)
Notes Funding/declarations of interest: none reported
Study dates: November 2009-October 2014
Article in Chinese. Data for study characteristics taken from English abstract, and from
study report tables, with translation using Google Translate
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised. Data for ’Risk of bias’
assessment taken from English abstract only
Allocation concealment (selection bias) Unclear risk No details. Data for ’Risk of bias’ assessment taken
from English abstract only
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for this outcome
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for this outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk Data for ’Risk of bias’ assessment taken from En-
glish abstract only. No details of clinical trials reg-
istration in English abstract
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Baseline characteristics Low risk Baseline characteristics appeared largely compara-
ble
Other bias Unclear risk We could not be certain of other risks of bias be-






Participants Total number of randomised participants: 105
Inclusion criteria: perforation peritonitis; 18-60 years of age
Exclusion criteria: pregnancy; known allergies or manifesting symptoms of possible
anaphylaxis with test dose of HES; major coagulation disorders; renal failure because of
medical renal disease; severe hepatic insufficiency; congestive cardiac failure at admission;
traumatic perforation cases; < 18 years of age or > 60 years of age; people who had been
resuscitated before reaching emergency surgical unit; denied consent
Participant condition: perforation peritonitis
Baseline characteristics
Colloids group
• Age, mean (SD): 35.75 (± 11.84) years
• Gender, M:F: 50:5
• Physiological score, mean (SD): 27.73 (± 7.50)
Crystalloids group
• Age, mean (SD): 33.44 (± 13.08) years
• Gender, M:F: 47:5




• Participants: n = 55; losses = 0; analysed = 55
• Details: 6% HES 130/0.4; at a rate of 15 mL/kg body weight/h; up to a total dose
of 30 mL/kg body weight; after presentation for surgery, before start of emergency
laparotomy
• Additional details: test dose 10 mL-20 mL HES given slowly whilst observing for
possible anaphylactic response; participants who had anuria or oliguria were given 1 L
crystalloids IV within 30-60 min to improve urine output; if urine output did not
improve, participants were given 40 mg furosemide, and if this did not improve urine
output then participants were excluded; also given crystalloids as required
Crystalloids group
• Participants: n = 52; losses = 0; analysed = 52
• Details: RL; amount and rate determined by participant condition
• Additional details: participants who had anuria or oliguria were given 1 L
crystalloids IV within 30-60 min to improve urine output; if urine output did not
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improve, participants were given 40 mg furosemide, and if this did not improve urine
output then participants were excluded; also given crystalloids as required
Outcomes Outcomes measured/reported: time to achieve goals of fluid resuscitation, morbidity,
mortality, length of hospital stay, complications attributable to type of fluid administra-
tion
Outcomes relevant to the review: mortality (up to 30 days from hospital discharge)
Notes Funding/declarations of interest: no funding and no conflicts of interest
Study dates: October 2006-April 2009
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomised with the help of
computer-generated random table”
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for this outcome
Blinding of outcome assessment (detection
bias): mortality
Low risk Quote: “Administered the fluid therapy according
to randomisation without knowledge of the ob-
server”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Unclear risk We noted differences in physiological scores be-
tween groups. We could not be certain whether this
difference could influence the outcome data
Other bias High risk Note the length of time since completion of trial,
and publication of full study report. Also, note that
the study was reported by a single author
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Participants Total number of randomised participants: 60
Inclusion criteria: not reported in abstract
Exclusion criteria: not reported in abstract
Participant condition: patients with septic shock
Baseline characteristics
Colloids group (HES)
• Age, mean (SD): 44.8 (± 23.7) years
• Gender, M:F: 10:5
• BP, mean (SD): SBP: 78.33 (± 10.03) mmHg; DBP: 47.87 (± 8.84) mmHg
Colloids group (HES with HS)
• Age, mean (SD): 46.0 (± 22.2) years
• Gender, M:F: 10:5
• BP, mean (SD): SBP: 78.80 (± 8.94) mmHg; DBP: 43.53 (± 6.35) mmHg
Crystalloids group (NS)
• Age, mean (SD): 38.6 (± 19.5) years
• Gender, M:F: 11:4
• BP, mean (SD): SBP: 80.93 (± 4.35) mmHg; DBP: 40.93 (± 6.22) mmHg
Crystalloids group (HS)
• Age, mean (SD): 50.2 (± 28.4) years
• Gender, M:F: 10:5
• BP, mean (SD): SBP: 79.60 (± 5.41) mmHg; DBP: 42.00 (± 4.42) mmHg
Country: China
Setting: hospital
Interventions Colloids group (HES)
• Participants: n = 15; losses = 0; analysed = 15
• Details: HES
• Additional details: no additional details in abstract
Colloids group (HES with HS)
• Participants: n = 15; losses = 0; analysed = 15
• Details: hypertonic sodium chloride HES 40 solution
• Additional details: no additional details in abstract
Crystalloids group (NS)
• Participants: n = 15; losses = 0; analysed = 15
• Details: NS
• Additional details: no additional details in abstract
Crystalloids group (HS)
• Participants: n = 15; losses = 0; analysed = 15
• Details: 4% NaCl
• Additional details: no additional details in abstract
Outcomes Outcomes measured/reported: haemodynamic parameters, blood lactate clearance,
mortality (at 28 days)
Outcomes relevant to the review: mortality
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Notes Funding/declarations of interest: not reported in abstract
Study dates: not reported in abstract
Article in Chinese. Data for study characteristics taken from English abstract, and from
study report tables, with translation using Google Translate
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Risk of bias’ assessment made using English ab-
stract only. Described as randomised, no additional
detail
Allocation concealment (selection bias) Unclear risk No details. ’Risk of bias’ assessment made using
English abstract only
Blinding of participants and personnel
(performance bias): mortality
Low risk No details. ’Risk of bias’ assessment made using En-
glish abstract only. However, lack of blinding un-
likely to introduce bias for mortality
Blinding of outcome assessment (detection
bias): mortality
Low risk No details. ’Risk of bias’ assessment made using En-
glish abstract only. However, lack of blinding un-
likely to introduce bias for mortality
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias. ’Risk of bias’ assessment
made using English abstract only
Baseline characteristics Low risk Baseline characteristics appeared largely compara-
ble
Other bias Unclear risk We could not be certain about other risks of bias






Participants Total number of randomised participants: 141
Inclusion criteria: people undergoing laparotomy for acute abdominal trauma
Exclusion criteria: associated chest injury
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Participant condition: laparotomy for acute abdominal trauma
Baseline characteristics
Colloids group
• Age, mean (SD): 32.3 (± 12.5) years (data for 2 participants missing)
• Gender, M:F: 52:3 (data for 2 participants missing)
Crystalloids group
• Age, mean (SD): 27.6 (± 9.6) (data for 2 participants missing) years
• Gender, M:F: 73:9 (data for 2 participants missing)
Country: USA
Setting: hospital, trauma unit
Interventions Colloids group
• Participants: randomised = 57; losses = 0; analysed = 57 (see note below)
• Details: human serum albumin; 50 g albumin in 200 mL fluid with each litre of
RL
• Additional details: to maintain normal pulse rate and BP, urine output > 50 mL/
h, and a haematocrit of 29%-35%
Crystalloids group
• Participants: randomised = 84; losses = 0; analysed = 84 (see note below)
• Details: RL
• Additional details: to maintain normal pulse rate and BP, urine output > 50 mL/
h, and a haematocrit of 29%-35%
Outcomes Outcomes measured/reported: red blood cell transfusions, urine output, mortality,
ventilator support, pulmonary function test variables
Outcomes relevant to the review: mortality (at 28 days); blood transfusion (0-9 units)
Notes Funding/declarations of interest: supported by a grant formUSArmyMedical Research
and Development Command
Study dates: not reported
Note: we edited the number of randomised participants in each group as reported in the
previous version of this review (Perel 2013); we did not include participants who were
excluded because of chest injury
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk The use of cards in sealed envelopes is an appropri-
ate method of randomisation but additional details
are required. It is unclear why there was a difference
in participant numbers between groups once those
with chest injuries were excluded. The study author
provided an explanation following the discussion
but it is possible that the study was not truly ran-
domised
Allocation concealment (selection bias) Unclear risk No details
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Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Blinding of participants and personnel
(performance bias): transfusion/renal re-
placement therapy/adverse events
Unclear risk No details
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for this outcome
Blinding of outcome assessment (detection
bias): transfusion/renal replacement ther-
apy/adverse events
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk Study authors reported exclusion of 30 participants
because of chest injury, and the reported results are
for the remaining 141 participants. We have as-
sumed that these 30 participants were not ’lost’ but
were excluded because of prespecified exclusion cri-
teria, We noted missing data in the baseline char-
acteristics for 4 participants; this loss was not ex-
plained, but we did not expect it to influence out-
come data
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or a prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Low risk Baseline characteristics appeared comparable





Participants Total number of randomised participants: 42
Inclusion criteria: septic shock; admitted to ICU
Exclusion criteria: no details
Participant condition: septic shock
Baseline characteristics
Colloids group
• Age, mean (SD): 65.7 (± 15.1) years
• Gender, M:F: 8:14
Crystalloids group
• Age, mean (SD): 64.7 (± 13.7) years
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• Participants: n = 22; losses = 0; analysed = 22
• Details: HES 130/0.4
Crystalloids group
• Participants: n = 20; losses = 0; analysed = 20
• Details: RL
Outcomes Outcomes measured/reported: prothrombin time, activated partial thromboplastin
time, plasma tissue plasminogen activator, plasminogen activator inhibitor, length of
ICU stay, mortality, fluid volume, vasoactive drugs
Outcomes relevant to the review: mortality (time point not reported)
Notes Funding/declarations of interest: not reported in abstract
Study dates: September 2009-June 2011
Article in Chinese. Data for study characteristics taken from English abstract, and from
study report tables, with translation using Google Translate
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; no additional details.
’Risk of bias’ assessment made using English ab-
stract only
Allocation concealment (selection bias) Unclear risk No details. ’Risk of bias’ assessment made using
English abstract only
Blinding of participants and personnel
(performance bias): mortality
Low risk ’Risk of bias’ assessment made using English ab-
stract only. No details of blinding; unlikely to in-
troduce bias for mortality
Blinding of outcome assessment (detection
bias): mortality
Low risk ’Risk of bias’ assessment made using English ab-
stract only. No details of blinding; unlikely to in-
troduce bias for mortality
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or a prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias. ’Risk of bias’ assessment
made using English abstract only
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Baseline characteristics Low risk Baseline characteristics appeared comparable
Other bias Unclear risk We could not be certain about other risks of bias






Participants Total number of randomised participants: 52
Inclusion criteria: serious injuries requiring multiple transfusions
Exclusion criteria: no details
Participant condition: hypovolaemic shock
Baseline characteristics
Colloids group
• Age, mean (SD): 33 (± 14.7) years
• BP, mean (SD): SBP: 79.8 (± 36.4) mmHg
Crystalloids group
• Age, mean (SD): 33.8 (± 11.5) years




• Participants: n = 27; losses = 0; analysed = 27 (see notes)
• Details: salt-poor albumin; 150 g during operation then 150 g/d over the next 5
days
Crystalloids group
• Participants: n = 25; losses = 0; analysed = 25 (see notes)
• Details: standard regimen of balanced electrolyte solution, blood and FFP
Outcomes Outcomes measured/reported: fluid volumes - input and output, protein variables,
serum protein variables
Outcomes relevant to the review: mortality (time point not reported)
Notes Funding/declarations of interest: supported by the Detroit General Hospital Research
Corporation
Study dates: November 1975-February 1977
Note:We found adiscrepancy between the study reports for Lucas 1978. A later published
report (Lucas 1980) covers a longer time period, with a larger number of randomised
participants. Lucas 1980 reports 5 deaths (3 in the albumin group and 2 in the crystalloid
group). The earlier report, Lucas 1978, is for fewer participants and reports 7 deaths in
the albumin group, and no deaths in the crystalloid group. We have used data from the
earlier report because this was used in the previous published version of the review (Perel
2013). We assessed this decision in sensitivity analysis
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Randomisation decision was based on last
digit of each participant’s case number
Allocation concealment (selection bias) High risk Randomisation decision was based on last
digit of each participant’s case number
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce
bias for mortality
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce
bias for mortality
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk Nodetails of clinical trials registration or pre-
published protocol; not feasible to assess risk
of selective outcome reporting bias
Baseline characteristics Low risk Baseline characteristics appeared comparable
Other bias High risk We were concerned by differences in the re-
ported number of deaths in the associated





Participants Total number of randomised participants: 56
Inclusion criteria: febrile neutropenic patients with severe sepsis and septic shock
Exclusion criteria: no details
Participant condition: severe sepsis; septic shock
Baseline characteristics
Colloids group
• No baseline characteristics reported
Crystalloids group
• No baseline characteristics reported
Country: Saudi Arabia
Setting: hospital
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Interventions Colloids group
• Participants: n = 30; losses = unclear; analysed for mortality = unclear; analysed
for RRT = 30
• Details: HES 130/0.4 (Voluven)
Crystalloids group
• Participants: n = 26; losses = unclear; analysed for mortality = unclear; analysed
for RRT = 26
• Details: RL
Outcomes Outcomes measured/reported: acute renal failure, need for RRT, 28-day mortality
Outcomes relevant to the review: mortality (at 28 days), RRT
Notes Funding/declarations of interest: none reported
Study dates: not reported
Abstract only.We did not include mortality data from this report, which were reported as
percentages; we could not be certainwhether the datawere for all randomised participants
or whether some participant data were lost (crystalloid group: 63.4%; colloid group: 73.
3%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomly assigned, no additional
details. Abstract only
Allocation concealment (selection bias) Unclear risk No details. Abstract only
Blinding of participants and personnel
(performance bias): mortality
Low risk Abstract only. However, lack of blinding unlikely
to introduce bias for mortality
Blinding of participants and personnel
(performance bias): transfusion/renal re-
placement therapy/adverse events
Unclear risk No details. Abstract only
Blinding of outcome assessment (detection
bias): mortality
Low risk Abstract only. However, lack of blinding unlikely
to introduce bias for mortality
Blinding of outcome assessment (detection
bias): transfusion/renal replacement ther-
apy/adverse events
Unclear risk No details. Abstract only
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Abstract only. We could not be certain whether this
study had participant losses for mortality because
of apparent discrepancies in reported data in the
abstract
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Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Unclear risk Not possible to assess baseline characteristics from
abstract






Participants Total number of randomised participants: 117
Inclusion criteria: children with clinical feature of severe malaria; Plasmodium falci-
parum parasitaemia; metabolic acidosis with base deficit of > 8 mmol/L; haemoglobin
concentration of > 50 g/L
Exclusion criteria:pulmonary oedema; oedematousmalnutrition; papilledema; parental
refusal of consent
Participant condition: severe malaria
Baseline characteristics
Colloids group
• No baseline characteristics reported
Crystalloids group
• No baseline characteristics reported
Country: Kenya
Setting: hospital (paediatric high-dependency unit)
Interventions Colloids group
• Participants: n = 56; losses = 0; analysed = 56
• Details: 4.5% human albumin solution; 20 mL/kg if base deficit was 8 mmol/L-
15 mmol/L or 40 mL/kg if base deficit was >15 mmol/L
• Additional details: single boluses infused over first hour; additional boluses if
rescue therapy required; standard treatment given to both groups
Crystalloids group
• Participants: n = 61; losses = 0; analysed = 61
• Details: 0.9% NS; 20 mL/kg if base deficit was 8 mmol/L-15 mmol/L or 40 mL/
kg if base deficit was > 15 mmol/L
• Additional details: same as colloid group
Outcomes Outcomes measured/reported: percentage reduction in base deficit (8 h); requirement
for rescue therapies; neurological sequelae; mortality
Outcomes relevant to the review: mortality (time point not reported)
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Notes Funding/declarations of interest: supported by a grant from the Wellcome Trust, and
from senior fellowship funding
Study dates: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised but no additional details
Allocation concealment (selection bias) Unclear risk Use of sealed cards, but insufficient details
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nine losses of 159 randomised participants. Losses
because of early requirement of randomisation prior
to complete diagnoses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Unclear risk Baseline characteristics reported in moderate and
severe acidosis groups. There were no significant
clinical differences at the time of hospital admis-
sion, although among children in the severe aci-
dosis group who received albumin, seizures, hy-
potension and hypoglycaemia were more common
than among children assigned to the saline group.
We could not be certain whether these differences
would influence the data





Participants Total number of randomised participants: 2126 (2097 in group A; 29 in group B)
Inclusion criteria: between 60 days and 12 years of age; severe febrile illness complicated
by impaired consciousness or respiratory distress; impaired perfusion
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Exclusion criteria: severe malnutrition; gastroenteritis; non-infectious causes of shock
and conditions for which volume expansion is contraindicated
Participant condition group A: severe febrile illness, without hypotension
Participant condition group B: severe febrile illness with hypotension
Baseline characteristics group A
Colloids group
• Age, median (IQR): 23 (14-37) months
• Gender, M:F: 576:474
• BP, median (IQR): SBP: 92 (85-101) mmHg
Crystalloids group
• Age, median (IQR): 23 (13-37) months
• Gender, M:F: 567:480
• BP, median (IQR): SBP: 93 (85-101) mmHg
Baseline characteristics group B
Colloids group
• Age, median (IQR): 28 (22-84) months
• Gender, M:F: 8:5
• BP, median (IQR): SBP: 59 (51-60) mmHg
Crystalloids group
• Age, median (IQR): 21 (10-47) months
• Gender, M:F: 8:8
• BP, median (IQR): SBP: 56 (47-59) mmHg
Country: Kenya, Tanzania, Uganda
Setting: hospital
Interventions Colloids group
• Participants: group A, n = 1050; losses = 0; analysed = 1050
• Participants: group B, n = 13; losses = 0; analysed = 13
• Details: 5% human albumin; 20 mL/kg over 1 h; if impaired perfusion persisted
an additional 20 mL/kg was given at 1 h; if severe hypotension developed a further 40
mL/kg was given
• Additional details: given IV maintenance fluids, antibiotics, antimalarial,
antipyretic, and anticonvulsant drugs; treatment for hypoglycaemia and transfusion of
whole blood if required
Crystalloids group
• Participants: group A, n = 1047; losses = 0; analysed = 1047
• Participants: group B, n = 16; losses = 0; analysed = 16
• Details: 0.9% NS; 20 mL/kg over 1 h; if impaired perfusion persisted an
additional 20 mL/kg was given at 1 h; if severe hypotension developed a further 40
mL/kg was given
• Additional details: same as colloids group
Outcomes Outcomes measured/reported: mortality at 48 h, mortality at 4 weeks, neurologic
sequelae at 4 and 24 weeks, episodes of hypertensive shock within 48 h, adverse events
Outcomes relevant to the review: mortality (4 weeks)
Notes Funding/declarations of interest: supported by a grant fromMedical Research Council
UK; resuscitation fluids donated by BaxterHealthcare.Neither had involvement in study
Study dates: January 2009-January 2011
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomizationwas performed in permuted
blocks of random sizes and was stratified according
to clinical center”
Allocation concealment (selection bias) Low risk Quote: “Trial numbers were kept inside opaque,
sealed envelopes, which were numbered consecu-
tively and opened in numerical order by a study clin-
ician”
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias for
mortality
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias for
mortality
Incomplete outcome data (attrition bias)
All outcomes
Low risk Few losses, which are clearly reported
Selective reporting (reporting bias) Unclear risk Retrospective clinical
trials registration (ISRCTN69856593); not feasible
to assess risk of selective outcome reporting
Baseline characteristics Low risk Baseline characteristics appeared comparable





Participants Total number of randomised participants: 40
Inclusion criteria: American-European Consensus Conference definition of ALI; serum
protein level < 6.0 g/dL; ongoing nutritional support; mechanical ventilation ≥ 24 h
Exclusion criteria: haemodynamic instability; renal disease; clinically documented cir-
rhosis; allergy to albumin or furosemide; < 18 years of age; pregnancy; serum sodium
level > 155 mEq/L or potassium level < 2.5 mEq/L
Participant condition: ALI; acute respiratory distress syndrome
Baseline characteristics
Colloids group
• Age, mean (SD): 48.9 (± 21.6) years
• Gender, M:F: 9:11
• APACHE II, mean (SD): 13.4 (± 5.5)
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• SOFA, mean (SD): 4.9 (± 2.0)
Crystalloids group
• Age, mean (SD): 46.4 (± 18.0) years
• Gender, M:F: 10:10
• APACHE II, mean (SD): 14.0 (± 7.5)




• Participants: n = 20; losses = 0; analysed = 20
• Details: 25% human serum albumin; 25 g IV over 30 min; then doses
administered every 8 h for 3 days
Crystalloids group
• Participants: n = 20; losses = 0; analysed = 20
• Details: 0.9% sodium chloride; equivalent volume
Outcomes Outcomes measured/reported: need for mechanical ventilation, shock, documented
nosocomial infections, mortality
Outcomes relevant to the review: mortality (30 days)
Notes Funding/declarations of interest: supported in part by theNational Institutes ofHealth
and Bayer Healthcare, Inc. (provision of study drug and an unrestricted grant)
Study dates: February 1999-December 2002
Study also included study of furosemide, given in each group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Computer-generated four-subject-block
randomization list held by the investigational phar-
macy at each hospital”
Allocation concealment (selection bias) Low risk Quote: “List held by the investigational pharmacy at
each hospital, which was also responsible for study
drug preparation, camouflaged, blinding, and dis-
pensation”
Blinding of participants and personnel
(performance bias): mortality
Low risk Quote: “Albumin study drug was concealed within
a sterile plastic container and infused in opaque in-
travenous tubing to obscure visual detail”
Blinding of outcome assessment (detection
bias): mortality
Low risk Outcome assessors blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses
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Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Low risk Baseline characteristics appeared comparable





Participants Total number of randomised participants: 100
Inclusion criteria: traumatic haemorrhagic shock
Exclusion criteria: heart failure; people who received blood before study was completed; death; sensitivity to serum;
transfer to operating room before study completed; hepatic insufficiency; respiratory failure; renal impairment; sepsis;
severe anaemia; non-haemorrhagic shock; history of sensitivity to intervention fluids; < 16 years of age
Participant condition: traumatic haemorrhagic shock
Baseline characteristics
Colloids group
• Age, mean (SD): 48 (29.61 ± 13) years - unclear what the mean was from this reported number
Crystalloids group
• Age, mean (SD): 27 (28 ± 9.13) years - unclear what the mean was from this reported number
• Overall




• Participants: not reported
• Details: Voluven; concentration not reported; 1.5L of NS and 0.5L of Voluven
Crystalloids group
• Participants: not reported
• Details: 2L NS
Outcomes Outcomes measured/reported: base excess (using measures of arterial blood gas); shock index
Outcomes relevant to the review: none (see note below)
Notes Funding/declarations of interest: none reported
Study dates: not reported
Note: study authors report, “Five subjects (10% inHES group (Voluven) and seven (14%) inNS group were excluded
from the study due to death, blood transfusion, and transfer to the operating room and their info was not included
in the final analysis”. Number of participants was not reported for each outcome and we were unable to include these
data in our analysis
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Participants Total number of randomised participants: 422
Inclusion criteria: ≥ 16 years of age; victim of penetrating or blunt trauma within last
hour before randomisation; initial field SBP ≤ 90 mmHg
Exclusion criteria: initial trauma score≤ 2; revised trauma score≤ 1; pregnancy; history
of seizures; coagulopathy; liver or renal disease; application ofmedical anti-shock trousers
Participant condition: victims of penetrating or blunt trauma
Baseline characteristics
Colloids group
• No baseline characteristics reported
Crystalloids group
• No baseline characteristics reported
Country: USA
Setting: out-of-hospital. Ambulance paramedic service
Interventions Colloids group
• Participants: n = 211; losses = 27 (study authors did not report reasons for losses
by group); analysed = 184
• Details: 7.5% NaCl in 6 % dextran 70; 250 mL
• Additional details: if < 250 mL given, then participant excluded from analysis
Crystalloids group
• Participants: n = 211; losses = 36 (study authors did not report reasons for losses
by group); analysed = 175
• Details: isotonic resuscitation fluid; plasmalyte; RL or saline
• Additional details: if < 250 mL given, then participant excluded from analysis
Outcomes Outcomes measured/reported:mortality, change in revised trauma score, complication
(to include acute renal failure), fluid and urine output, laboratory variables, adverse
events (allergic reaction)
Outcomes relevant to the review: mortality (30 days; study authors report that most
deaths were within 24 h), adverse events (allergic reaction)
Notes Funding/declarations of interest: supported by grant from Pharmacia AB, Sweden and
Pharmacia, Inc., New Jersey
Study dates: October 1987-November 1988
Note: for mortality data we used data reported for participants that were analysed by
study investigators (for 184 participants in colloids group, and 175 participants in the
crystalloid group). In the previous version of the review (Perel 2013), review authors
used total number randomised (211 in each group) for analysis of mortality data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk No details of randomisation method, but completed
externally. We have assumed low risk. Fluid bags la-
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belled with consecutive numbers
Allocation concealment (selection bias) Low risk Randomisation sequence generated externally. Per-
sonnel involved in treatment of participants were un-
likely to be aware of code
Blinding of participants and personnel
(performance bias): mortality
Low risk Blinded. Use of identical, coded treatment bags
Blinding of outcome assessment (detection
bias): mortality
Low risk Personnel blinded until end of study
Incomplete outcome data (attrition bias)
All outcomes
Low risk High number of losses postrandomisation. 63 or 424
participants, reasons given were because of eligibility
criteria, and being given < 250 mL of allocated fluid.
Data reported as per-protocol data. Study authors re-
ported analysis was performed to compare ITT with
per-protocol, with no difference in results
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Unclear risk Study authors did not report baseline characteristics





Participants Total number of randomised participants: 40
Inclusion criteria: early septic shock; hypotension; systemic inflammatory response
syndrome; a suspected or confirmed infectious source
Exclusion criteria:peoplewho received >500mLof colloid (5%albuminor pentastarch)
or 2000 mL of crystalloid fluid; other forms of shock (haemorrhagic, cardiogenic or
obstructive shock); acute myocardial infarction or cardiogenic pulmonary oedema; von
Willebrand’s disease; previous severe reaction to HES; chronic renal failure requiring
dialysis; immediate need for surgery; a contraindication to internal jugular or subclavian
line insertion; projected life expectancy < 3 months; < 18 years of age; pregnant or
lactating; previous ICU admission with septic shock during the present hospitalisation
Participant condition: septic shock
Baseline characteristics
Colloids group
• Age, mean (SD): 63.1 (± 13.1) years
• Gender, M:F: 13:8
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• APACHE II, mean (SD): 21.1 (± 6.1)
• GCS, mean (SD): 13.0 (± 3.4)
Crystalloids group
• Age, mean (SD): 63.6 (± 16.3) years
• Gender, M:F: 11:8
• APACHE II, mean (SD): 20.2 (± 6.3)




• Participants: n = 21; losses = 0; analysed = 21
• Details: pentastarch; after maximum dose given, open-label 500 mL boluses of NS
given for remaining 12 h; thereafter type and quantity dictated by treating physician
Crystalloids group
• Participants: n = 19; losses = 0; analysed = 19
• Details: not stated, we have assumed from information in the study report that it
was 0.9% NS; administered in 500 mL boluses according to prespecified algorithm;
maximum of 28 mL/kg (or 3000 mL) during 12-h period; after maximum dose given,
open-label 500 mL boluses of NS given for remaining 12 h; thereafter type and
quantity dictated by treating physician
Outcomes Outcomes measured/reported: feasibility measure, clinical events such as hospital, 28-
day and 90-day mortality, ICU and hospital LoS, organ failure
Outcomes relevant to the review: mortality (28 days); blood transfusion (any volume)
; RRT
Notes Funding/declarations of interest: lead author received unrestricted funds from Bristol
Myers Squibb and Edwards Life Sciences to conduct trial. Also unrestricted funds from
Abbott Laboratories
Study dates: not reported
Trial was terminated early because of lower than anticipated recruitment and the results
from another similar trial (Brunkhorst 2008).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central randomisation using a computerised per-
muted four-block randomisation scheme (generated
by an independent bio-statistician)
Allocation concealment (selection bias) Low risk Quote: “Only the designated research pharmacist at
each institutionwas aware of the treatment allocation
for individual patients”
Blinding of participants and personnel
(performance bias): mortality
Low risk Quote: “Study fluids were prepared and blinded
ahead of time by the site research pharmacist”
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Blinding of participants and personnel
(performance bias): transfusion/renal re-
placement therapy/adverse events
Low risk Quote: “Study fluids were prepared and blinded
ahead of time by the site research pharmacist”
Blinding of outcome assessment (detection
bias): mortality
Low risk Only pharmacist aware of group allocation, therefore
assume that outcome assessors were blinded
Blinding of outcome assessment (detection
bias): transfusion/renal replacement ther-
apy/adverse events
Low risk Only pharmacist aware of group allocation, therefore
assume that outcome assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data reported for all randomised participants. One
participant was excluded post-randomisation be-
cause of meeting exclusion criteria
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selec-
tive outcome reporting bias. We noted that 90-day
mortality was listed as an outcome in the methods
section of the published report but not included in
the results
Baseline characteristics Unclear risk Baseline characteristics were similar between groups
with the exception of the need for organ support at
baseline. Fewer patients in the saline group (versus
pentastarch group) were on a vasopressor at baseline.
We could not be certain whether these differences
would influence outcome data





Participants Total number of randomised participants: 50
Inclusion criteria: ≥ 18 years of age; suspected septic shock (refractory hypotension
plus ≥ 2 criteria for systemic inflammatory response syndrome)
Exclusion criteria: > 8 h passed from the first hypotensive episode; received > 250 mL of
colloid fluid (albumin or HES); shock (e.g. haemorrhagic, obstructive, or cardiogenic);
previous ICU admission with severe sepsis or septic shock during the current hospitalisa-
tion; burn or traumatic brain injury before the current hospitalisation; history of chronic
liver disease; religious objection to use of albumin; known previous severe reaction to
albumin; lack of commitment of the patient, family, or clinical team to full therapeutic
management; pregnant; enrolled in another related interventional trial
Participant condition: septic shock
115Colloids versus crystalloids for fluid resuscitation in critically ill people (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
McIntyre 2012 (Continued)
Overall baseline characteristics
• Age, median (IQR): 64.5 (55-17) years
• Gender, M:F: 22:28




• Participants: not reported
• Details: 5% albumin; fluid administered as 500 mL boluses as rapidly as possible
for the first 7 days after enrolment (or until discharge or death)
Crystalloids group
• Participants: not reported
• Details: 0.9% NaCl; fluid administered as 500mL boluses as rapidly as possible
for the first 7 days after enrolment (or until discharge or death)
Outcomes Outcomes measured/reported: related to study feasibility; overall mortality (at 28 days)
Outcomes relevant to the review: mortality (but number randomised to each group
not reported and therefore no available data for the review)
Notes Funding/declarations of interest: supported by funding from Canadian Institute of
Health Research and CSL Behring. Also partial funding from SAFE trial, and unlimited
grant from Univerisity of Alberta
Study dates: April 2009-December 2009
Mortality was reported overall, but not by group; 12 out of 50 participants died
This was a feasibility pilot study.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Used randomisation lists but no additional details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias): mortality
Low risk Identical glass containerswith opaque coveringswere
used to conceal study fluids from all participants and
personnel
Blinding of outcome assessment (detection
bias): mortality
Low risk Identical glass containerswith opaque coveringswere
used to conceal study fluids from outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Few losses, which were reported and explained
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration; not feasible
to assess risk of selective reporting bias
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Baseline characteristics Unclear risk Not reported for each group





Participants Total number of randomised participants: 46
Inclusion criteria: established pulmonary failure; intrapulmonary shunt > 20% and a
roentgenogram of the chest demonstrating interstitial and intra-alveolar oedema
Exclusion criteria: no details
Participant condition: severe pulmonary insufficiency
Baseline characteristics
Colloids group
• Age, mean (SD): 44 (± 22) years
• Gender, M:F: 16:4
Crystalloids group
• Age, mean (SD): 50 (± 20) years
• Gender, M:F: 17:9
Country: USA
Setting: hospital, surgical ICU
Interventions Colloids group
• Participants: n = 20; losses = 0; analysed = 20
• Details: 50 g of salt-poor serum albumin in 1 L of RL; fluid administered to
maintain PCWP and CO sufficient to meet metabolic needs of participant
Crystalloids group
• Participants: n = 26; losses = 0; analysed = 26
• Details: RL; fluid administered to maintain PCWP and CO sufficient to meet
metabolic needs of participant
Outcomes Outcomes measured/reported: colloid osmotic pressure, PCWP, cardiac index, stroke
work, intrapulmonary shunt, fluid volume, mortality, length of ICU stay
Outcomes relevant to the review:mortality (time point not reported, some deaths were
within 48 h)
Notes Funding/declarations of interest: supported by ONR Contract (definition of ONR
not provided in study report)
Study dates: June 1978-May 1979
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Assigned by random number. No additional details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Low risk Baseline characteristics appeared comparable





Participants Total number of randomised participants: 31
Inclusion criteria: severe traumatic shock with a SBP < 70 mmHg
Exclusion criteria:<18years of age; > 75 years of age; considered to be in a terminal stage;
associated major cerebral, thoracic or abdominal injuries; long-bone fractures requiring
major primary anaesthetic and surgical intervention
Participant condition: severe traumatic shock
Baseline characteristics
Colloids group
• Age, mean (range): 37 (18-56) years
• Gender, M:F: 10:4
• BP, mean (range): SBP: 60 (40-70) mmHg
Crystalloids group
• Age, mean (range): 40 (22-60) years
• Gender, M:F: 11:6
• BP, mean (range): SBP: 65 (45-70) mmHg
Country: Sweden
Setting: hospital
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Interventions Colloids group
• Participants: n = 14; losses = 0; analysed = 14
• Details: 0.5 L dextran 70 daily for 7-8 days after initial shock treatment
• Additional details: participants in dextran group were given 20 mL IV dextran 1
immediately before dextran 70, to avoid possible anaphylactic reaction
Crystalloids group
• Participants: n = 17; losses = 0; analysed = 17
• Details: Ringer’s acetate; 1.0 L-1.5 L Ringer’s acetate for 7-8 days after initial
shock treatment
Outcomes Outcomes measured/reported: development of ARDS, complications to include mor-
tality
Outcomes relevant to the review: mortality (during study period)
Notes Funding/declarations of interest: supported by grants from Swedish National Defense
Research Institute, SwedishAssociation againstHeart andChestDiseases, and the Laerdal
Foundation
Study dates: February 1980-February 1983
Note: only one author for this study report. In previous version of the review (Perel
2013), the study ID was Modig 1983. Some discrepancies between reports of Modig
1983 and Modig 1986, however they appear to be reports of the same study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Randomisation based on even/uneven data
of admission to emergency department
Allocation concealment (selection bias) High risk No concealment. No randomisation se-
quence
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce
bias for this outcome
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce
bias for this outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk Nodetails of clinical trials registration or pre-
published protocol; not feasible to assess risk
of selective outcome reporting bias
Baseline characteristics Low risk Baseline characteristics appeared comparable
Other bias Low risk No other sources of bias identified
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Participants Total number of randomised participants: 107
Inclusion criteria: ≥ 16 years of age; initial assessment of GCS ≤ 8; blunt traumatic
mechanism of injury
Exclusion criteria: known pregnancy; primary penetrating injury; vital signs absent
before randomisation; previous IV therapy ≥ 50 mL; time interval between arrival at
scene and IV access > 4 h; amputation above wrist or ankle; any burn (thermal, chemical,
electrical, radiation); suspected environmental hypothermia; asphyxia (strangulation,
hanging, choking, suffocation, drowning); fall from height ≤ 1 m or ≤ 5 stairs
Participant condition: blunt trauma
Baseline characteristics
Colloids group
• Age, mean (SD): 46 (± 21) years
• Gender, M:F: 30:20
Crystalloids group
• Age, mean (SD): 43 (± 21) years
• Gender, M:F: 43:14
Country: Canada
Setting: out-of-hospital, paramedic service, air and land
Interventions Colloids group
• Participants: n = 50; losses = 0; analysed = 50
• Details: 7.5 % HS in 6 % dextran 70; 250 mL
Crystalloids group
• Participants: n = 57; losses = 0; analysed = 57
• Details: 9% NS; 250 mL
Outcomes Outcomes measured/reported: survival at 30 days, 48-h survival, cerebral performance
at discharge, Functional Independence Measure, Disability Rating Scale, Glasgow Out-
come Scale, Extended Glasgow Outcome Scale, neuropsychological assessments
Outcomes relevant to the review: mortality (30 days)
Notes Funding/declarations of interest: Defence Research and Development Canada
(DRDC) and Biophausia Sweden provided the study fluid (RescueFlow) free of charge
without obligation to the investigators for the duration of the trial
Study dates: unclearly reported. Completion date December 2008 (from clinical trials
registration documents). Study dates in an associated publication with a subset of par-
ticipants were September 2004-January 2006
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation used (fromMorrison 2009 (see
Morrison 2011) - use of computer-generated ran-
dom table or block randomisation)
120Colloids versus crystalloids for fluid resuscitation in critically ill people (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Morrison 2011 (Continued)
Allocation concealment (selection bias) Low risk Concealment with use of sealed opaque envelopes
Blinding of participants and personnel
(performance bias): mortality
Low risk Personnel remained blinded until after opening of
envelopes. Lack of blinding unlikely to introduce
bias for mortality
Blinding of outcome assessment (detection
bias): mortality
Low risk Lack of blinding unlikely to introduce bias for mor-
tality
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk Study dates are not clearly reported. However, study
appears to have retrospective clinical trials registra-
tion (NCT00878631), and publication of retrospec-
tive protocols. Not feasible to assess risk of selective
reporting bias
Baseline characteristics Low risk We noted a higher number of male participants in
the crystalloid group, but we did not expect this to
influence outcome data





Participants Total number of randomised participants: 7000
Inclusion criteria: requiring fluid resuscitation in the ICU; > 18 years of age
Exclusion criteria: > 1000 mL HES before screening; impending or current dialysis-
dependent renal failure; evidence of intracranial haemorrhage on cranial computed to-
mography




• Age, mean (SD): 63.1 (± 17.0) years
• Gender, M:F: 2030:1328
• Weight, mean (SD): 79.4 (± 21.0) kg
• APACHE II, median (IQR): 17.0 (12.0-22.0)
Crystalloids group
• Age, mean (SD): 62.9 (± 16.9) years
• Gender, M:F: 2041:1343
• Weight, mean (SD): 78.6 (± 20.8) kg
• APACHE II, median (IQR): 17.0 (12.0-23.0)
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Country: Australia and New Zealand
Setting: ICU, 32 hospitals
Interventions Colloids group
• Participants: n = 3500; losses = 142; analysed for mortality at 28 days = 3313;
analysed for RRT = 3352
• Details: 6% HES 130/0.4; treating clinicians determined the initial and
subsequent volumes and the rate of administration of resuscitation fluid, depending on
clinical signs and subsequent response to fluid administration; maximum dose of 50
mL/kg of body weight/h, followed by open-label 0.9% NS for remainder of 24-h
period; for all fluid resuscitation in the ICU, until ICU discharge, death or 90 days
after randomisation
• Additional details: study fluid was stopped in participants who were treated with
any mode of RRT. In these participants, treatment with saline was recommended, but
any other fluid, apart from HES, was permitted. The administration of resuscitation
fluids outside the ICU was not controlled.
Crystalloids group
• Participants: n = 3500; losses = 116; analysed for mortality at 28 days = 3331;
analysed for RRT = 3375
• Details: 0.9% NS; volume determined by treating clinicians.
• Additional details: same as colloid group
Outcomes Outcomes measured/reported: all cause mortality (at 90 days, in the ICU, in hospital,
and within 28 days); acute kidney injury (using RIFLE); need for RRT; new organ
failure for cardiovascular; respiratory; coagulation; liver systems that were not present at
baseline; duration of mechanical ventilation; adverse events (to include allergic reaction,
itching, rashes), cause-specific mortality; duration of ICU and hospital stay; rate of death
in the ICU, hospital, and at 28 days
Outcomes relevant to the review: mortality (within 28 days, within 90 days); need for
RRT (dialysis); adverse events (to include allergic reaction, itching, rashes)
Notes Funding/declarations of interest: supported by a grant from the National Health and
Medical ResearchCouncil of Australia, and by unrestricted grants fromNewSouthWales
Ministry of Health, and Fresenius Kabi (supplied study fluids and distributed them to
sites). Funding agencies had no input into the design, conduct, data collection, statistical
analysis, or writing of the manuscript
Study dates: December 2009-January 2012
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used web-based randomisation program
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias for
mortality
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Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias for
mortality
Incomplete outcome data (attrition bias)
All outcomes
Low risk There are an inconsistent number of losses between
flow chart and data tables. However, loss of partici-
pants is < 10%
Selective reporting (reporting bias) Low risk Prospective clinical trials registra-
tion (NCT00935168). Most outcomes (all review
outcomes) were reported according to clinical trials
registration
Baseline characteristics Low risk Baseline characteristics appeared balanced between
groups
Other bias High risk 15% of participants in each group had HES before






Participants Total number of randomised participants: 41
Inclusion criteria: adults with measurable SBP < 90 mmHg because of haemorrhage
Exclusion criteria: no details
Participant condition: haemorrhagic shock
Baseline characteristics
Colloids group
• No baseline characteristics reported
Crystalloids group




• Participants: n = 21; losses = 0; analysed = 21
• Details: pentastarch; boluses given until SBP > 100 mmHg and urine output > 30
mL/h; then study fluid continued to maintain haemodynamic stability; maximum 4 L,
after which RL given as needed
• Additional details: participants received blood or blood products as necessary.
Crystalloids group
• Participants: n = 20; losses = 0; analysed = 20
• Details: RL; boluses given until SBP > 100 mmHg and urine output > 30 mL/h;
then study fluid continued to maintain haemodynamic stability
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• Additional details: same as colloid group
Outcomes Outcomes measured/reported: haemodynamic parameters, arterial blood gases, blood
product requirement (transfusion) respiratory measurements
Outcomes relevant to the review: mortality (during study), blood transfusion (packed
red blood cells)
Notes Funding/declarations of interest: supported by a grant from American Critical Care,
McGaw Park, Illinois
Study dates: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants described as randomised, but no addi-
tional details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Blinding of participants and personnel
(performance bias): transfusion/renal re-
placement therapy/adverse events
Unclear risk No details
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Blinding of outcome assessment (detection
bias): transfusion/renal replacement ther-
apy/adverse events
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Low risk Baseline characteristics not reported. Study authors
state “There was no difference between groups with
regard to race, age, sex or weight”
Other bias Low risk No other sources of bias identified
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Participants Total number of randomised participants: 222
Inclusion criteria: children from 1-15 years of age; dengue haemorrhagic fever (grade
III or IV); had not received any IV fluid therapy; with a parent or guardian who gave
consent
Exclusion criteria: severe haemorrhagic manifestations for whom transfusion seemed
likely; children with chronic disorders
Participant condition: DSS
Baseline characteristics
Colloids group (dextran 70)
• Age, mean (SD): 7.9 (± 3.5) years
• Gender, M:F: 24:31
Colloids group (gelatins)
• Age, mean (SD): 7.5 (± 3.0) years
• Gender, M:F: 24:32
Crystalloids group (RL)
• Age, mean (SD): 8.3 (± 3.2) years
• Gender, M:F: 26:29
Crystalloids group (NS)
• Age, mean (SD): 7.3 (± 2.7) years
• Gender, M:F: 20:36
Country: Vietnam
Setting: ICU, paediatric hospital
Interventions Colloids group (dextran 70)
• Participants: n = 55; losses = 0; analysed = 55
• Details: 20 mL of dextran 70 over 15 min. Then all participants received RL
according to standard fluid protocols. If participant’s pulse and BP failed to improve, or
deteriorated, additional boluses of dextran 70 were given at the discretion of the
treating physician
Colloids group (gelatins)
• Participants: n = 56; losses = 0; analysed = 56
• Details: 20 mL of 3% gelatin (Gelafundin) over 15 min. Then RL, and dextran
70 if required, as above
Crystalloids group (RL)
• Participants: n = 55; losses = 0; analysed = 55
• Details: 20 mL RL over 15 min. Then RL, and dextran 70 if required, as above
Crystalloids group (NS)
• Participants: n = 56; losses = 0; analysed = 56
• Details: 20 mL NS over 15 min. Then RL, and dextran 70 if required, as above
Outcomes Outcomes measured/reported: initial pulse pressure recovery time, occurrence and
timing of subsequent episodes of shock, drop in haematocrit and pulse rate after the
first hour, total volume of dextran 70 required after first hour, mortality (time point not
reported), adverse events (allergic reactions, severe epistaxis requiring blood transfusion)
Outcomes relevant to the review: mortality (time point not reported), transfusion of
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Ngo 2001 (Continued)
blood products, adverse events (allergic reactions)
Notes Funding/declarations of interest: study drugs all supplied by manufacturer (B Braun)
Study dates: September 1996-September 1997
Note: study authors report that 222 children had dengue haemorrhagic fever that was
grade III, and 8 children had dengue haemorrhagic fever that was grade IV. Because of
the small number of grade IV children, the study authors decided to exclude these from
the report. Therefore, analysis is for 222 participants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation done externally in blocks of 10
Allocation concealment (selection bias) Low risk Use of opaque envelopes containing only a treat-
ment pack number
Blinding of participants and personnel
(performance bias): mortality
Low risk Fluid solutions were in bottles covered in opaque
black insulating tape to ensure blinding
Blinding of participants and personnel
(performance bias): transfusion/renal re-
placement therapy/adverse events
Low risk Fluid solutions were in bottles covered in opaque
black insulating tape to ensure blinding
Blinding of outcome assessment (detection
bias): mortality
Low risk No details; lack of blinding unlikely to influence
outcome data
Blinding of outcome assessment (detection
bias): transfusion/renal replacement ther-
apy/adverse events
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Low risk Appear comparable
Other bias High risk 36.4% participants in the RL group also received
dextran 70 after the first hour; 30.4% participants
in the NS group also received dextran 70 after the
first hour
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Participants Total number of randomised participants: 31
Inclusion criteria: 25% or > TBSA burn with smoke inhalation, or > 40% TBSA burn
if inhalation injury was not present
Exclusion criteria: patients who had withdrawal of support without efforts of resusci-




• Age, mean (SD): 44.6 (± 19.3) years
• Weight, mean (SD): 87.0 (± 10.3) kg
Crystalloids group
• Age, mean (SD): 46.4 (± 20.5) years




• Participants: n = 16; losses = 0; analysed = 16
• Details: FFP + RL; initiated at hourly rate based on 24-h goal of 2000 mL of RL
(83 mL/h) and 75 mL/kg of FFP; volume of FFP titrated to maintain urine output
between 0.5 mL/kg/h and 1.0 mL/kg/h
• Additional details: FFP continued for 48 h after burn, then participants converted
to crystalloid maintenance fluids
Crystalloids group
• Participants: n = 15; losses = 0; analysed = 15
• Details: RL; initiated at rate calculated as 4 mL/kg/% TBSA; first half given over
initial 8 h; rate was titrated hourly to maintain urine output between 05 mL/kg/h and
1.0 mL/kg/h
Outcomes Outcomes measured/reported: fluid volumes; intra-abdominal pressure; urine output;
renal function; peak airway pressure; mortality
Outcomes relevant to the review: mortality (time point not reported)
Notes Funding/declarations of interest: none reported
Study dates: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Usedpredetermined randomisation codewhichwas
maintained by primary investigator
Allocation concealment (selection bias) Unclear risk No details
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O’Mara 2005 (Continued)
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Low risk Baseline characteristics appeared comparable





Participants Total number of randomised participants: 29
Inclusion criteria: newly admitted to ICU; clinically suspected infection; fulfilled ≥ 2
criteria of systemic inflammatory response syndrome; presence of perfusion abnormalities
Exclusion criteria: adjustment of catecholamine doses or aggressive volume resuscitation
(fluid administration > 200 mL within 30 min) during 180-min study period; coma
after pulmonary cardiocerebral resuscitation; renal failure; hypernatraemia; pregnant
Participant condition: severe sepsis
Baseline characteristics
Colloids group
• Age, mean (SD): 43.7 years
• Gender, M:F: 7:6
• APACHE II, mean (SD): 14.1 (± 5.2)
Crystalloids group
• Age, mean (SD): 47.9 years
• Gender, M:F: 11:5




• Participants: n = 13; losses = 0; analysed = 13
• Details: 7.5% NaCl in dextran 8% 70; 250 mL
• Additional details: 10-min infusion via central venous catheter
Crystalloids group
• Participants: n= 16; losses = 0; analysed = 16
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Oliveira 2002 (Continued)
• Details: 0.9% NS; 250 mL
• Additional details: same as colloid group
Outcomes Outcomes measured/reported: haemodynamic parameters; PAOP; cardiac index; sys-
temic vascular resistance; stroke volume; metabolic variables; mortality rate
Outcomes relevant to the review: mortality (time point not reported)
Notes Funding/declarations of interest: supported by The Wellcome Trust
Study dates: study was completed over 23 months, dates not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used random number table
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Unclear risk We noted that participants in the colloids group
were younger, with statistically significantly lower
APACHE II scores. We could not be certain
whether these differences would influence outcome
data
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Park 2015 (Continued)
Participants Total number of randomised participants: 110
Inclusion criteria: patients with cancer and septic shock
Exclusion criteria: no details
Participant condition: patients with cancer and septic shock
Baseline characteristics
Colloids group
• Age, mean (range): 63 (57-70) years
• Gender, M:F: 29:21
Crystalloids group
• Age, mean (range): 61 (51-71) years




• Participants: n = 50; losses = 0; analysed = 50
• Details: albumin 4%; bolus of solution; started within 12 h of ICU admission
Crystalloids group
• Participants: n = 60; losses = 0; analysed = 60
• Details: RL
Outcomes Outcomes measured/reported: mortality (30 days, 90 days, in the ICU), ICU and
hospital LoS, daily SOFA scores, rates and duration of mechanical ventilation, renal
replacement, need for vasopressor drugs, status performance, fluid balance
Outcomes relevant to the review:mortality (30 days), RRT (outcome data not reported
in the abstract)
Notes Funding/declarations of interest: none reported
Study dates: start date not reported, recruitment up to November 2014
Available report is from an abstract only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised. No additional details in
abstract
Allocation concealment (selection bias) Unclear risk No details in abstract
Blinding of participants and personnel
(performance bias): mortality
Low risk Described as double-blind but no additional details.
However, lack of blinding unlikely to influence out-
come data for mortality
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
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Park 2015 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details. Assume all participants were accounted
for (although the percentage data for mortality,
which did not give whole numbers, suggests some
loss of participants)
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Unclear risk Baseline characteristics not reported in abstract






Participants Total number of randomised participants: 800
Inclusion criteria: adults who needed fluid resuscitation in the ICU and who had
fulfilled criteria for severe sepsis within the previous 24 h according to the SCCM/ACCP
and where informed consent was obtainable either from the patient or by proxy (in
Denmark, 2 physicians followed by delayed consent from next of kin and the patient’s
general practitioner. In Iceland, Finland and Norway, next of kin)
Exclusion criteria: < 18 years of age; previously randomised in the 6S trial; allergy
towards HES or malic acid; treatment with > 1000 mL of any synthetic colloid within
the last 24 h prior to randomisation; any form of RRT; acute burn injury > 10% TBSA;
severe hyperkalaemia, pK >6mM; liver or kidney transplantation during current hospital
admission; intracranial bleeding within current hospitalisation; enrolment into another
ICU trial of drugs with potential action on circulation, renal function or coagulation;
withdrawal of active therapy
Participant condition: severe sepsis
Baseline characteristics
Colloids group
• Age, median (IQR): 66 (56-75) years
• Gender, M:F: 239:159
• SOFA, median (IQR): 7 (5-9)
Crystalloids group
• Age, median (IQR): 67 (56-76) years
• Gender, M:F: 244:156
• SOFA, median (IQR): 7 (5-9)
Country: Denmark, Norway, Finland and Iceland
Setting: 26 ICUs
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Perner 2012 (Continued)
Interventions Colloids group
• Participants: n = 400; losses = 2; analysed = 398
• Details: 6% HES (Tetraspan) 130/0.4; 33 mL/kg/ideal body weight; if doses >
maximum daily dose were required then unmasked Ringer’s acetate
Crystalloids group
• Participants: n = 400; losses = 0; analysed = 400
• Details: Ringer’s acetate; 33 mL/kg/ideal body weight; if doses > maximum daily
dose were required then used unmasked Ringer’s acetate
Outcomes Outcomes measured/reported: haemodynamic parameters; PAOP; cardiac index; sys-
temic vascular resistance; stroke volume; metabolic variables; mortality (at 28 days, at
90 days); transfusion of blood products (packed red blood cells, FFP, platelets; at day 1,
day 2, day 3, and cumulative); adverse events (allergic reactions)
Outcomes relevant to the review: mortality (at 28 days, and at 90 days); RRT; transfu-
sion of blood products (packed red blood cells at day 1); adverse events (allergic reactions)
Note: in order to avoid double of counting of participants we only included transfusion
of one type of blood products (red blood cells) and on the first day
Notes Funding/declarations of interest: Danish Research Council. Study fluids supplied free
of charge by B Braun. Neither funders nor B Braun had influence on protocol, trial
conduct, data analyses and reporting
Study dates: December 2009-November 2011
Note: the previous version of this review used mortality data at 90 days (Perel 2013); in
this review we have analysed mortality data at 28 days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated allocation concealment
Allocation concealment (selection bias) Low risk Centralised, blinded randomisation
Blinding of participants and personnel
(performance bias): mortality
Low risk Used identical fluid bags, covered in black opaque
plastic
Blinding of participants and personnel
(performance bias): transfusion/renal re-
placement therapy/adverse events
Low risk Used identical fluid bags, covered in black opaque
plastic
Blinding of outcome assessment (detection
bias): mortality
Low risk Outcome assessors were blinded to treatment groups
Blinding of outcome assessment (detection
bias): transfusion/renal replacement ther-
apy/adverse events
Low risk Outcome assessors were blinded to treatment groups
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Perner 2012 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Very few losses, which were explained in flow chart
(804 participants randomised, but ITT data for only
798)
Selective reporting (reporting bias) Low risk Prospective clinical trials
registration (NCT00962156). Generally all 90-day
outcomes listed in the protocol were well reported
in the primary manuscript. Length of hospital stay
was not reported in primary publication but was in
the long-term outcomes paper
Baseline characteristics Low risk Baseline characteristics appear comparable
Other bias High risk Most participants in each group received other fluids
(study authors listed other fluids as crystalloids, nu-
trition, water, fluid with medications, synthetic col-
loids, and albumin); because some participants re-






Participants Total number of randomised participants: 308
Inclusion criteria: patients with cirrhosis and who had sepsis-induced hypotension
Exclusion criteria: no details
Participant condition: cirrhosis and sepsis-induced hypotension
Baseline characteristics
Colloids group
• Age, mean: 49.7 years
• Gender, M:F: 117:37
• SOFA, mean (SD): 9.99 (± 2.5)
Crystalloids group
• Age, mean : 47 years
• Gender, M:F: 122:32




• Participants: n = 154; losses = 0; analysed = 154
• Details: human albumin 5%; 250 mL bolus over 15 min
Crystalloids group
• Participants: n = 154; losses = 0; analysed = 154
• Details: NS; 30 mL/kg over 30 min
133Colloids versus crystalloids for fluid resuscitation in critically ill people (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Philips 2015 (Continued)
Outcomes Outcomes measured/reported: MAP; HR; lactate; lactate clearance; urine output; sur-
vival at 1 week
Outcomes relevant to the review: mortality (7 days)
Notes Funding/declarations of interest: none reported
Study dates: not reported
Abstract only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Abstract only with limited detail on randomisation
methods
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk Clinical trials registration (NCT02462902). We do
not know if this was prospectively registered; not
feasible to assess risk of selective outcome reporting
bias
Baseline characteristics Low risk Baseline characteristics appeared comparable






Participants Total number of randomised participants: 107
Inclusion criteria: adults with metastatic cancer whose standard treatment had failed
and had expected survivals of > 3 months
Exclusion criteria: no details
Participant condition: vascular leak syndrome
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• Age, range: 11-70 years
• Gender, M:F: 30:24
Crystalloids group
• Age, range: 21-70 years




• Participants: n = 54; 18 participants did not complete full course. Outcome data
for blood transfusion for all participants, data for mortality for 36 participants
• Details: 5% albumin with 145 mEq/L NaCl; 250 mL; given over a 10- to 15-min
period to keep heart rate < 120 bpm; SBP > 80 mmHg and urine output > 24 mL/h
• Additional details: participants given I L-2 therapy; all participants given
maintenance fluid D5 0.5 NS + 10 mEq KCl at 35 mL/kg/d; fluid boluses repeated as
necessary; participants who became refractory to fluid boluses were given vasopressors.
Crystalloids group
• Participants: n = 53; 13 participants did not complete full course of therapy.
Outcome data for all participants for blood transfusion, but only 40 participants were
reported for mortality data
• Details: 0.9% NS with 154 mEq/L NaCl; 250 mL; given over a 10- to 15-min
period to keep heart rate < 120 bpm; SBP > 80 mmHg and urine output > 24 mL/h
• Additional details: same as colloid group
Outcomes Outcomes measured/reported: volume of fluid; number of doses of interleukin-2;
weight gain; pulse; SBP; days in ICU; time to discharge; laboratory changes (haematocrit
etc.); blood transfusion; mortality
Outcomes relevant to the review:mortality (time point not reported); blood transfusion
(any volume)
Notes Funding/declarations of interest: none reported
Study dates: March 1990-August 1990
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomised but no additional de-
tails
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
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Pockaj 1994 (Continued)
Blinding of participants and personnel
(performance bias): transfusion/renal re-
placement therapy/adverse events
Unclear risk No details
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Blinding of outcome assessment (detection
bias): transfusion/renal replacement ther-
apy/adverse events
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
High risk Some participants did not complete the full course
of treatment and reasons were explained. Outcome
data for participants requiring blood transfusion
were for all randomised participants, but data for
mortality were for 76 participants (loss of 18 partic-
ipants in colloid group, and loss of 13 participants
in crystalloid group)
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Low risk Baseline characteristics appeared comparable





Participants Total number of randomised participants: 20
Inclusion criteria: people fulfilling American-European Consensus criteria for ALI (in-
cluding ARDS)




• Age, mean: 49.6 years
• Gender, M:F: 5:5
Crystalloids group
• Age, mean: 33.5 years
• Gender, M:F: 6:4
Country: USA
Setting: hospital ICU
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Quinlan 2004 (Continued)
Interventions Colloids group
• Participants: n = 10; losses = 0; analysed = 10
• Details: 25 g human albumin every 8 h targeted to normalisation of serum total
protein
• Additional details: albumin treatment substituted with placebo if serum total
protein exceeded the upper normal limit
Crystalloids group
• Participants: n = 10; losses = 0; analysed = 10
• Details: NS every 8 h
• Additional details: no details
Outcomes Outcomes measured/reported: fluid volume; total protein; thiols; antioxidant; iron-
binding anti-oxidant protection; iron-oxidising antioxidant protection; mortality
Outcomes relevant to the review: mortality (28 days)
Notes Funding/declarations of interest: supported by grants from theDunhill Medical Trust,
British Lung Foundation, and the Plasma Protein Therapeutics Association
Study dates: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but no additional details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias for
mortality
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias for
mortality
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Unclear risk We noted that participants in the crystalloid group
were younger. We could not be certain whether this
might influence outcome data
Other bias Low risk No other sources of bias identified
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Participants Total number of randomised participants: 26
Inclusion criteria: included if pretreatment determinations revealed: systolic intra-ar-
terial pressure of < 90 mmHg; CI < 2.2 L/min/m²; serum arterial lactate > 18 mg/dL;
WP < 15 mmHg
Exclusion criteria: < 18 years of age; considered to be in a terminal state; manifesting a
significant coagulopathy
Participant condition: septic or hypovolaemic shock
Baseline characteristics
Colloids group (HES)
• Age, mean: 78.7 years
• Gender, M:F: 8:1
Colloids group (albumin)
• Age, mean: 78.2 years
• Gender, M:F: 5:4
Crystalloids group
• Age, mean: 74.9 years
• Gender, M:F: 4:4
Country: USA
Setting: hospital
Interventions Colloids group (HES)
• Participants: n = 9; losses = 0; analysed = 9
• Details: 6% hetastarch; 250 mL every 15 min until WP = 15 mmHg; thereafter
fluid given to maintain WP at 15 mmHg for next 24 h
Colloids group (albumin)
• Participants: n = 9; losses = 0; analysed = 9
• Details: 5% human serum albumin; 250 mL every 15 min until WP = 15 mmHg;
thereafter fluid given to maintain WP at 15 mmHg for next 24 h
Crystalloids group
• Participants: n = 8; losses = 0; analysed = 8
• Details: 0.9% NaCl; 250 mL every 15 min until WP = 15 mmHg; thereafter fluid
given to maintain WP at 15 mmHg for next 24 h
Outcomes Outcomes measured/reported: haemodynamic variables; respiratory data; survival
(during study period and hospital stay)
Outcomes relevant to the review: mortality (within 24 h)
Notes Funding/declarations of interest: supported by a grant from American Critical Care
Study dates: October 1979-June 1981
Risk of bias
Bias Authors’ judgement Support for judgement
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Rackow 1983 (Continued)
Random sequence generation (selection
bias)
Unclear risk Participants were randomly assigned but no addi-
tional details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Low risk We noted a larger number of male participants in
the colloids group. However, overall numbers of
participants were few and we assumed that gender
differences would not influence outcome data





Participants Total number of randomised participants: 20
Inclusion criteria: severe multiple trauma and shock; SBP < 90 mmHg
Exclusion criteria: no details
Participant condition: severe multiple trauma and shock
Baseline characteristics
Colloids group
• Age, range: 19-71 years
• Gender, M:F: 6:3
Crystalloids group
• Age, range: 19-74 years




• Participants: n = 9; losses = 0; analysed = 9
• Details: 5% salt-poor albumin in RL alternated with equal volumes of RL; to
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Shah 1977 (Continued)
maintain stroke work index of left ventricle > 5 x 10
dynes-cm/m² or pulmonary WP > 10 mmHg
• Additional details: packed red blood cells transfused as required
Crystalloids group
• Participants: n = 11; losses = 3 participants not included in baseline characteristics
because of death during fluid resuscitation
• Details: RL; to maintain stroke work index of left ventricle > 5 x 10
dynes-cm/m² or pulmonary WP > 10 mmHg
• Additional details: same as colloid group
Outcomes Outcomes measured/reported: mortality; respiratory and haemodynamic variables
Outcomes relevant to the review: mortality (during study period)
Notes Funding/declarations of interest: supported by grants from National Institute of Gen-
eral Medical Sciences
Study dates: not reported
Data in baseline characteristics only given for 8 participants in crystalloid group (3 had
died because it was not possible to resuscitate them)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomised using a sealed enve-
lope technique. Insufficient details
Allocation concealment (selection bias) Unclear risk Sealed envelope containing fluid group. Insufficient
details
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 participants were excluded from all analyses be-
cause of death. However, we have included these
mortality data for this review
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Low risk Baseline characteristics appeared comparable
Other bias Low risk No other sources of bias identified
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Participants Total number of randomised participants: 60
Inclusion criteria: 1 month-12 years of age; septic shock
Exclusion criteria: features of multiorgan failure such as disseminated intravascular
coagulation with bleeding manifestation; jaundice; acute renal failure; adult respiratory
distress syndrome; coma; < 1 month old; underlying immunodeficiency status such as
leukaemia; lymphoma; long-term immunosuppressive therapy
Participant condition: paediatric septic shock
Baseline characteristics
Colloids group
• Age, median (IQR): 30 (11.5-96) months
• Gender, M:F: 24:5
• Weight, median (IQR): 11.0 (5.5-30.0) kg
• BP, median (IQR): SBP: 85 (84-90) mmHg; DBP: 60 (48-60) mmHg
Crystalloids group
• Age, median (IQR): 36 (9-72) months
• Gender, M:F: 21:10
• Weight, median (IQR): 11.8 (5.0-24.8) kg




• Participants: n = 29; losses = 0; analysed = 29
• Details: Haemaccel; in boluses of 20 mL/kg every 10-20 min until BP returned to
normal and perfusion improved, CVP > 10 cm H2O
• Additional details: episodes of hypotension, if any, after initial stabilisation were
also treated with the same fluid
Crystalloids group
• Participants: n = 31; losses = 0; analysed = 31
• Details: NS; in boluses of 20 mL/kg every 10-20 min until BP returned to normal
and perfusion improved, CVP > 10 cm H2O
• Additional details: same as colloids group
Outcomes Outcomes measured/reported: fluid volumes; haemodynamic stability; organ failure;
acute respiratory distress syndrome; acute renal failure; mortality
Outcomes relevant to the review: mortality (time point not reported)
Notes Funding/declarations of interest: none reported
Study dates: March 1999-April 2000
Risk of bias
Bias Authors’ judgement Support for judgement
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Upadhyay 2005 (Continued)
Random sequence generation (selection
bias)
Low risk Random number tables
Allocation concealment (selection bias) Low risk Random number generation kept in sealed en-
velopes by one investigator
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Low risk Baseline characteristics appeared comparable
Other bias Low risk No other sources of bias identified




Participants Total number of randomised participants: 48
Inclusion criteria: mechanically ventilated and critically ill people with clinical hypo-
volaemia and at risk for, or with, ALI/ARDS
Exclusion criteria: > 78 years of age; pregnant; known anaphylactoid reaction to colloid
fluids; life expectancy < 24 h
Participant condition: clinical hypovolaemia
Baseline characteristics
Colloids group (HES)
• Age, median (range): 57 (22-75) years
• Gender, M:F: 9:3
• APACHE II, median (range): 12 (6-23)
Colloids group (albumin)
• Age, median (range): 61 (39-77) years
• Gender, M:F: 8:4
• APACHE II, median (range): 15 (5-18)
Colloids group (gelatin)
• Age, median (range): 61 (27-74) years
• Gender, M:F: 9:3
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• APACHE II, median (range): 10 (4-20)
Crystalloids group
• Age, median (range): 62 (25-77) years
• Gender, M:F: 9:3
• APACHE II, median (range): 10 (6-23)
Country: the Netherlands
Setting: hospital
Interventions Colloids group (HES)
• Participants: n = 12; losses = 0; analysed = 12
• Details: 6% HES 200/0.45-0.55
• Additional details: fluids given during 90 min on basis of response to predefined
pressure limits and CVP, according to a protocol; boluses at maximum of 200 mL/10
min, so that maximum fluid challenge was 1800 mL in 90 min
Colloids group (albumin)
• Participants: n = 12; losses = 0; analysed = 12
• Details: albumin 5%; 100 mL Cealb 20%; diluted in 300 mL of saline
• Additional details: same as colloids group (HES)
Colloids group (gelatin)
• Participants: n = 12; losses = 0; analysed = 12
• Details: 4% Gelofusine 40 g/L; in 154/120 mM NaCl
• Additional details: same as colloids group (HES)
Crystalloids group
• Participants: n = 12; losses = 0; analysed = 12
• Details: 0.9% (assume NS)
• Additional details: same as colloids group (HES)
Outcomes Outcomes measured/reported: haemodynamic variables; respiratory variables; mortal-
ity
Outcomes relevant to the review: mortality (until discharge from the ICU)
Notes Funding/declarations of interest: supported in part by B Braun Medical, Melsungen,
Germany and the Netherlands Heart Foundation, The Hague
Study dates: not reported
Patients stratified into septic and non-septic. We combined these groups. Use of online
supplementary information for some data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation performed by pharmacist; no addi-
tional detail on methods used to generate codes
Allocation concealment (selection bias) Low risk Used sealed envelopes prepared by pharmacist
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
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Van der Heijden 2009 (Continued)
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Low risk Baseline characteristics appeared comparable




Single centre (assumed, but not reported by study authors)
Participants Total number of randomised participants: 47
Inclusion criteria: people attending the emergency department with ≤ SBP 90 mmHg
Exclusion criteria: people who appeared to be < 18 years of age; pregnant women;
known severe pre-existing cardiac, hepatic, or renal disease
Participant condition: SBP ≤ 80 mmHg
Baseline characteristics
Colloids group
• Age, mean (SEM): 35 (± 3) years
• BP, mean (SEM): 52 (± 8) mmHg
• Revised trauma score (SEM): 4.0 (± 0.6)
Crystalloids group
• Age, mean (SEM): 33 (± 3) years
• BP, mean (SEM): 55 (± 8) mmHg




• Participants: n = 23; losses = 0; analysed = 23
• Details: 250 mL 7.5% NaCl in 6% dextran 70
Crystalloids group
• Participants: n = 24; losses = 0; analysed = 24
• Details: RL; 250 mL
Outcomes Outcomes measured/reported: haemodynamic variables; blood chemistry; mortality;
adverse events (allergic reactions)
Outcomes relevant to the review:mortality (28 days); adverse events (allergic reactions)
144Colloids versus crystalloids for fluid resuscitation in critically ill people (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Vassar 1990 (Continued)
Notes Funding/declarations of interest: supported in part from the National Institutes of
Health
Study dates: April 1987-May 1988
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; no additional de-
tails
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias): mortality
Low risk Identical bottles used to conceal study flu-
ids from participants and personnel
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to intro-
duce bias for mortality
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration; not
feasible to assess risk of selective reporting
bias
Baseline characteristics Low risk Baseline characteristics appeared compara-
ble




Single centre (assumed, but not reported by study authors)
Participants Total number of randomised participants: 166
Inclusion criteria: trauma patients being transported to hospital by helicopter; SBP ≤
100 mmHg; palpable peripheral pulse or a sinus complex on ECG; ≥ 18 years of age
Exclusion criteria: women who appeared to be pregnant; chronically debilitated people




• Age, median (IQR): 29 (21-42) years
• BP, median (IQR): 80 (60-90) mmHg
• GCS, median (IQR): 10 (3-14)
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• Injury severity score, median (IQR): 27 (22-43)
Crystalloids group
• Age, median (IQR): 33 (21-42) years
• BP, median (IQR): 80 (66-90) mmHg
• GCS, median (IQR): 10 (3-15)




• Participants: n = 83; losses = 0; analysed = 83
• Details: change to concentration of solutions part way through the study; up to
February 1988 participants were given a solution of 7.5% NaCl in 4.2% dextran 70
solution; then from March 1988, solution was 7.5% NaCl with 6% dextran 70.
During the first 11 months, participants were given an initial infusion of 20 mL
dextran 1 from a coded syringe; after 11 months this pre-infusion was no longer given.
• Additional details: solutions given via a peripheral vein within ≤ 5 min;
supplemental isotonic fluids given at discretion of flight nurses to restore BP
Crystalloids group
• Participants: n = 83; losses = 0; analysed = 83
• Details: during first 11 months participants were given an initial infusion of 20
mL RL from a coded syringe; after 11 months, this pre-infusion was no longer given.
• Additional details: same as colloids group
Outcomes Outcomes measured/reported: survival (to hospital discharge, and in emergency de-
partment); haemodynamic parameters; HR; volume of fluid given; volume of surgical
blood loss and blood replacement in first 24 h; intracranial bleed in those with head
injury; survival in patients with head injury; complications; adverse events (allergic re-
actions)
Outcomes relevant to the review: mortality; adverse events (allergic reactions)
Notes Funding/declarations of interest: supported in part by a grant fromNational Institutes
of Health and by pharmacia. HSD provided by pharmaceutical company
Study dates: June 1986-February 1988
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used random number tables
Allocation concealment (selection bias) Low risk Bags were identical and placed in order by
a code established by hospital pharmacy
team to be used by helicopter paramedics
Blinding of participants and personnel
(performance bias): mortality
Low risk Study solutions were prepared by pharma-
cist in identical 250 mL bags with codes
determined by random number tables
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Vassar 1991 (Continued)
Blinding of outcome assessment (detection
bias): mortality
Low risk All personnel involved in participant care
were blinded to study groups for at least
one month after participants were entered
into trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or
prepublished protocol; not feasible to assess
risk of selective outcome reporting bias
Baseline characteristics Low risk Baseline characteristics appeared compara-
ble
Other bias High risk Study authors changed concentration of
HSD during study period. It is unclear
whether this could have influenced out-
come data. 14 of the 83 participants in the
crystalloids group and 15 of the 83 partic-
ipants in the colloids group were given un-
specified resuscitation before flight nurses





Single centre (assumed, but not reported by study authors)
Participants Total number of randomised participants: 258
Inclusion criteria: SBP < 90 mmHg
Exclusion criteria: asystolic or undergoing cardiopulmonary resuscitation; lacked a sinus
complex on ECG; appeared to be < 18 years of age; seen > 2 h from time of injury;
pregnant; known to have a history of seizures or a bleeding disorder; appeared to have a
pre-existing hepatic cardiac, or renal disease, as indicated by ascites or peripheral oedema;





• Age, mean (SD): 31 (± 14) years
• BP, mean (SD): SBP: 56 (± 38) mmHg
• GCS, mean (SD): 11 (± 5)
Crystalloids group (NS)
• Age, mean (SD): 31 (± 12) years
• BP, mean (SD): 64 (± 32) mmHg
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Vassar 1993a (Continued)
• GCS, mean (SD): 12 (± 4)
Crystalloids group (HS)
• Age, mean (SD): 32 (± 15) years
• BP, mean (SD): 65 (± 29) mmHg
• GCS, mean (SD): 12 (± 4)
Country: USA
Setting: out-of-hospital, ambulance service
Interventions Colloids group (HSD)
• Participants: n = 89; losses = 0; analysed = 89
• Details: 7.5 % NaCl in 6 % dextran 70; 250 mL bag administered at a wide-open
rate
• Additional details: in some cases the test solution was the first fluid that a
participant received; in others, a participant was already receiving conventional fluids
when becoming eligible for the study
Crystalloids group (NS)
• Participants: n = 84; losses = 0; analysed = 84
• Details: 0.9 % NaCl; 250 mL bag administered at a wide-open rate
• Additional details: same as colloids group
Crystalloids group (HS)
• Participants: n = 85; losses = 0; analysed = 85
• Details: 7.5 % NaCl; 250 mL bag administered at a wide-open rate
• Additional details: same as colloids group
Outcomes Outcomes measured/reported: BP response; mortality (at hospital discharge); survival
compared with that predicted by norms from the MTOS
Outcomes relevant to the review: mortality
Notes Funding/declarations of interest: supported by a grant from national Institutes of
Health, and Kabi Pharmaceuticals, Inc
Study dates: September 1988-July 1991
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number list
Allocation concealment (selection bias) Low risk Assignment made at pharmacy level,
and fluid bag contents concealed from
paramedic personnel
Blinding of participants and personnel
(performance bias): mortality
Low risk Study fluids were prepared in identical
bags, and personnel were blinded to group
allocation
Blinding of outcome assessment (detection
bias): mortality
Low risk All investigators and personnel were
blinded throughout the trial
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Vassar 1993a (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Large number of exclusions post-randomi-
sation (36 participants) because these par-
ticipants did not meet the eligibility. Ac-
ceptable loss of participants recruited in a
trauma setting (minimal inclusion criteria
but large exclusion criteria established once
in hospital)
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or
prepublished protocol; not feasible to assess
risk of selective outcome reporting bias
Baseline characteristics Low risk Baseline characteristics appeared compara-
ble




Single centre (assumed, but not reported by study authors)
Participants Total number of randomised participants: 194
Inclusion criteria: SBP < 90 mmHg
Exclusion criteria: asystolic or undergoing cardiopulmonary resuscitation; lacked a sinus
complex on ECG; appeared to be < 18 years of age; > 2 h from the time of injury; thought
to be pregnant; known to have a history of seizures or a bleeding disorder; appeared to
have pre-existing hepatic, cardiac, or renal disease, as indicated by ascites or peripheral




• Age, mean (SD): 30 (± 12) years
• BP, mean (SD): SBP: 62 (± 34) mmHg
• GCS, mean (SD): 9 (± 5)
Colloids group (HSD 12% dextran)
• Age, mean (SD): 34 (± 15) years
• BP, mean (SD): SBP: 65 (± 22) mmHg
• GCS, mean (SD): 8 (± 5)
Crystalloids group (RL)
• Age, mean (SD): 37 (± 18) years
• BP, mean (SD): SBP: 72 (± 15) mmHg
• GCS, mean (SD): 9 (± 6)
Crystalloids group (HS)
• Age, mean (SD): 31 (± 13) years
• BP, mean (SD): SBP: 66 (± 27) mmHg
• GCS, mean (SD): 8 (± 5)
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Interventions Colloids group (HSD)
• Participants: n = 50; losses = 0; analysed = 50
• Details: 7.5 % NaCl in 6% dextran 70; 250 mL bags; fluid infused at a wide-open
rate; conventional fluids also given if necessary
Colloids group (HSD 12% dextran)
• Participants: n = 49; losses = 0; analysed = 49
• Details: 7.5% NaCl with 12% dextran 70
Crystalloids group (RL)
• Participants: n = 45; losses = 0; analysed = 45
• Details: RL
Crystalloids group (HS)
• Participants: n = 50; losses = 0; analysed = 50
• Details: 7.5% NaCl
Outcomes Outcomes measured/reported: mortality (until hospital discharge)
Outcomes relevant to the review: mortality
Notes Funding/declarations of interest: supported in part by grant from Kabi-Pharmacia
Study dates: March 1990-June 1991
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used computer-generated random number
tables
Allocation concealment (selection bias) Low risk Bagswere coded, and allocated sequentially
to helicopters
Blinding of participants and personnel
(performance bias): mortality
Low risk All personnel were blinded. Used sealed
bags with coded identification label
Blinding of outcome assessment (detection
bias): mortality
Low risk All investigators kept blinded throughout
trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk High number of exclusions after study flu-
ids administered because of late assess-
ment of inclusion/exclusion criteria, but in-
evitable because of the out-of-hospital set-
ting. No additional apparent losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or
prepublished protocol; not feasible to assess
risk of selective outcome reporting bias
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Baseline characteristics Low risk Baseline characteristics appeared largely
comparable





Participants Total number of randomised participants: 26
Inclusion criteria: adult acute burns admission with injury > 15% TBSA
Exclusion criteria: < 16 years of age or > 80 years of age; burn > 80% TBSA; pregnant;
transfer delay > 6 h from time of injury; history or biochemical evidence of renal impair-
ment on admission; history or haematological evidence of a bleeding diathesis; failure
to obtain consent
Participant condition: burns > 15% TBSA
Baseline characteristics
Colloids group
• Age, mean (SD): 40.8 (± 20.1) years
• Gender, M:F: 7:5
Crystalloids group
• Age, mean (SD): 42.4 (± 23.5) years




• Participants: n = 12; losses = 0; analysed = 12
• Details: 6% HES 200/0.6; supplemented with Hartmann’s solution to maintain
limit of 33 mL/kg/24 h; titrated to meet criteria of urine output 0.5 mL/kg/h-1 mL/
kg/h or 1 mL/kg/h-2 mL/kg/h depending on degree of injury; MPA > 70 mmHg; HR
< 120 bpm
Crystalloids group
• Participants: n = 14; losses = 3 (participants were given a colloid); analysed = 11
• Details: Hartmann’s solution; titrated to meet criteria of urine output 0.5 mL/kg/
h-1 mL/kg/h or 1 mL/kg/h-2 mL/kg/h depending on degree of injury; MPA > 70
mmHg; HR < 120 bpm
Outcomes Outcomes measured/reported: fluid intake and balance; weight; urinary albumin; res-
piratory function; serum C-reactive protein; mortality; RRT
Outcomes relevant to the review: mortality (during hospital stay); RRT; blood trans-
fusion (any volume)
Notes Funding/declarations of interest: none
Study dates: May 2004-May 2006
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation in blocks of 10 participants
Allocation concealment (selection bias) Unclear risk Used sealed envelopes, but no additional details
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Blinding of participants and personnel
(performance bias): transfusion/renal re-
placement therapy/adverse events
Unclear risk No details
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Blinding of outcome assessment (detection
bias): transfusion/renal replacement ther-
apy/adverse events
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 3 participants excluded from crystalloid group be-
cause they were given colloid. Small study, so this
represents a large percentage of losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Low risk Baseline characteristics appeared comparable





Participants Total number of randomised participants: 383
Inclusion criteria: 2-15 years of age; presenting directly to the hospital with clinical
DSS; parent or guardian provided consent
Exclusion criteria: not reported
Participant condition: DSS
Baseline characteristics
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Colloids group (dextran)
• Age, median (range): 10 (6-14) years
• Gender, M:F: 57:69
• Weight (median): 25 (15-43) kg
• BP, median (range): SBP: 90 (75-110); DBP: 75 (57-90) mmHg
Colloids group (HES)
• Age, median (range): 10 (4.5-14) years
• Gender, M:F: 70:59
• Weight (median): 25 (14-40) kg
• BP, median (range): SBP: 90 (80-110); DBP: 75 (60-90) mmHg
Crystalloids group
• Age, median (range): 10 (5-14) years
• Gender, M:F: 66:62
• Weight (median): 25 (15-42) kg
• BP, median (SD): SBP: 90 (72-113); DBP: 75 (55-95) mmHg
Country: Vietnam
Setting: paediatric ICU
Interventions Colloids group (dextran)
• Participants: n = 126; losses = 0; analysed = 126
• Details: 6% dextran, described as an isotonic colloid
• Additional details: each participant received 15 mL/kg of body weight of allocated
fluid over 1-h period followed by 10 mL/kg over the second hour; after infusion of
study fluid participants received a standard schedule of RL
Colloids group (HES)
• Participants: n = 129; losses = 0; analysed = 129
• Details: 6% HES, described as an isotonic colloid
• Additional details: same as dextran group
Crystalloids group
• Participants: n = 128; losses = 0; analysed = 128
• Details: RL
• Additional details: same as dextran group
Outcomes Outcomes measured/reported: requirement for supplemental intervention with rescue
colloid; time taken to achieve initial and sustained cardiovascular stability; pattern of
change in haematocrit; days in hospital; adverse effects (including need for blood trans-
fusion, rashes), mortality
Outcomes relevant to the review: need for transfusion of a blood product; mortality
(time point not reported); adverse events (rashes)
Notes Funding/declarations of interest: supported by the Wellcome Trust
Study dates: August 1999-March 2004
Note: this study included a separate arm comparing two colloids for participants with
severe shock (pulse pressure,≤ 10mmHg); we did not include these participants because
colloids were not compared with a crystalloid
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Use of computer-generated random numbers com-
pleted by independent research staff
Allocation concealment (selection bias) Low risk Allocation concealed through treatment packs of
fluid prepared in advance, in cardboard containers,
and only identifiable by a study number
Blinding of participants and personnel
(performance bias): mortality
Low risk Treatment packs of fluid were prepared in advance,
in cardboard containers, and only identifiable by a
study number
Blinding of participants and personnel
(performance bias): transfusion/renal re-
placement therapy/adverse events
Low risk Treatment packs of fluid were prepared in advance,
in cardboard containers, and only identifiable by a
study number
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding for assessment of mortality;
lack of blinding unlikely to influence data for this
outcome
Blinding of outcome assessment (detection
bias): transfusion/renal replacement ther-
apy/adverse events
Low risk Blinding reported for assessment of other outcomes,
and we assumed that assessment of transfusion data
was also blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Low risk Baseline characteristics appear comparable
Other bias High risk 31% participants in the crystalloid group were also






Participants Total number of randomised participants: 34
Inclusion criteria:≥ 16years of age;MAP<80mmHgor SBP < 100mmHg; impression
of haemorrhagic or spinal shock
Exclusion criteria: pregnant; history of congestive heart disease; intubated mechanically
ventilated patients; refractory to initial fluid challenge
Participant condition: hypovolaemic shock
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• Age, mean (SD): 41.3 (± 19.1) years
• Gender, M:F: 13:5
• BP, mean (SD): SBP: 82 (± 15) mmHg
Crystalloids group
• Age, mean (SD): 47.8 (± 19.1) years
• Gender, M:F: 8:8
• BP, mean (SD): SBP: 87 (± 13) mmHg
Country: Taiwan
Setting: hospital, emergency department
Interventions Colloids group
• Participants: n = 18; losses = 0; analysed = 18
• Details: Gelofusine; 1000 mL infused within 10-15 min
• Additional details: 1000 mL of RL infused continually in both groups
Crystalloids group
• Participants: n = 16; losses = 0; analysed = 16
• Details: RL; 1000 mL infused within 10-15 min
• Additional details: same as colloids group
Outcomes Outcomes measured/reported: haemodynamic variables; haemoglobin and haemat-
ocrit levels; survival rates
Outcomes relevant to the review: mortality (time point not reported), also reported
blood transfusion (although not by group) but these participants were excluded from
the study
Notes Funding/declarations of interest: none reported
Study dates: July 1997-February 1998
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants described as randomly allocated to
groups, but no additional details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses of participants for reporting of mortality
data
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Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Low risk We noted some differences in gender balance be-
tween groups; we did not anticipate that these dif-
ferences would influence outcome data





Participants Total number of randomised participants: 105
Inclusion criteria: > 18 years of age; admitted with haemorrhagic hypovolaemia (SBP
< 80 mmHg) with a palpable pulse or positive ECG; not pregnant, and with a previous
history of cardiac or metabolic diseases
Exclusion criteria: no details
Participant condition: hypovolaemic shock
Baseline characteristics
Colloids group
• Age, mean (SEM): 27 (± 8) years
• Gender, M:F: 28:7
Crystalloids group (NS)
• Age, mean (SEM): 28 (± 9) years
• Gender, M:F: 28:7
Crystalloids group (HS)
• Age, mean (SEM): 31 (± 10) years




• Participants: n = 35; losses = 0; analysed = 35
• Details: 7.5% NaCl plus 6% dextran 70; 250 mL bolus infused over 2-3 min;
immediately followed by 0.9% NaCl and blood replacement until SBP > 100 mmHg
Crystalloids group (NS)
• Participants: n = 35; losses = 0; analysed = 35
• Details: 0.9% NaCl; 250 mL bolus infused over 2-3 min; immediately followed
by 0.9% NaCl and blood replacement until SBO > 100 mmHg
Crystalloids group (HS)
• Participants: n = 35; losses = 0; analysed = 35
• Details: 7.5% NaCl; 250 mL bolus infused over 2-3 min; immediately followed
by 0.9% NaCl and blood replacement until SBO > 100 mmHg
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Outcomes Outcomes measured/reported: pulmonary complications; renal complications; cardiac
complications; infectious complications; haemodynamic variables; mortality
Outcomes relevant to the review: mortality (until hospital discharge)
Notes Funding/declarations of interest: supported by Laboratorios B Braun
Study dates: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants randomised, but no additional details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias): mortality
Low risk Solutions prepared in similar and unmarked bottles
to ensure blinding
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Low risk Baseline characteristics appeared comparable





Participants Total number of randomised participants: 212
Inclusion criteria: people being treated for haemorrhagic hypovolaemia and requiring
blood transfusion
Exclusion criteria: < 16 years of age; pregnant; having cardiac or renal failure previous
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• Age, median (range): 30 (16-83) years
• Gender, M:F: 93:8
• GCS, median (range): 14 (3-15)
Crystalloids group
• Age, median (range): 29 (16-89) years
• Gender, M:F: 92:19




• Participants: n = 101; losses = 0; analysed = 101
• Details: 7.5% NaCl in 6% dextran 70; given immediately on presentation of
hypovolaemia; 250 mL; then given standard hospital resuscitation (crystalloid solution
to reach SBP > 100 mmHg, and blood infusion to maintain haematocrit level > 29%)
Crystalloids group
• Participants: n = 111; losses = 0; analysed = 111
• Details: 0.9% NaCl; given immediately on presentation of hypovolaemia; 250
mL; then given standard hospital resuscitation (crystalloid solution to reach SBP > 100
mmHg, and blood infusion to maintain haematocrit level > 29%)
Outcomes Outcomes measured/reported: fluid volumes; survival at 24 h and 30 days; complica-
tions (renal failure, cardiac, pulmonary, infectious, and neurologic complications)
Outcomes relevant to the review: mortality (30 days)
Notes Funding/declarations of interest: none reported
Study dates: February 1991-November 1992
Study ID was Younes 1994 in previous version of the review (Perel 2013)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but no additional details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias): mortality
Low risk Fluids in “coded, externally identical vials”. Quote:
“Neither the investigators nor the ER team had any
control or knowledge of the infused solution during
the entire study period”
Blinding of outcome assessment (detection
bias): mortality
Low risk Quote: “Neither the investigators nor the ER team
had any control or knowledge of the infused solu-
tion during the entire study period”
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Four losses in HSD and 3 in NS group. Explana-
tions for losses given. Few losses; unlikely to intro-
duce significant risk of bias
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Low risk Baseline characteristics appeared comparable





Participants Total number of randomised participants: 23
Inclusion criteria: people with SBP < 90 mmHg; admitted to emergency department
with no previous treatment




• Age, mean (SD): 34.4 (± 14.9) years
• Gender, M:F: 11:1
• BP, mean (SD): SBP: 70.6 (± 17.4) mmHg
• GCS, mean (SD): 11.5 (± 4.1)
Crystalloids group
• Age, mean (SD): 31.1 (± 9.5) years
• Gender, M:F: 9:2
• BP, mean (SD): SBP: 73.3 (± 13.9) mmHg




• Participants: n = 12; losses = 0; analysed = 12
• Details: 10% pentastarch; 250 mL repeatedly until SBP > 100 mmHg
Crystalloids group
• Participants: n = 11; losses = 0; analysed = 11
• Details: 0.9% NaCl; 250 mL repeatedly until SBP > 100 mmHg
Outcomes Outcomes measured/reported: MAP; fluid volumes; transfusion (by volume); compli-
cations (not specified); survival (24 h)
Outcomes relevant to the review: mortality (24 h)
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Younes 1998 (Continued)
Notes Funding/declarations of interest: none reported
Study dates: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised by closed envelopes. Insufficient de-
tails provided
Allocation concealment (selection bias) Unclear risk Used closed envelopes. Insufficient details provided
Blinding of participants and personnel
(performance bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Blinding of outcome assessment (detection
bias): mortality
Low risk No details of blinding; unlikely to introduce bias
for mortality
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Low risk Baseline characteristics appeared comparable





Participants Total number of randomised participants: 120
Inclusion criteria: 18-60 years of age; diagnosed with severe acute pancreatitis
Exclusion criteria: heart disease; severe renal and hepatic dysfunction; coagulation dis-
turbances; allergy to HES or glutamine; manifestation for > 48 h, or received resuscita-
tion from another hospital
Participant condition: severe acute pancreatitis
Baseline characteristics
Colloids group (HES)
• Age, mean (SD): 44.5 (± 9.77) years
• Gender, M:F: 22:18
• Weight, mean (SD): 69 (± 9.68) kg
• APACHE II, mean (SD): 10.9 (± 0.6)
160Colloids versus crystalloids for fluid resuscitation in critically ill people (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Zhao 2013 (Continued)
Colloids group (HES and glutamine)
• Age, mean (SD): 45.11 (± 11.57) years
• Gender, M:F: 21:19
• Weight, mean (SD): 72.38 (± 8.43) kg
• APACHE II, mean (SD): 11.3 (± 0.4)
Crystalloids group (NS)
• Age, mean (SD): 41.86 (±13.85) years
• Gender, M:F: 20:20
• Weight, mean (SD): 66.5 (± 8.63) kg
• APACHE II, mean (SD): 11.2 (± 0.7)
Country: China
Setting: hospital
Interventions Colloids group (HES)
• Participants: n = 40; losses = 0; analysed = 40
• Details: HES 130; ratio of NS to HES 3:1; 500 mL NS and 500 mL HES in the
first 2 h to achieve CVP 8 mmHg-12 mmHg; then continually infused at 150 mL/h,
depending on reaction of resuscitation parameters, to maintain urine output of 0.5
mL/kg/h-1 mL/kg/h
• Additional details: vasopressors or vasodilators given to maintain MAP at > 65
mmHg, < 90 mmHg
Colloids group (HES and glutamine)
• Participants: n = 40; losses = 0; analysed = 40
• Details: HES 130; ratio of NS to HES 3:1 with addition of 20% glutamine
dipeptide, 100 mL/d; 500 mL NS and 500 mL HES + glutamine in the first 2 h to
achieve CVP 8-12 mmHg; then continually infused at 150 mL/h, depending on
reaction of resuscitation parameters, to maintain urine output of 0.5 mL/kg/h-1 mL/
kg/h
• Additional details: vasopressors or vasodilators given to maintain MAP at > 65
mmHg, < 90 mmHg
Crystalloids group
• Participants: n = 40; losses = 0; analysed = 40
• Details: NS; 1 L infused to achieve CVP of 8 mmHg-12 mmHg; continually
infused at 150 mL/h, depending on reaction of resuscitation parameters, to maintain
urine output of 0.5 mL/kg/h-1 mL/kg/h
• Additional details: vasopressors or vasodilators given to maintain MAP at > 65
mmHg, < 90 mmHg
Outcomes Outcomes measured/reported: respiratory infection; abdominal infection; sepsis; ab-
dominal haemorrhage; intra-abdominal hypertension; abdominal compartment syn-
drome; renal failure; acute respiratory distress syndrome; multiple organ dysfunction
syndrome; operation intervention; length of ICU and hospital stay; laboratory variables
Outcomes relevant to the review: mortality (day 60)
Notes Funding/declarations of interest: supported by grants from National Science Founda-
tion Committee of China, and Fundamental Research Funds of Central Universities of
China
Study dates: January 2007-March 2010
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were described as randomly divided
into group; no additional details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias): mortality
Low risk No details; lack of blinding unlikely to influence
data for this outcome
Blinding of outcome assessment (detection
bias): mortality
Low risk No details; lack of blinding unlikely to influence
data for this outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk No details of clinical trials registration or prepub-
lished protocol; not feasible to assess risk of selective
outcome reporting bias
Baseline characteristics Low risk Baseline characteristics appear comparable





Participants Total number of randomised participants: 135
Inclusion criteria: people with severe sepsis
Exclusion criteria: no details
Participant condition: severe sepsis
Baseline characteristics
Colloids group (HES)
• Age, mean (SD): 59.9 (± 9.4) years
• Gender, M:F: 25:20
• APACHE I, mean (SD): 17.0 (± 1.6)
Colloids group (HES + HS)
• Age, mean (SD): 59.4 (± 8.8) years
• Gender, M:F: 22:23
• APACHE I, mean (SD): 17.3 (± 1.8)
Crystalloids group
• Age, mean (SD): 59.8 (± 9.3) years
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• Gender, M:F: 24:21
• APACHE I, mean (SD): 17.2 (± 1.7)
Country: China
Setting: ICU
Interventions Colloids group (HES)
• Participants: n = 45; losses = 0; analysed = 45
• Details: RL followed by 500 mL 6% HES 130.0.4
Colloids group (HES + HS)
• Participants: n = 45; losses = 0; analysed = 45
• Details: RL followed by 4 mL/kg 7.5% HS and 500 mL 6% HES 130/0.4
Crystalloids group
• Participants: n = 45; losses = 0; analysed = 45
• Details: RL only
Outcomes Outcomes measured/reported: MAP; oxygenation; arterial lactate; lactate clearance
rate; APACHE I score; fluid infusion volume; urine output; MODS; mortality
Outcomes relevant to the review: mortality (time point not reported)
Notes Funding/declarations of interest: none reported
Study dates: not reported in English abstract
Note: article in Chinese. Data for study characteristics taken from English abstract, and
from study report tables, with translation using Google Translate
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Risk of bias’ assessment made using English ab-
stract. No details provided
Allocation concealment (selection bias) Unclear risk ’Risk of bias’ assessment made using English ab-
stract. No details provided
Blinding of participants and personnel
(performance bias): mortality
Low risk ’Risk of bias’ assessment made using English ab-
stract. Lack of blinding unlikely to introduce bias
for mortality
Blinding of outcome assessment (detection
bias): mortality
Low risk ’Risk of bias’ assessment made using English ab-
stract. Lack of blinding unlikely to introduce bias
for mortality
Incomplete outcome data (attrition bias)
All outcomes
Low risk No apparent losses
Selective reporting (reporting bias) Unclear risk ’Risk of bias’ assessment made using English ab-
stract. Not feasible to assess risk of selective out-
come reporting bias
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Zhu 2011 (Continued)
Baseline characteristics Low risk Baseline characteristics appeared comparable
Other bias Unclear risk We could not be certain of other risks of bias be-
cause ’Risk of bias’ assessment made using English
abstract only
ACCP: American College of Chest Physicians
AFR: additional fluid rate
AIDS: Acquired Immune Deficiency Syndrome
AKIN: Acute Kidney Injury Network
ALI: acute lung injury
ANH: acute normovolaemic haemodilution
APACHE II: Acute Physiology and Chronic Health Evaluation II
ARDS: acute respiratory deficiency syndrome
ASA: American Society of Anaesthesiologists
ATLSG: Advanced Trauma Life Support Guidelines
BMI: body mass index
BP: blood pressure
bpm: beats per minute
BR: basal rate
CO: cardiac output
CPP: cerebral perfusion pressure
CSL: Central Science Laboratory
CVP: central venous pressure
Da: dalton(s)
DBP: diastolic blood pressure
DSS: Dengue Shock Syndrome
FFP: fresh frozen plasma
ECG: electrocardiogram
EMS: emergency medical services
ER: emergency room






HSD: dextran solution with hypertonic saline
ICP: intracranial pressure




LoS: length of stay
MAP: mean arterial BP
M:F: male:female
MIU: major injuries unit
MMP-9: matrix metalloproteinase-9
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MMSE: Mini-Mental State Exam
MODS: Multiple Organ Dysfunction Syndrome
MPA: mega pascal(s)
MTOS: Major Trauma Outcome Study
NS: normal saline
NYHA: New York Heart Association classification
PAOP: pulmonary artery occlusion pressure
PCWP: pulmonary capillary wedge pressure
POCD: postoperative cognitive disorder
RCT: randomised control trial
RL: Ringer’s lactate
RRT: renal replacement therapy
SAG M: saline-adenine-glucose-mannitol
SAPS II: Simplified Acute Physiology Score II
SBP: systolic blood pressure
SCCM: Society of Critical Care Medicine
SD: standard deviation
SE: standard error
SEM: standard error of the mean
SOFA: Sequential Organ Failure Assessment
TBSA: total body surface area
TEG: thromboelastography
TFV: tidal flow volume
TIMP-1: tissue inhibitor of metalloproteinases-1
TRISS: Trauma Injury Severity Score
WHO: World Health Organization
WP: wedge pressure
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Boutros 1979 Included in previous version of review (Perel 2013). Excluded because participants were elective surgical
patients scheduled for major abdominal aortic surgery
Bowser-Wallace 1986 Included in previous version of review (Perel 2013). Excluded because study was not an RCT
Dawidson 1991 Included in previous version of review (Perel 2013). Excluded because participants were elective surgical
patients scheduled for abdominal aortic surgery
Dehne 2001 Included in previous version of review (Perel 2013). Excluded because participants were elective surgical
patients scheduled for middle ear surgery
Eleftheriadis 1995 Included in previous version of review (Perel 2013). Excluded because participants were elective cardiac
surgical patients
Evans 2003 Included in previous version of review (Perel 2013). Excluded because participants were elective surgical
patients scheduled for hip replacement
165Colloids versus crystalloids for fluid resuscitation in critically ill people (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Fries 2004 Included in previous version of review (Perel 2013). Excluded because participants were elective surgical
patients scheduled for knee replacement
Gallagher 1985 Included in previous version of review (Perel 2013). Excluded because participants were elective cardiac
surgical patients
Grundmann 1982 Included in previous version of the review (Perel 2013). Does not appear to be an RCT, and associated
reference does not include crystalloid group; therefore, we have excluded this study from the review
Guo 2003 Included in previous version of review (Perel 2013). Excluded because participants were elective surgical
patients scheduled for cytoreductive surgery
Hartmann 1993 Included in previous version of review (Perel 2013). Excluded because participants were elective surgical
patients scheduled for major abdominal surgery
Hondebrink 1997 Included in previous version of review (Perel 2013); hypoalbuminaemia after major surgery. Study ID was
Woittiez 1997 in previous version of the review
Karanko 1987 Included in previous version of review (Perel 2013). Excluded because participants were elective cardiac
surgical patients
Lee 2011 Included in previous version of review (Perel 2013). Excluded because participants were elective cardiac
surgical patients
Ley 1990 Included in previous version of review (Perel 2013). Excluded because participants were elective cardiac
surgical patients
Mazher 1998 Included in previous version of review (Perel 2013). Excluded because participants were elective cardiac
surgical patients
McNulty 1993 Included in previous version of review (Perel 2013). Excluded because participants were elective cardiac
surgical patients
Moretti 2003 Included in previous version of review (Perel 2013). Excluded because participants were elective surgical
patients scheduled for general, gynaecological, orthopaedic, or urological procedures
Nielsen 1985 Included in previous version of review (Perel 2013). Excluded because participants were elective surgical
patients scheduled for abdominal aortic surgery
Prien 1990 Included in previous version of review (Perel 2013). Excluded because participants were elective surgical
patients scheduled for modified Whipple’s operation
Rocha e Silva 1994 Abstract only. Included in previous version of review (Perel 2013). Protocol for a study that has not been
published. We have excluded this study because we no longer expect that results for this study will be
published
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(Continued)
Shires 1983 Included in previous version of review (Perel 2013). Excluded because participants were elective surgical
patients scheduled for aortic reconstruction surgery
Sirieix 1999 Included in previous version of review (Perel 2013). Excluded because participants were elective cardiac
surgical patients
Skillman 1975 Included in previous version of review (Perel 2013). Excluded because participants were elective surgical
patients scheduled for abdominal reconstructive surgery
Tollusfrud 1995 Included in previous version of review (Perel 2013). Excluded because participants were elective cardiac
surgical patients
Tollusfrud 1998 Included in previous version of review (Perel 2013). Excluded because participants were elective cardiac
surgical patients
Verheij 2006 Included in previous version of review (Perel 2013). Excluded because participants were elective cardiac
surgical patients
Virgilio 1979 Included in previous version of review (Perel 2013). Excluded because participants were elective surgical
patients scheduled for abdominal aortic surgery
Wahba 1996 Included in previous version of review (Perel 2013). Excluded because participants were elective cardiac
surgical patients
Zetterstorm 1981a Included in previous version of review (Perel 2013). Excluded because participants were elective surgical
patients scheduled for abdominal surgery
Zetterstorm 1981b Included in previous version of review (Perel 2013). Excluded because participants were elective surgical
patients scheduled for abdominal aortic surgery
RCT: randomised control trial




Participants Number of randomised participants: no details
Inclusion criteria: no details
Exclusion criteria: no details
Participant condition: no details
Country: Russia
Setting: no details
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Bulanov 2004 (Continued)
Interventions Colloids group 1
Details: 6% HES 200/0.5
Colloids group 2
Details: 6% HES 130/0.4
Crystalloids group
Details: NS
Outcomes Outcomes measured/reported: no details
Outcomes relevant to the review: no details
Notes Funding/declarations of interest: no details
Study dates: no details





Participants Number of randomised participants: 798
Inclusion criteria: informed consent; any patient with septic shock 6 h after catecholamine introduction
Exclusion criteria: overweight; previous severe heart failure; neutropenia; cirrhosis and primary peritonitis and severe
burns




Details: 20% albumin; 100 mL
Crystalloids group
Details: 0.9% NaCl; 100 mL
Outcomes Outcomes measured/reported: all-cause mortality (at day 28); SOFA score; LoS in ICU and in hospital
Outcomes relevant to the review: mortality
Notes Funding/declarations of interest: none reported
Study dates: July 2006 to March 2010




Participants Number of randomised participants: no details
Inclusion criteria: no details
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Exclusion criteria: no details




Details: 4% gelatin; 500 mL every 30 min
Crystalloids group
Details: 0.9% saline; 500 mL every 30 min
Outcomes Outcomes measured/reported: haemodynamic variables
Outcomes relevant to the review: no details
Notes Funding/declarations of interest: no details
Study dates: no details





Participants Estimated number of randomised participants: 50
Inclusion criteria: between 18 and 65 years of age; > 40 kg; onset of trauma ≤ 48 h prior to assessment; clinically
judged to be in haemorrhagic shock by the attending surgeon; 2 or more of the following characteristics: penetrating
or blunt etiology with haemodynamic instability at ER or intra-operatively; ISS > 15; hypotension defined as either≥
10mmHg change in SBP orMAP≤ 65mmHg or needing vasopressors (dopamine≥ 5 µg/kg/min or norepinephrine
at any dose) at the time of admission; hypoperfusion defined as base deficit ≥ 4 mmol/L
Exclusion criteria: known severe congestive heart failure (EF ≤ 35%); chronic renal, liver or pancreatic disease;
TB, COPD, asthma; coagulopathy or bleeding tendency; allergy to HES; participation in a clinical drug trial within
the last 2 months; pregnancy or lactation; GCS < 9; advanced cancer (stage IV or metastatic disease); receiving
immunosuppressive drugs; do-not-resuscitate status; advanced directives restricting implementation of the protocol;
skeletal deformity, scarring, infection, gross contamination or previous surgery at the CVP insertion site; severe




Setting: 2 × medical centres
Interventions Colloids group
Details: tetrastarch (Voluven); goal directed volume therapy for severe trauma resuscitation
Crystalloids group
Details: crystalloid only; participants will receive crystalloid fluids only for volume therapy for severe trauma
Outcomes Outcomes measured/reported: intra-abdominal hypertension; abdominal compartment syndrome
Outcomes relevant to the review: none
169Colloids versus crystalloids for fluid resuscitation in critically ill people (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT00890383 (Continued)
Notes Funding/declarations of interest: sponsored by University of the Philippines and Fresenius Kabi
Study dates: May 2009 to December 2009
Study described as completed in clinical trials record. Study results not posted. Awaiting publication of completed





Participants Estimated number of randomised participants: 360
Inclusion criteria: ≥ 18 years of age; severe sepsis or septic shock into 6 h of evolution; written informed consent
Exclusion criteria: shock from other causes; adverse reactions to human albumin; previous fluid resuscitation during
current disease; previous use of albumin in the last 72 h; religion objection; enrolment in another study; traumatic
brain injury; hepatic cirrhosis; end stage renal disease; plasmapheresis; patients receiving end-of-life care







Outcomes Outcomes measured/reported: mortality (at 7 days); SOFA score; ICU LoS; hospital LoS; ventilator-free days; need
for RRT (at 28 days); days free of vasopressor; mortality (at 28 days)
Outcomes relevant to the review: mortality; need of RRT
Notes Funding/declarations of interest: sponsored by University of Sao Paulo
Study dates: October 2013 to December 2017
Study described as completed in clinical trials record. Study results not posted. Awaiting publication of completed





Participants Estimated number of randomised participants: 96
Inclusion criteria: between 18 and 80 years of age; subarachnoid haemorrhage; Hunt-Hess grade I to III
Exclusion criteria: patients with Hunt-Hess grade IV to V
Participant condition: subarachnoid haemorrhage
Country: Hungary
Setting: medical centre
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NCT02064075 (Continued)
Interventions Colloids group
Details: 15 mL/kg RL and 15 to 50 mL/kg HES
Crystalloids group
Details: 15 mL/kg to 50 mL/kg RL
Outcomes Outcomes measured/reported: incidence rate of vasospasm; 30-day survival; neurological status; GOS scores
Outcomes relevant to the review: mortality
Notes Funding/declarations of interest: sponsored by University of Debrecen
Study dates: February 2013 to October 2013
Study described as completed in clinical trials record. Study results not posted. Awaiting publication of completed





Participants Number of randomised participants: no details
Inclusion criteria: no details
Exclusion criteria: no details







Outcomes Outcomes measured/reported: correction of hypovolaemia, and stabilising haemodynamics
Outcomes relevant to the review: no details
Notes Funding/declarations of interest: no details
Study dates: no details
Study report requires translation from Russian to assess eligibility
COPD: chronic obstructive pulmonary disease
CVP: central venous pressure
EF: ejection fraction
ER: emergency room
GCS: Glasgow Coma Scale
HES: hydroxyethyl starch
ISS: Injury Severity Score
MAP: mean arterial blood pressure
NS: normal saline
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RCT: randomised control trial
RL: Ringer’s lactate
RRT: renal replacement therapy
SBP: systolic blood pressure
SOFA: Sequential Organ Failure Assessment
TB: tuberculosis
Characteristics of ongoing studies [ordered by study ID]
NCT01763853
Trial name or title Impact of fluid resuscitation therapy on pulmonary edema as measured by alveolar fluid clearance in patients




Participants Estimated number of randomised participants: 70
Inclusion criteria: ≥ 18 years of age; ICU patients under mechanical ventilation; within the first 24 h after
onset of moderate or severe ARDS; hypovolaemia requiring fluid resuscitation therapy
Exclusion criteria: pregnancy; < 18 years of age; refusal of the protocol; contraindications for the use of
Voluven or RL; contraindications for femoral artery catheterisation or subclavian venous catheterisation







Outcomes Outcomes measured/reported: rate of alveolar fluid clearance; alveolar oedema fluid resorption; mortality
(at 20 days)
Outcomes relevant to the review: mortality
Starting date December 2012
Contact information Patrick LACARIN; email: placarin@chu-clermontferrand.fr
Notes Funding/declarations of interest: sponsored by University Hospital, Clermont-Ferrand
NCT02721238
Trial name or title Comparison of colloid (20% albumin) versus crystalloid (Plasmalyte) for fluid resuscitation in cirrhotics with
sepsis induced hypotension
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Participants Estimated number of randomised participants: 90
Inclusion criteria: between 18 and 75 years of age; cirrhosis with suspected or documented sepsis with MAP
< 65 mm Hg
Exclusion criteria: already received colloid or 2 L of fluid within the first 12 h of presentation; already
on vasopressors and/or inotropes; spontaneous bacterial peritonitis and serum albumin less then 1.5 g/dL;
structural heart disease; on maintenance haemodialysis; other causes of hypotension; pregnant or lactating
women; in need of emergent surgical interventions; chronic obstructive lung disease and congestive heart
failure; previous adverse reaction to human albumin solution







Outcomes Outcomes measured/reported: reversal of hypotension; mortality (at 7 and 28 days); proportion of patients
with new organ failures; duration of mechanical ventilation; requirement of RRT; length of ICU stay
Outcomes relevant to the review: mortality; requirement of RRT
Starting date March 31, 2016
Contact information Dr Abhinav Verma; email: abhinav.3183@gmail.com
Notes Funding/declarations of interest: sponsored by Institute of Liver and Biliary Sciences, India
NCT02782819




Participants Estimated number of randomised participants: 320
Inclusion criteria: ≥ 18 years of age; new onset of shock within 24 h; MAP < 65 mmHg or SBP < 60%
of baseline BP; evidence of poor tissue perfusion including: urine output < 0.5 mL/kg/h, lactate > 2 mmol/
L, alteration of consciousness without other explanation; evidence of fluid inadequacy (CVP < 12 mmHg,
PCWP < 18 mmHg) or evidence of fluid responsive (IVC diameter variation > 15%, pulse pressure variation
> 15%, positive fluid challenge test)
Exclusion criteria: prolonged shock > 24 h; received colloid solution > 1000 mL in previous 72 h; do-
not-resuscitate order; contraindication for fluid therapy including: suspected cardiogenic shock, evidence of
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NCT02782819 (Continued)





Details: colloid solution resuscitation
Crystalloids group
Details: isotonic crystalloid solution resuscitation
Outcomes Outcomes measured/reported: proportion of patients who had shock reversal; mortality (at 28 and 90 days)
; total fluid resuscitation within 24 h; need of RRT
Outcomes relevant to the review: mortality; need of RRT
Starting date September 2014
Contact information Surat Tongyoo, MD; email: surat Ty@yahoo.co.uk; Prapan Laophannarai, MD; email:
praphan113@hotmail.com
Notes Funding/declarations of interest: sponsored by Mahidol University
ARDS: Acute Respiratory Distress Syndrome
CVP: central venous pressure
HES: hydroxyethyl starch
ICU: intensive care unit
IVC: inferior vena cava
MAP: mean arterial blood pressure
PCWP: pulmonary capillary wedge pressure
RCT: randomised control trial
RRT: renal replacement therapy
SBP: systolic blood pressure
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D A T A A N D A N A L Y S E S
Comparison 1. Starches vs crystalloid




participants Statistical method Effect size
1 Mortality at end of follow-up 24 11177 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.86, 1.09]
2 Mortality within 90 days 15 10415 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.90, 1.14]
3 Mortality within 30 days 11 10135 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.90, 1.09]
4 Transfusion of blood product 8 1917 Risk Ratio (M-H, Random, 95% CI) 1.19 [1.02, 1.39]
5 Renal replacement therapy 9 8527 Risk Ratio (M-H, Random, 95% CI) 1.30 [1.14, 1.48]
6 Adverse event: allergic reaction 3 7757 Risk Ratio (M-H, Random, 95% CI) 2.59 [0.27, 24.91]
7 Adverse event: itching 2 6946 Risk Ratio (M-H, Random, 95% CI) 1.38 [1.05, 1.82]
8 Adverse event: rash 2 7007 Risk Ratio (M-H, Random, 95% CI) 1.61 [0.90, 2.89]
Comparison 2. Dextrans vs crystalloid




participants Statistical method Effect size
1 Mortality at end of follow-up 19 4736 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.88, 1.11]
2 Mortality within 90 days and 30
days
10 3353 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.87, 1.12]
3 Transfusion of blood products 3 1272 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.77, 1.10]
4 Adverse events: allergic reaction 4 738 Risk Ratio (M-H, Random, 95% CI) 6.0 [0.25, 144.93]
Comparison 3. Gelatins vs crystalloid




participants Statistical method Effect size
1 Mortality at end of follow-up 6 1698 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.74, 1.08]
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Comparison 4. Albumin or FFP vs crystalloid




participants Statistical method Effect size
1 Mortality at end of follow-up 20 13047 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.92, 1.06]
2 Mortality within 90 days 10 12492 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.92, 1.04]
3 Mortality within 30 days 10 12506 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.93, 1.06]
4 Transfusion of blood product 3 290 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.95, 1.80]
5 Renal replacement therapy 2 3028 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.96, 1.27]
Comparison 5. Dextrans vs crystalloid: subgroup by tonicity of crystalloid




participants Statistical method Effect size
1 All-cause mortality at end of
follow-up
16 4247 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.90, 1.13]
1.1 colloid + hypertonic
crystalloid vs isotonic
crystalloid
8 2845 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.87, 1.13]
1.2 colloid + isotonic
crystalloid vs hypertonic
crystalloid
2 493 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.62, 2.06]
1.3 colloid + hypertonic
crystalloid vs hypertonic
crystalloid
6 909 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.74, 1.41]
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Analysis 1.1. Comparison 1 Starches vs crystalloid, Outcome 1 Mortality at end of follow-up.
Review: Colloids versus crystalloids for fluid resuscitation in critically ill people
Comparison: 1 Starches vs crystalloid
Outcome: 1 Mortality at end of follow-up








Annane 2013 (1) 181/645 372/1107 16.7 % 0.84 [ 0.72, 0.97 ]
Bechir 2013 (2) 8/23 6/22 1.7 % 1.28 [ 0.53, 3.08 ]
Brunkhorst 2008 (3) 107/261 93/274 12.8 % 1.21 [ 0.97, 1.51 ]
Cifra 2003 (4) 1/11 3/16 0.3 % 0.48 [ 0.06, 4.08 ]
Du 2011 (5) 1/21 2/21 0.3 % 0.50 [ 0.05, 5.10 ]
Dubin 2010 (6) 3/12 7/13 1.1 % 0.46 [ 0.15, 1.40 ]
Guidet 2012 (7) 31/100 24/95 5.4 % 1.23 [ 0.78, 1.93 ]
Heradstveit 2010 (8) 2/10 2/9 0.5 % 0.90 [ 0.16, 5.13 ]
James 2011 (9) 12/58 6/57 1.6 % 1.97 [ 0.79, 4.88 ]
Jie 2015 (10) 18/44 24/40 5.7 % 0.68 [ 0.44, 1.05 ]
Kumar 2017 (11) 8/55 9/52 1.7 % 0.84 [ 0.35, 2.01 ]
Li 2008 (12) 14/30 20/30 5.3 % 0.70 [ 0.44, 1.11 ]
Lu 2012 (13) 7/22 12/20 2.6 % 0.53 [ 0.26, 1.08 ]
McIntyre 2008 (14) 9/21 6/19 1.9 % 1.36 [ 0.59, 3.10 ]
Myburgh 2012 (15) 597/3315 566/3336 19.2 % 1.06 [ 0.96, 1.18 ]
Nagy 1993 (16) 2/21 2/20 0.4 % 0.95 [ 0.15, 6.13 ]
Perner 2012 (17) 201/398 172/400 16.7 % 1.17 [ 1.01, 1.36 ]
Rackow 1983 (18) 5/9 6/8 2.6 % 0.74 [ 0.36, 1.50 ]
Van der Heijden 2009 (19) 4/12 3/12 0.9 % 1.33 [ 0.38, 4.72 ]
Vlachou 2010 (20) 2/12 2/11 0.4 % 0.92 [ 0.15, 5.44 ]
Wills 2005 (21) 0/129 0/128 Not estimable
Younes 1998 (22) 2/12 3/11 0.6 % 0.61 [ 0.12, 3.00 ]
Zhao 2013 (23) 5/80 5/40 1.0 % 0.50 [ 0.15, 1.63 ]
Zhu 2011 (24) 3/90 4/45 0.7 % 0.38 [ 0.09, 1.60 ]
Total (95% CI) 5391 5786 100.0 % 0.97 [ 0.86, 1.09 ]
0.01 0.1 1 10 100
Favours starch Favours crystalloid
(Continued . . . )
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(. . . Continued)








Total events: 1223 (Starch), 1349 (Crystalloid)
Heterogeneity: Tau2 = 0.02; Chi2 = 33.27, df = 22 (P = 0.06); I2 =34%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours starch Favours crystalloid
(1) At 90 days. Colloid: HES. We combined two crystalloid groups: isotonic saline, and RL
(2) At 90 days. Colloid: HES + RL
(3) At 90 days. Colloid: HES
(4) Time point unknown. Colloid: Haes-Steril
(5) Time point during hospital stay. Colloid: HES
(6) Within 24 hours. Colloid: HES
(7) At 28 days. Colloid: HES + crystalloid
(8) At 1 year. Colloid: HES + crystalloid
(9) Time point unknown. Colloid: HES
(10) Time point unknown. Colloid: HES
(11) Up to 30 days after hospital discharge. Colloid: HES + crystalloid
(12) At 28 days. Multi-arm study. We combined data for two colloid groups: HES and HES HS; and two crystalloid groups: NS and HS
(13) Time point unknown. Colloid: HES
(14) At 28 days. Colloid: pentastarch + NS
(15) At 90 days. Colloid: HES + NS
(16) Time point not reported. Colloid: pentastarch
(17) At 90 days. Colloid: HES
(18) Within 24 hours. Colloid: HES
(19) Timepoint until discharge. Colloid: HES
(20) Time point during hospital stay. Colloid: HES
(21) Time point unknown. Colloid: HES
(22) Within 24 hours. Colloid: pentastarch
(23) At 60 days. Multi-arm study. We combined two colloid groups: HES and HES + glutamine
(24) Unknown time point. Multi-arm study. We combined two colloid groups: HES and HES + HS
178Colloids versus crystalloids for fluid resuscitation in critically ill people (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.2. Comparison 1 Starches vs crystalloid, Outcome 2 Mortality within 90 days.
Review: Colloids versus crystalloids for fluid resuscitation in critically ill people
Comparison: 1 Starches vs crystalloid
Outcome: 2 Mortality within 90 days








Annane 2013 (1) 181/645 372/1107 19.7 % 0.84 [ 0.72, 0.97 ]
Bechir 2013 (2) 8/23 6/22 1.7 % 1.28 [ 0.53, 3.08 ]
Brunkhorst 2008 (3) 107/261 93/274 14.4 % 1.21 [ 0.97, 1.51 ]
Dubin 2010 (4) 3/12 7/13 1.1 % 0.46 [ 0.15, 1.40 ]
Guidet 2012 (5) 31/100 24/95 5.5 % 1.23 [ 0.78, 1.93 ]
Kumar 2017 (6) 8/55 9/52 1.7 % 0.84 [ 0.35, 2.01 ]
Li 2008 (7) 14/30 20/30 5.4 % 0.70 [ 0.44, 1.11 ]
McIntyre 2008 (8) 9/21 6/19 1.9 % 1.36 [ 0.59, 3.10 ]
Myburgh 2012 (9) 597/3315 566/3336 23.4 % 1.06 [ 0.96, 1.18 ]
Perner 2012 (10) 201/398 172/400 19.7 % 1.17 [ 1.01, 1.36 ]
Rackow 1983 (11) 5/9 6/8 2.6 % 0.74 [ 0.36, 1.50 ]
Van der Heijden 2009 (12) 4/12 3/12 0.9 % 1.33 [ 0.38, 4.72 ]
Vlachou 2010 (13) 2/12 2/11 0.4 % 0.92 [ 0.15, 5.44 ]
Younes 1998 (14) 2/12 3/11 0.5 % 0.61 [ 0.12, 3.00 ]
Zhao 2013 (15) 5/80 5/40 1.0 % 0.50 [ 0.15, 1.63 ]
Total (95% CI) 4985 5430 100.0 % 1.01 [ 0.90, 1.14 ]
Total events: 1177 (Starch), 1294 (Crystalloid)
Heterogeneity: Tau2 = 0.01; Chi2 = 22.00, df = 14 (P = 0.08); I2 =36%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours starch Favours crystalloid
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(1) At 90 days. Colloid: HES. We combined two crystalloid groups: isotonic saline, and RL
(2) At 90 days. Colloid: HES + RL
(3) At 90 days. Colloid: HES
(4) Within 24 hours. Colloid: HES
(5) At 28 days. Colloid: HES + crystalloid
(6) Up to 30 days after hospital discharge. Colloid: HES + crystalloid
(7) At 28 days. Multi-arm study. We combined data for two colloid groups: HES and HES HS; and two crystalloid groups: NS and HS
(8) At 28 days. Colloid: pentastarch + NS
(9) At 90 days. Colloid: HES + NS
(10) At 90 days. Colloid: HES
(11) Within 24 hours. Colloid: HES
(12) Timepoint until discharge. Colloid: HES
(13) Time point during hospital stay. Colloid: HES
(14) Within 24 hours. Colloid: pentastarch
(15) At 60 days. Multi-arm study. We combined two colloid groups: HES and HES + glutamine
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Analysis 1.3. Comparison 1 Starches vs crystalloid, Outcome 3 Mortality within 30 days.
Review: Colloids versus crystalloids for fluid resuscitation in critically ill people
Comparison: 1 Starches vs crystalloid
Outcome: 3 Mortality within 30 days








Annane 2013 (1) 149/645 297/1107 22.3 % 0.86 [ 0.73, 1.02 ]
Bechir 2013 (2) 4/23 4/22 0.6 % 0.96 [ 0.27, 3.36 ]
Brunkhorst 2008 70/262 66/274 9.5 % 1.11 [ 0.83, 1.48 ]
Dubin 2010 (3) 3/12 7/13 0.7 % 0.46 [ 0.15, 1.40 ]
Guidet 2012 (4) 31/100 24/95 4.2 % 1.23 [ 0.78, 1.93 ]
Li 2008 (5) 14/30 20/30 4.1 % 0.70 [ 0.44, 1.11 ]
McIntyre 2008 (6) 9/21 6/19 1.3 % 1.36 [ 0.59, 3.10 ]
Myburgh 2012 (7) 458/3313 437/3331 34.5 % 1.05 [ 0.93, 1.19 ]
Perner 2012 (8) 154/398 144/400 20.7 % 1.07 [ 0.90, 1.29 ]
Rackow 1983 (9) 5/9 6/8 1.8 % 0.74 [ 0.36, 1.50 ]
Younes 1998 (10) 2/12 3/11 0.4 % 0.61 [ 0.12, 3.00 ]
Total (95% CI) 4825 5310 100.0 % 0.99 [ 0.90, 1.09 ]
Total events: 899 (Starch), 1014 (Crystalloid)
Heterogeneity: Tau2 = 0.00; Chi2 = 11.33, df = 10 (P = 0.33); I2 =12%
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours starches Favours crystalloids
(1) At 28 days. Colloid: HES. We combined two crystalloid groups: isotonic saline, and RL
(2) At 28 days. Colloid: HES + RL
(3) Within 24 hours. Colloid: HES
(4) At 28 days. Colloid: HES + crystalloid
(5) At 28 days. Multi-arm study. We combined data for two colloid groups: HES and HES HS; and two crystalloid groups: NS and HS
(6) At 28 days. Colloid: pentastarch + NS
(7) At 28 days. Colloid: HES + NS
(8) At 28 days. Colloid: HES
(9) Within 24 hours. Colloid: HES
(10) Within 24 hours. Colloid: pentastarch
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Analysis 1.4. Comparison 1 Starches vs crystalloid, Outcome 4 Transfusion of blood product.
Review: Colloids versus crystalloids for fluid resuscitation in critically ill people
Comparison: 1 Starches vs crystalloid
Outcome: 4 Transfusion of blood product








Brunkhorst 2008 (1) 199/262 189/275 61.3 % 1.11 [ 1.00, 1.23 ]
Cifra 2003 (2) 1/10 3/13 0.5 % 0.43 [ 0.05, 3.57 ]
Guidet 2012 (3) 29/100 20/96 8.7 % 1.39 [ 0.85, 2.29 ]
McIntyre 2008 (4) 10/21 5/19 3.0 % 1.81 [ 0.75, 4.35 ]
Nagy 1993 (5) 11/21 10/20 6.1 % 1.05 [ 0.58, 1.91 ]
Perner 2012 84/397 59/400 19.9 % 1.43 [ 1.06, 1.94 ]
Vlachou 2010 (6) 0/12 0/14 Not estimable
Wills 2005 (7) 1/129 3/128 0.5 % 0.33 [ 0.03, 3.14 ]
Total (95% CI) 952 965 100.0 % 1.19 [ 1.02, 1.39 ]
Total events: 335 (Starch), 289 (Crystalloid)
Heterogeneity: Tau2 = 0.01; Chi2 = 6.95, df = 6 (P = 0.33); I2 =14%
Test for overall effect: Z = 2.20 (P = 0.028)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours starches Favours crystalloids
(1) Colloid: HES
(2) Colloid: HAES-steril
(3) Colloid: HES + crystalloid
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Analysis 1.5. Comparison 1 Starches vs crystalloid, Outcome 5 Renal replacement therapy.
Review: Colloids versus crystalloids for fluid resuscitation in critically ill people
Comparison: 1 Starches vs crystalloid
Outcome: 5 Renal replacement therapy








Bechir 2013 (1) 6/23 6/22 1.8 % 0.96 [ 0.36, 2.52 ]
Brunkhorst 2008 81/261 51/272 17.9 % 1.66 [ 1.22, 2.25 ]
Guidet 2012 (2) 22/100 17/96 5.2 % 1.24 [ 0.70, 2.19 ]
James 2011 (3) 2/56 3/53 0.5 % 0.63 [ 0.11, 3.63 ]
Mahrous 2013 (4) 13/30 10/26 4.2 % 1.13 [ 0.60, 2.13 ]
McIntyre 2008 (5) 3/21 1/19 0.4 % 2.71 [ 0.31, 23.93 ]
Myburgh 2012 (6) 235/3352 196/3375 50.0 % 1.21 [ 1.00, 1.45 ]
Perner 2012 (7) 87/398 65/400 20.0 % 1.35 [ 1.01, 1.80 ]
Vlachou 2010 (8) 0/12 0/11 Not estimable
Total (95% CI) 4253 4274 100.0 % 1.30 [ 1.14, 1.48 ]
Total events: 449 (Starch), 349 (Crystalloid)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.77, df = 7 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 3.93 (P = 0.000084)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours starches Favours crystalloids
(1) Colloid: HES + RL
(2) Colloid: HES + crystalloid
(3) RRT = dialysis. Colloid: HES
(4) Colloid: HES
(5) Dialysis. Colloid: pentastarch
(6) Dialysis. Colloid: HES
(7) Colloid: HES
(8) Colloid: HES
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Analysis 1.6. Comparison 1 Starches vs crystalloid, Outcome 6 Adverse event: allergic reaction.
Review: Colloids versus crystalloids for fluid resuscitation in critically ill people
Comparison: 1 Starches vs crystalloid
Outcome: 6 Adverse event: allergic reaction








Bulger 2008 0/110 0/99 Not estimable
Myburgh 2012 1/3871 0/2879 50.0 % 2.23 [ 0.09, 54.76 ]
Perner 2012 1/398 0/400 50.0 % 3.02 [ 0.12, 73.79 ]
Total (95% CI) 4379 3378 100.0 % 2.59 [ 0.27, 24.91 ]
Total events: 2 (Starch), 0 (Crystalloid)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours colloid Favours crystalloid
Analysis 1.7. Comparison 1 Starches vs crystalloid, Outcome 7 Adverse event: itching.
Review: Colloids versus crystalloids for fluid resuscitation in critically ill people
Comparison: 1 Starches vs crystalloid
Outcome: 7 Adverse event: itching








Guidet 2012 3/100 3/96 3.1 % 0.96 [ 0.20, 4.64 ]
Myburgh 2012 137/3871 73/2879 96.9 % 1.40 [ 1.06, 1.85 ]
Total (95% CI) 3971 2975 100.0 % 1.38 [ 1.05, 1.82 ]
Total events: 140 (Starch), 76 (Crystalloid)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.29 (P = 0.022)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours colloid Favours crystalloid
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Analysis 1.8. Comparison 1 Starches vs crystalloid, Outcome 8 Adverse event: rash.
Review: Colloids versus crystalloids for fluid resuscitation in critically ill people
Comparison: 1 Starches vs crystalloid
Outcome: 8 Adverse event: rash








Myburgh 2012 34/3871 16/2879 96.7 % 1.58 [ 0.87, 2.86 ]
Wills 2005 1/129 0/128 3.3 % 2.98 [ 0.12, 72.40 ]
Total (95% CI) 4000 3007 100.0 % 1.61 [ 0.90, 2.89 ]
Total events: 35 (Starch), 16 (Crystalloid)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours colloid Favours crystalloid
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Analysis 2.1. Comparison 2 Dextrans vs crystalloid, Outcome 1 Mortality at end of follow-up.
Review: Colloids versus crystalloids for fluid resuscitation in critically ill people
Comparison: 2 Dextrans vs crystalloid
Outcome: 1 Mortality at end of follow-up








Alpar 2004 (1) 7/90 12/90 1.6 % 0.58 [ 0.24, 1.41 ]
Baker 2009 (2) 6/31 4/33 0.9 % 1.60 [ 0.50, 5.13 ]
Bulger 2008 (3) 32/110 22/99 5.4 % 1.31 [ 0.82, 2.09 ]
Bulger 2010 (4) 96/359 236/923 22.7 % 1.05 [ 0.85, 1.28 ]
Bulger 2011 (5) 56/220 166/632 15.4 % 0.97 [ 0.75, 1.26 ]
Chavez-Negrete 1991 (6) 1/26 5/23 0.3 % 0.18 [ 0.02, 1.41 ]
Hall 1978 (7) 18/86 16/86 3.4 % 1.13 [ 0.62, 2.06 ]
Mattox 1991 (8) 35/184 42/175 7.4 % 0.79 [ 0.53, 1.18 ]
Modig 1986 (9) 0/14 0/17 Not estimable
Morrison 2011 (10) 15/50 15/57 3.3 % 1.14 [ 0.62, 2.09 ]
Ngo 2001 (11) 0/55 0/111 Not estimable
Oliveira 2002 (12) 4/13 10/16 1.6 % 0.49 [ 0.20, 1.21 ]
Vassar 1990 (13) 12/23 13/24 4.2 % 0.96 [ 0.56, 1.65 ]
Vassar 1991 (14) 30/83 34/83 7.8 % 0.88 [ 0.60, 1.30 ]
Vassar 1993a (15) 49/99 43/95 12.4 % 1.09 [ 0.81, 1.47 ]
Vassar 1993b (16) 21/89 25/169 4.5 % 1.60 [ 0.95, 2.68 ]
Wills 2005 (17) 0/126 0/128 Not estimable
Younes 1992 (18) 7/35 15/70 2.0 % 0.93 [ 0.42, 2.08 ]
Younes 1997 (19) 27/101 40/111 7.1 % 0.74 [ 0.49, 1.11 ]
Total (95% CI) 1794 2942 100.0 % 0.99 [ 0.88, 1.11 ]
Total events: 416 (Dextran), 698 (Crystalloid)
Heterogeneity: Tau2 = 0.00; Chi2 = 16.20, df = 15 (P = 0.37); I2 =7%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
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(1) Time point not reported. Colloid: HSD
(2) Within 30 days. Colloid: HSD
(3) At 28 days. Colloid: HSD
(4) At 28 days. Colloid: HSD. We combined two crystalloid groups: NS and HS
(5) At 28 days. Colloid: HSD. We combined two crystalloid groups: NS and HS
(6) Within 24 hours. Colloid: HSD
(7) Within 48 hours. Colloid: dextran 70 + NS
(8) At 30 days. Colloid: HSD
(9) Time point not reported. Colloid: dextran 70
(10) At 30 days. Colloid: HSD
(11) Time point unknown. Colloid: dextran 70. We combined two crystalloid groups: RL and NS
(12) Time point not reported. Colloid: HSD 8%
(13) At 28 days. Colloid: HSD
(14) Until hospital discharge. Colloid: HSD
(15) Until hospital discharge. Multi-arm study. We combined both HSD groups (6% and 12%) versus both crytalloid groups (RL and HS)
(16) Until hospital discharge. Multi-arm study. We combined two crystalloid groups (NS and HS) versus colloid (HSD 12%)
(17) Time point unknown. Colloid: dextran
(18) Until hospital stay. Multi-arm study. We combined both crystalloid groups (NS and HS) versus colloid (HSD)
(19) At 30 days. Colloid: HSD
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Analysis 2.2. Comparison 2 Dextrans vs crystalloid, Outcome 2 Mortality within 90 days and 30 days.
Review: Colloids versus crystalloids for fluid resuscitation in critically ill people
Comparison: 2 Dextrans vs crystalloid
Outcome: 2 Mortality within 90 days and 30 days








Baker 2009 (1) 6/31 4/33 1.1 % 1.60 [ 0.50, 5.13 ]
Bulger 2008 (2) 32/110 22/99 6.9 % 1.31 [ 0.82, 2.09 ]
Bulger 2010 (3) 96/359 236/923 36.8 % 1.05 [ 0.85, 1.28 ]
Bulger 2011 (4) 56/220 166/632 22.4 % 0.97 [ 0.75, 1.26 ]
Chavez-Negrete 1991 (5) 1/26 5/23 0.4 % 0.18 [ 0.02, 1.41 ]
Hall 1978 (6) 18/86 16/86 4.2 % 1.13 [ 0.62, 2.06 ]
Mattox 1991 (7) 35/184 42/175 9.6 % 0.79 [ 0.53, 1.18 ]
Morrison 2011 (8) 15/50 15/57 4.1 % 1.14 [ 0.62, 2.09 ]
Vassar 1990 (9) 12/23 13/24 5.3 % 0.96 [ 0.56, 1.65 ]
Younes 1997 (10) 27/101 40/111 9.2 % 0.74 [ 0.49, 1.11 ]
Total (95% CI) 1190 2163 100.0 % 0.99 [ 0.87, 1.12 ]
Total events: 298 (Dextran), 559 (Crystalloid)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.48, df = 9 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours dextrans Favours crystalloid
(1) Within 30 days. Colloid: HSD
(2) At 28 days. Colloid: HSD
(3) At 28 days. Colloid: HSD. We have combined two crystalloid groups: NS and HS
(4) At 28 days. Colloid: HSD. We have combined two crystalloid groups: NS and HS
(5) Within 24 hours. Colloid: HSD
(6) Within 48 hours. Colloid: dextran 70 + NS
(7) At 30 days. Colloid: HSD
(8) At 30 days. Colloid: HSD
(9) At 28 days. Colloid: HSD
(10) At 30 days. Colloid: HSD
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Analysis 2.3. Comparison 2 Dextrans vs crystalloid, Outcome 3 Transfusion of blood products.
Review: Colloids versus crystalloids for fluid resuscitation in critically ill people
Comparison: 2 Dextrans vs crystalloid
Outcome: 3 Transfusion of blood products








Bulger 2011 92/220 286/632 99.4 % 0.92 [ 0.77, 1.10 ]
Ngo 2001 (1) 0/55 0/111 Not estimable
Wills 2005 1/126 3/128 0.6 % 0.34 [ 0.04, 3.21 ]
Total (95% CI) 401 871 100.0 % 0.92 [ 0.77, 1.10 ]
Total events: 93 (Dextran), 289 (Crystalloid)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.77, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
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Favours colloid Favours crystalloid
(1) We combined data in both crystalloid groups (RL and NS)
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Analysis 2.4. Comparison 2 Dextrans vs crystalloid, Outcome 4 Adverse events: allergic reaction.
Review: Colloids versus crystalloids for fluid resuscitation in critically ill people
Comparison: 2 Dextrans vs crystalloid
Outcome: 4 Adverse events: allergic reaction








Mattox 1991 0/184 0/175 Not estimable
Ngo 2001 1/55 0/111 100.0 % 6.00 [ 0.25, 144.93 ]
Vassar 1990 0/23 0/24 Not estimable
Vassar 1991 0/83 0/83 Not estimable
Total (95% CI) 345 393 100.0 % 6.00 [ 0.25, 144.93 ]
Total events: 1 (Dextran), 0 (Crystalloid)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours colloid Favours crystalloid
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Analysis 3.1. Comparison 3 Gelatins vs crystalloid, Outcome 1 Mortality at end of follow-up.
Review: Colloids versus crystalloids for fluid resuscitation in critically ill people
Comparison: 3 Gelatins vs crystalloid
Outcome: 1 Mortality at end of follow-up








Annane 2013 (1) 84/281 372/1107 90.3 % 0.89 [ 0.73, 1.08 ]
Evans 1996 (2) 1/11 2/14 0.7 % 0.64 [ 0.07, 6.14 ]
Ngo 2001 (3) 0/56 0/111 Not estimable
Upadhyay 2005 (4) 9/29 9/31 5.9 % 1.07 [ 0.49, 2.32 ]
Van der Heijden 2009 (5) 3/12 3/12 1.8 % 1.00 [ 0.25, 4.00 ]
Wu 2001 (6) 2/18 3/16 1.3 % 0.59 [ 0.11, 3.11 ]
Total (95% CI) 407 1291 100.0 % 0.89 [ 0.74, 1.08 ]
Total events: 99 (Gelatins), 389 (Crystalloids)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.56, df = 4 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours gelatins Favours crystalloids
(1) At 90 days. Colloid: gelatins. We combined two crystalloid groups: isotonic saline, and RL
(2) Time point unknown. Colloid: Haemaccel
(3) Time point unknown. Colloid: gelafundin
(4) Time point not reported. Colloid: Haemaccel
(5) Timepoint until discharge. Colloid: Gelofusine
(6) Time point not reported. Colloid: Gelofusine
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Analysis 4.1. Comparison 4 Albumin or FFP vs crystalloid, Outcome 1 Mortality at end of follow-up.
Review: Colloids versus crystalloids for fluid resuscitation in critically ill people
Comparison: 4 Albumin or FFP vs crystalloid
Outcome: 1 Mortality at end of follow-up








Annane 2013 (1) 28/80 346/1035 4.9 % 1.05 [ 0.77, 1.43 ]
Caironi 2014 (2) 365/888 389/893 28.2 % 0.94 [ 0.85, 1.05 ]
Cooper 2006 (3) 3/19 1/23 0.1 % 3.63 [ 0.41, 32.13 ]
Finfer 2004 (4) 726/3473 729/3460 34.8 % 0.99 [ 0.91, 1.09 ]
Goodwin 1983 (5) 11/15 3/14 0.5 % 3.42 [ 1.20, 9.76 ]
Jelenko 1979 (6) 1/7 3/12 0.1 % 0.57 [ 0.07, 4.49 ]
Lowe 1977 (7) 3/57 3/84 0.2 % 1.47 [ 0.31, 7.05 ]
Lucas 1978 (8) 7/27 0/25 0.1 % 13.93 [ 0.84, 231.93 ]
Maitland 2005 (9) 2/56 11/61 0.2 % 0.20 [ 0.05, 0.85 ]
Maitland 2011 (10) 137/1063 135/1063 9.1 % 1.01 [ 0.81, 1.27 ]
Martin 2005 (11) 7/20 9/20 0.8 % 0.78 [ 0.36, 1.68 ]
Metildi 1984 (12) 12/20 13/26 1.8 % 1.20 [ 0.71, 2.03 ]
O’Mara 2005 (13) 3/16 4/15 0.3 % 0.70 [ 0.19, 2.63 ]
Park 2015 (14) 30/50 31/60 4.3 % 1.16 [ 0.83, 1.62 ]
Philips 2015 (15) 87/154 95/154 12.4 % 0.92 [ 0.76, 1.10 ]
Pockaj 1994 (16) 0/36 0/40 Not estimable
Quinlan 2004 (17) 4/10 4/10 0.4 % 1.00 [ 0.34, 2.93 ]
Rackow 1983 (18) 6/9 6/8 1.3 % 0.89 [ 0.48, 1.64 ]
Shah 1977 (19) 2/9 3/11 0.2 % 0.81 [ 0.17, 3.87 ]
Van der Heijden 2009 (20) 2/12 3/12 0.2 % 0.67 [ 0.13, 3.30 ]
Total (95% CI) 6021 7026 100.0 % 0.98 [ 0.92, 1.06 ]
Total events: 1436 (Natural colloid), 1788 (Crystalloid)
Heterogeneity: Tau2 = 0.00; Chi2 = 19.27, df = 18 (P = 0.38); I2 =7%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours natural colloid Favours crystalloid
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(1) At 90 days. Colloid: albumin
(2) At 90 days. Colloid: albumin
(3) At 28 days. Colloid: albumin + NS
(4) At 28 days. Colloid: albumin
(5) Time point unknown. Colloid: albumin + RL
(6) Time point not reported. Multi-arm study. We combined both crystalloid groups (RL and HS) versus colloid (albumin)
(7) Time point not reported. Colloid: albumin + RL
(8) Time point not reported. Colloid: albumin
(9) Time point not reported. Colloid: albumin
(10) At 4 weeks. Colloid: albumin
(11) At 30 days. Colloid: albumin
(12) Time point not reported. Colloid: albumin + RL
(13) Time point not reported. Colloid: FFP + RL
(14) At 30 days. Colloid: albumin
(15) Within 7 days. Colloid: albumin
(16) Time point not reported. Colloid: albumin + NS query data
(17) At 28 days. Colloid: albumin
(18) Within 24 hours. Colloid: albumin
(19) Time point not reported. Colloid: albumin + RL
(20) Timepoint until discharge. Colloid: albumin
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Analysis 4.2. Comparison 4 Albumin or FFP vs crystalloid, Outcome 2 Mortality within 90 days.
Review: Colloids versus crystalloids for fluid resuscitation in critically ill people
Comparison: 4 Albumin or FFP vs crystalloid
Outcome: 2 Mortality within 90 days








Annane 2013 (1) 28/80 346/1035 3.7 % 1.05 [ 0.77, 1.43 ]
Caironi 2014 (2) 365/888 389/893 30.5 % 0.94 [ 0.85, 1.05 ]
Cooper 2006 (3) 3/19 1/23 0.1 % 3.63 [ 0.41, 32.13 ]
Finfer 2004 (4) 726/3473 729/3460 43.0 % 0.99 [ 0.91, 1.09 ]
Maitland 2011 (5) 137/1063 135/1063 7.3 % 1.01 [ 0.81, 1.27 ]
Martin 2005 (6) 7/20 9/20 0.6 % 0.78 [ 0.36, 1.68 ]
Park 2015 (7) 30/50 31/60 3.2 % 1.16 [ 0.83, 1.62 ]
Philips 2015 (8) 87/154 95/154 10.3 % 0.92 [ 0.76, 1.10 ]
Quinlan 2004 (9) 4/10 4/10 0.3 % 1.00 [ 0.34, 2.93 ]
Rackow 1983 (10) 6/9 6/8 1.0 % 0.89 [ 0.48, 1.64 ]
Total (95% CI) 5766 6726 100.0 % 0.98 [ 0.92, 1.04 ]
Total events: 1393 (Natural colloid), 1745 (Crystalloid)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.16, df = 9 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours natural colloid Favours crystalloid
(1) At 90 days. Colloid: albumin
(2) At 90 days. Colloid: albumin
(3) At 28 days. Colloid: albumin + NS
(4) At 28 days. Colloid: albumin
(5) At 4 weeks. Colloid: albumin
(6) At 30 days. Colloid: albumin
(7) At 30 days. Colloid: albumin
(8) Within 7 days. Colloid: albumin
(9) At 28 days. Colloid: albumin
(10) Within 24 hours. Colloid: albumin
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Analysis 4.3. Comparison 4 Albumin or FFP vs crystalloid, Outcome 3 Mortality within 30 days.
Review: Colloids versus crystalloids for fluid resuscitation in critically ill people
Comparison: 4 Albumin or FFP vs crystalloid
Outcome: 3 Mortality within 30 days








Annane 2013 (1) 24/80 275/1035 3.3 % 1.13 [ 0.80, 1.60 ]
Caironi 2014 (2) 285/895 288/900 22.2 % 1.00 [ 0.87, 1.14 ]
Cooper 2006 (3) 3/19 1/23 0.1 % 3.63 [ 0.41, 32.13 ]
Finfer 2004 (4) 726/3473 729/3460 48.6 % 0.99 [ 0.91, 1.09 ]
Maitland 2011 (5) 137/1063 135/1063 8.2 % 1.01 [ 0.81, 1.27 ]
Martin 2005 (6) 7/20 9/20 0.7 % 0.78 [ 0.36, 1.68 ]
Park 2015 (7) 30/50 31/60 3.7 % 1.16 [ 0.83, 1.62 ]
Philips 2015 (8) 87/154 95/154 11.7 % 0.92 [ 0.76, 1.10 ]
Quinlan 2004 (9) 4/10 4/10 0.4 % 1.00 [ 0.34, 2.93 ]
Rackow 1983 (10) 6/9 6/8 1.1 % 0.89 [ 0.48, 1.64 ]
Total (95% CI) 5773 6733 100.0 % 0.99 [ 0.93, 1.06 ]
Total events: 1309 (Natural colloid), 1573 (Crystalloid)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.01, df = 9 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours natural colloids Favours crystalloids
(1) At 28 days. Colloid: albumin
(2) At 28 days. Colloid: albumin
(3) At 28 days. Colloid: albumin + NS
(4) At 28 days. Colloid: albumin
(5) At 4 weeks. Colloid: albumin
(6) At 30 days. Colloid: albumin
(7) At 30 days. Colloid: albumin
(8) Within 7 days. Colloid: albumin
(9) At 28 days. Colloid: albumin
(10) Within 24 hours. Colloid: albumin
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Analysis 4.4. Comparison 4 Albumin or FFP vs crystalloid, Outcome 4 Transfusion of blood product.
Review: Colloids versus crystalloids for fluid resuscitation in critically ill people
Comparison: 4 Albumin or FFP vs crystalloid
Outcome: 4 Transfusion of blood product








Cooper 2006 (1) 1/19 3/23 2.2 % 0.40 [ 0.05, 3.57 ]
Lowe 1977 (2) 31/57 34/84 82.9 % 1.34 [ 0.95, 1.91 ]
Pockaj 1994 (3) 11/54 8/53 15.0 % 1.35 [ 0.59, 3.09 ]
Total (95% CI) 130 160 100.0 % 1.31 [ 0.95, 1.80 ]
Total events: 43 (Natural colloid), 45 (Crystalloid)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.17, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.65 (P = 0.098)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours natural colloids Favours crystalloids
(1) Colloid: albumin + NS
(2) Colloid: albumin + RL
(3) Colloid: albumin + NS
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Analysis 4.5. Comparison 4 Albumin or FFP vs crystalloid, Outcome 5 Renal replacement therapy.
Review: Colloids versus crystalloids for fluid resuscitation in critically ill people
Comparison: 4 Albumin or FFP vs crystalloid
Outcome: 5 Renal replacement therapy








Caironi 2014 222/903 194/907 66.1 % 1.15 [ 0.97, 1.36 ]
Finfer 2004 (1) 113/603 112/615 33.9 % 1.03 [ 0.81, 1.30 ]
Total (95% CI) 1506 1522 100.0 % 1.11 [ 0.96, 1.27 ]
Total events: 335 (Natural colloid), 306 (Crystalloid)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.56, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours colloids Favours crystalloids
(1) Results are for a subgroup of participants with severe sepsis. Colloid: albumin.
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Analysis 5.1. Comparison 5 Dextrans vs crystalloid: subgroup by tonicity of crystalloid, Outcome 1 All-
cause mortality at end of follow-up.
Review: Colloids versus crystalloids for fluid resuscitation in critically ill people
Comparison: 5 Dextrans vs crystalloid: subgroup by tonicity of crystalloid
Outcome: 1 All-cause mortality at end of follow-up








1 colloid + hypertonic crystalloid vs isotonic crystalloid
Baker 2009 (1) 6/31 4/33 1.0 % 1.60 [ 0.50, 5.13 ]
Bulger 2010 (2) 96/359 236/923 25.1 % 1.05 [ 0.85, 1.28 ]
Bulger 2011 (3) 56/220 166/632 16.8 % 0.97 [ 0.75, 1.26 ]
Morrison 2011 (4) 15/50 15/57 3.5 % 1.14 [ 0.62, 2.09 ]
Oliveira 2002 (5) 4/13 10/16 1.6 % 0.49 [ 0.20, 1.21 ]
Vassar 1993a (6) 49/99 43/95 13.4 % 1.09 [ 0.81, 1.47 ]
Younes 1992 (7) 7/35 15/70 2.1 % 0.93 [ 0.42, 2.08 ]
Younes 1997 (8) 27/101 40/111 7.6 % 0.74 [ 0.49, 1.11 ]
Subtotal (95% CI) 908 1937 71.0 % 0.99 [ 0.87, 1.13 ]
Total events: 260 (Colloids), 529 (Crystalloids)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.86, df = 7 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
2 colloid + isotonic crystalloid vs hypertonic crystalloid
Hall 1978 (9) 18/86 16/86 3.6 % 1.13 [ 0.62, 2.06 ]
Wills 2005 (10) 0/193 0/128 Not estimable
Subtotal (95% CI) 279 214 3.6 % 1.13 [ 0.62, 2.06 ]
Total events: 18 (Colloids), 16 (Crystalloids)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
3 colloid + hypertonic crystalloid vs hypertonic crystalloid
Alpar 2004 (11) 7/90 12/90 1.7 % 0.58 [ 0.24, 1.41 ]
Bulger 2008 (12) 32/110 22/99 5.8 % 1.31 [ 0.82, 2.09 ]
Chavez-Negrete 1991 (13) 1/26 5/23 0.3 % 0.18 [ 0.02, 1.41 ]
Vassar 1990 (14) 12/23 13/24 4.5 % 0.96 [ 0.56, 1.65 ]
Vassar 1991 (15) 30/83 34/83 8.4 % 0.88 [ 0.60, 1.30 ]
Vassar 1993b (16) 21/89 25/169 4.8 % 1.60 [ 0.95, 2.68 ]
0.01 0.1 1 10 100
Favours colloids Favours crystalloids
(Continued . . . )
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(. . . Continued)








Subtotal (95% CI) 421 488 25.4 % 1.02 [ 0.74, 1.41 ]
Total events: 103 (Colloids), 111 (Crystalloids)
Heterogeneity: Tau2 = 0.06; Chi2 = 8.75, df = 5 (P = 0.12); I2 =43%
Test for overall effect: Z = 0.12 (P = 0.91)
Total (95% CI) 1608 2639 100.0 % 1.01 [ 0.90, 1.13 ]
Total events: 381 (Colloids), 656 (Crystalloids)
Heterogeneity: Tau2 = 0.00; Chi2 = 14.88, df = 14 (P = 0.39); I2 =6%
Test for overall effect: Z = 0.12 (P = 0.91)
Test for subgroup differences: Chi2 = 0.17, df = 2 (P = 0.92), I2 =0.0%
0.01 0.1 1 10 100
Favours colloids Favours crystalloids
(1) Within 30 days. Colloid: HSD
(2) At 28 days. Colloid: HSD. We have combined two crystalloid groups: NS and HS
(3) At 28 days. Colloid: HSD. We have combined two crystalloid groups: NS and HS
(4) At 30 days. Colloid: HSD
(5) Time point not reported. Colloid: HSD 8%
(6) Until hospital discharge. Multi-arm study. We have combined both HSD groups (6% and 12%) versus both crytalloid groups (RL and HS)
(7) Until hospital stay. Multi-arm study. We have combined both crystalloid groups (NS and HS) versus colloid (HSD)
(8) At 30 days. Colloid: HSD
(9) Within 48 hours. Colloid: dextran 70 + NS
(10) Time point unknown. Colloid: dextran
(11) Time point not reported. Colloid: HSD 4.2%
(12) At 28 days. Colloid: HSD
(13) Within 24 hours. Colloid: HSD (dextran 60)
(14) At 28 days. Colloid: HSD
(15) Until hospital discharge. Colloid: HSD
(16) Until hospital discharge. Multi-arm study. We have combined two crystalloid groups (NS and HS) versus colloid (HSD)
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A D D I T I O N A L T A B L E S
Table 1. Summary of participant conditions
Participant condition Study ID
Admission to an ICUwith any condition (which included trauma,
sepsis, ARDS, head injury)
Finfer 2004; Myburgh 2012
Trauma (includes studies of ’any trauma admissions’, and head,
chest, and abdominal injuries, and trauma with haemorrhagic or
hypovolaemic shock)
Annane 2013*; Alpar 2004; Baker 2009; Bulger 2008; Bulger
2010; Bulger 2011; Evans 1996; Grba-Bujevic 2012; James 2011;
Lowe 1977; Lucas 1978;Masoumi 2016;Mattox 1991;Morrison
2011; Shah 1977; Vassar 1990; Vassar 1991; Vassar 1993a; Vassar
1993b; Wu 2001
Sepsis or septic shock Annane 2013*; Brunkhorst 2008; Caironi 2014; Dubin 2010;
Ernest 1999; Guidet 2012; Jie 2015; Li 2008; Lu 2012; Mahrous
2013; McIntyre 2008; McIntyre 2012; Modig 1986; Oliveira
2002; Park2015 (cancerwith sepsis); Perner 2012;Rackow1983*;
Upadhyay 2005; Zhu 2011
Hypovolaemia, hypovolaemic shock, haemorrhagic shock Annane 2013*; Chavez-Negrete 1991; Nagy 1993; Rackow
1983*; Van derHeijden 2009; Younes 1992; Younes 1997; Younes
1998
Burns Bechir 2013; Cooper 2006; Goodwin 1983; Hall 1978; Jelenko
1979; O’Mara 2005; Vlachou 2010
ALI, ARDS Martin 2005; Quinlan 2004
Spontaneous subarachnoid haemorrhage Bentsen 2006
Dengue shock syndrome Cifra 2003; Dung 1999; Wills 2005
Postcardiac arrest Heradstveit 2010
Perforation peritonitis Kumar 2017
Severe malaria Maitland 2005
Severe febrile illness Maitland 2011
Severe pulmonary insufficiency Metildi 1984
Vascular leak syndrome (cancer patients) Pockaj 1994
Cirrhosis and septic induced hypotension Philips 2015
Severe acute pancreatitis Du 2011; Zhao 2013
* included for more than one type of condition
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ALI: acute lung injury
ARDS: acute respiratory distress syndrome
ICU: intensive care unit
Table 2. Data for outcomes with a single study






Colloids (at the discretion of the clinician: HES, gelatins, or albumin) versus crystalloids
Annane 2013 Transfusion of blood prod-
ucts
377/1414 358/1443 RR 1.07, 95% CI 0.95 to
1.22; 2857 participants
Annane 2013 Renal replacement therapy 156/1414 181/1443 RR 0.88, 95% CI 0.72 to
1.08; 2857 participants
Gelatin versus crystalloids
Annane 2013 Mortality (within 90 days) 84/281 346/1035 RR 0.89, 95% CI 0.73 to
1.09; 1388 participants
Annane 2013 Mortality (within 30 days) 69/281 275/1035 RR 0.92, 95% CI 0.74 to
1.16; 1388 participants
Albumin versus crystalloid
Maitland 2011 Adverse events: allergic re-
actions




n: number of participants with an event
N: number of participants randomised to group
RR: risk ratio
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Plasma Volume explode all trees
#2 MeSH descriptor Fluid Therapy explode all trees
#3 MeSH descriptor Resuscitation explode all trees
#4 (fluid* OR volumeOR plasma OR rehydrat* OR blood ORoral) next (replac* OR therapy OR substitut* OR restor* OR resuscitat*
OR rehydrat*):ti,ab,kw
#5 (#1 OR #2 OR #3 or #4)
#6 MeSH descriptor Colloids explode all trees
#7 MeSH descriptor Hetastarch explode all trees
#8 MeSH descriptor Rehydration Solutions explode all trees
#9 MeSH descriptor Isotonic Solutions explode all trees
#10 MeSH descriptor Serum explode all trees
#11 MeSH descriptor Plasma explode all trees
#12 MeSH descriptor Plasma Substitutes explode all trees
#13 MeSH descriptor Albumins explode all trees
#14 MeSH descriptor Serum Albumin explode all trees
#15 (colloid* OR hydrocolloid* or crystalloid* OR albumin* OR albumen* OR plasma OR starch* OR dextran* OR gelofus* OR
hemaccel*ORhaemaccel*OR serumORhetastarchOR isotonicORringer*ORgelatin*ORgentran*ORpentastarch*ORpentaspan*
OR hartman OR sodium OR potassium OR saline):ti
#16 (Isotonic next saline next solution*) OR (Blood next substitut*) OR (blood next expan*) OR (plasma next volume next expan*)
OR (volume next expan*)
#17 (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16)
#18 (#5 AND #17)
Appendix 2. MEDLINE Ovid search strategy
1. exp Plasma Volume/
2. exp Fluid Therapy/
3. exp Resuscitation/
4. ((fluid* or volume or plasma or rehydrat* or blood or oral) adj1 (replac* or therapy or substitut* or restor* or resuscitat* or
rehydrat*)).ab,ti.
5. 1 or 2 or 3 or 4
6. exp Colloids/
7. exp Hetastarch/
8. exp Rehydration Solutions/
9. exp Isotonic Solutions/
10. exp Serum/
11. exp Plasma/
12. exp Plasma Substitutes/
13. exp Albumins/
14. exp Serum Albumin/
15. (colloid* or hydrocolloid* or crystalloid* or albumin* or albumen* or plasma or starch* or dextran* or gelofus* or hemaccel* or
haemaccel* or serum or hetastarch or isotonic or ringer* or gelatin* or gentran* or pentastarch* or pentaspan* or hartman or sodium
or potassium or saline).ti.
16. ((Isotonic adj1 saline adj1 solution*) or (Blood adj1 substitut*) or (blood adj1 expan*) or (plasma adj1 volume adj1 expan*) or
(volume adj1 expan*)).ab,ti.
17. or/6-16
18. 5 and 17
19. randomi?ed.ab,ti.
20. randomized controlled trial.pt.
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21. controlled clinical trial.pt.
22. placebo.ab.
23. clinical trials as topic.sh.
24. randomly.ab.
25. trial.ti.
26. 19 or 20 or 21 or 22 or 23 or 24 or 25
27. (animals not (humans and animals)).sh.
28. 26 not 27
29. 18 and 28
Appendix 3. Embase Ovid search strategy
1. exp plasma volume/
2. exp fluid therapy/
3. exp fluid resuscitation/
4. ((fluid* or volume or plasma or rehydrat* or blood or oral) adj1 (replac* or therapy or substitut* or restor* or resuscitat* or
rehydrat*)).ab,ti.
5. 1 or 2 or 3 or 4
6. exp colloid/
7. exp hetastarch/
8. exp “solution and solubility”/
9. exp isotonic solution/
10. exp serum/




15. exp plasma substitute/
16. exp albumin/
17. exp serum albumin/
18. or/6-17
19. (th or ad orIV).fs.
20. 18 and 19
21. (colloid* or hydrocolloid* or crystalloid* or albumin* or albumen* or plasma or starch* or dextran* or gelofus* or hemaccel* or
haemaccel* or serum or hetastarch or isotonic or ringer* or gelatin* or gentran* or pentastarch* or pentaspan* or hartman or sodium
or potassium or saline).ti.
22. ((Isotonic adj1 saline adj1 solution*) or (Blood adj1 substitut*) or (blood adj1 expan*) or (plasma adj1 volume adj1 expan*) or
(volume adj1 expan*)).ab,ti.
23. 20 or 21 or 22
24. exp Randomized Controlled Trial/






31. 24 or 25 or 26 or 27 or 28 or 29 or 30
32. exp animal/ not (exp human/ and exp animal/)
33. 31 not 32
34. 5 and 23 and 33
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Appendix 4. PubMed search strategy
(((((((colloid* OR hydrocolloid* OR crystalloid* OR albumin* OR albumen* OR plasma OR starch* OR dextran* OR gelofus*
OR hemaccel* OR haemaccel* OR serum OR hetastarch OR isotonic OR ringer* OR gelatin* OR gentran* OR pentastarch* OR
pentaspan* OR hartmanOR sodium OR potassium OR saline) AND title)) OR (colloids[MeSHTerms]))) AND ((((fluid* OR volume
OR plasma OR rehydrat* OR blood OR oral) AND (replac* OR therapy OR substitut* OR restor* OR resuscitat* OR rehydrat*)))
OR (((plasma volume[MeSH Terms]) OR fluid therapy) OR resuscitation)))) AND ((randomised OR randomized OR randomly OR
random order OR random sequence OR random allocation OR randomly allocated OR at randomOR randomized controlled trial[pt]
OR controlled clinical trial[pt] OR randomized controlled trials[mh]) NOT ((models, animal[mh] OR Animals[mh] OR Animal
Experimentation[mh] OR Disease Models, Animal[mh] OR Animals, Laboratory[mh]) NOT (Humans[mh])))
Appendix 5. Web of Science search strategy
#1 colloid* OR hydrocolloid* or crystalloid*
#2 (Isotonic NEAR/1 saline NEAR/1 solution*) OR (Blood NEAR/1 substitut*) OR (blood NEAR/1 expan*) OR (plasma NEAR/1
volume NEAR/1 expan*) OR (volume NEAR/1 expan*)
#3 #1 OR #2
#4 (fluid* OR volume OR plasma OR rehydrat* OR blood OR oral) NEAR/2 (replac* OR therapy OR substitut* OR restor* OR
resuscitat* OR rehydrat*)
#5 (random*) NEAR/3 (study or trial)
#6 (singl* OR doubl* OR trebl* OR tripl*) NEAR/3 (blind* OR mask*) NEAR/3 (study or trial)
#7 #6 OR #5
#8 #7 AND #4 AND #3
Appendix 6. ClinicalTrials.gov search strategy
colloid AND crystalloid
Appendix 7. WHO ICTRP search strategy
colloid AND crystalloid
Appendix 8. OpenGrey search strategy
colloid OR crystalloid
WH A T ’ S N E W
Last assessed as up-to-date: 23 February 2018.
Date Event Description
1 May 2018 New citation required and conclusions have changed We found that there was probably little or no difference in
mortality according to whether starches or crystalloids were
used for fluid resuscitation. Mortality data for other types of
colloids remained the same
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(Continued)
1 May 2018 New search has been performed New authors added (Sharon Lewis, Michael Pritchard, An-
drew Butler, David Evans, Andrew Smith, Phil Alderson).
Two review authors removed (Pablo Perel and Katharine Ker)
Edits made to the Background andMethods sections. Change
to criteria for considering studies in the review (we excluded
elective surgery). Added three new outcomes (transfusion of
blood products, need for renal replacement therapy; adverse
events - allergic reaction, itching, rashes). We reassessed all
studies included in the previous version of the review and ex-
cluded studies that did not meet the new inclusion criteria.
We completed data extraction and risk of bias on all studies,
including those from the previous version of the review. We
added a ’Summary of findings’ table for each of four com-
parisons by type of colloid (starches; dextrans; gelatins; and
albumin or fresh frozen plasma)
H I S T O R Y
Protocol first published: Issue 4, 1997
Review first published: Issue 4, 1997
Date Event Description
25 February 2013 Amended Minor corrections made to the results section.
31 January 2013 New citation required and conclusions have changed New study data have been included. The conclusions
of the review have changed
17 January 2013 New search has been performed Four new studies have been included (Guidet 2012,
Lee 2011, Myburgh 2012, and Perner 2012)
Mortality data from a reply letter (http://bja.oxford-
journals.org/content/107/5/693/reply) of a previous
included study was added (James 2011)
17 October 2012 Amended Copy edits made to graph labels.
8 June 2012 Amended Copy edits made and citation corrected.
14 May 2012 New citation required but conclusions have not
changed
Anupdated searchwas conducted inMarch 2012.Nine
new trials have been included (Bulger 2011; Cooper
2006; Du 2011; Dubin 2010; James 2011; Lu 2012;
Maitland 2011; McIntyre 2008; Zhu 2011). The anal-
ysis and results sections have been revised accordingly.
The conclusions remain unchanged. Three ongoing
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(Continued)
studies were identified (CHEST Trial; RASP trial; The
6S trial). We plan to update this review once the
CHEST Trial (a large phase 3 trial comparing 6% hy-
droxyethyl starch and saline) is published
16 March 2012 New search has been performed An updated search was conducted in March 2012.
10 February 2011 New citation required but conclusions have not
changed
The editorial group is aware that a clinical trial by Prof.
Joachim Boldt has been found to have been fabricated
(Boldt 2009). As the editors who revealed this fabrica-
tion point out (Reinhart 2011; Shafer 2011), this casts
some doubt on the veracity of other studies by the same
author. All Cochrane Injuries Group reviews which in-
clude studies by this author have therefore been edited
to show the results with this author’s trials included and
excluded. Readers can now judge the potential impact
of trials by this author (Boldt 1986, Boldt 1993, Boldt
2001, Lang 2001, Lang 2003) on the conclusions of
the review
The authors of the review have changed.
17 April 2009 New search has been performed April 2009
An updated search for new trials was conducted in Oc-
tober 2008. One new study was included (Brunkhorst
2008). The analysis, results anddiscussion sections have
been revised accordingly
16 July 2008 Amended Converted to new review format.
1 July 2007 New search has been performed August 2007
An updated search for new trials was conducted in De-
cember 2006. Ten new studies were included (Evans
2003, Cifra 2003, Fries 2004, Guo 2003, Lang 2003,
Maitland 2005,Moretti 2003,Upadhyay 2004, Verheij
2006, Wills 2005). The analysis, results and discussion
sections have been revised accordingly
C O N T R I B U T I O N S O F A U T H O R S
July 2007: PP and IR examined trials for inclusion or exclusion, reaching agreement by discussion. PP and IR extracted data from the
new studies. PP, IR and KK amended the text of the review.
April 2009: IR and MP examined trials for inclusion or exclusion, reaching agreement by discussion. IR and MP extracted data from
the new study. MP amended the text of the review. PP edited the final version.
February 2011: the Cochrane Injuries Group amended the text (Emma Sydenham, Managing Editor). Both authors agreed with the
changes to the manuscript.
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November 2012: PP and IR examined trials for inclusion or exclusion, reaching agreement by discussion. PP and KK extracted data
from the new studies. PP amended the text of the review. All the review authors agreed with the changes in the manuscript.
April 2018: SL, MP, DE, AB examined trials for inclusion or exclusion, reaching agreement by discussion with AS and PA. SL, MP,
DE and AB extracted data from all studies. SL and MP conducted the analysis and wrote the review. All review authors (SL, MP, AB,
DE, PA, AS, IR) agreed with changes in the manuscript.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have made the following changes to the review since its last publication (Perel 2013).
• We added six new review authors (Sharon Lewis, Michael Pritchard, Andrew Butler, David Evans, Andrew Smith, Phil Alderson)
and removed two review authors from the author list (Pablo Perel and Katharine Ker).
• Background: we rewrote the background section using current Cochrane headings. We used more recent references to
substantiate statements.
• Methods: we rewrote the methods section using current Cochrane headings, and following the Methodological Expectations of
Cochrane Intervention Reviews (MECIR) standards (Higgins 2016). We edited the criteria for considering studies in the review in
order to improve clarity.
• Types of studies: we excluded study reports that had been retracted after publication, following current guidance from Cochrane.
• Types of participants: we excluded people who were scheduled for elective surgery because, although they may have required
fluid resuscitation as part of standard perioperative clinical management, we believed that these people were not critically ill at the
point of randomisation.
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• Types of outcome measures: we added additional outcomes to the review (mortality within 90 days, mortality within 30 days,
transfusion of blood products, renal replacement therapy, and adverse events, specifically, allergic reactions, itching, or rashes) in order
to give consideration to other potential benefits of colloid or crystalloid fluid resuscitation.
• Data collection and analysis: we specified subgroup analyses (tonicity of crystalloid solution - this was considered in analysis in
the last review publication but was not reported as subgroup analysis), and sensitivity analyses (we added consideration of additional
use of colloids in the crystalloid group, analysis using the alternative effect estimate, and decisions made for individual studies in
which we noted serious discrepancies).
• Results: we wrote these sections using current Cochrane headings, and following MECIR standards.
• Excluded studies: because of changes made to the criteria for considering studies in the review, we excluded some studies that
were included in the previous version of the review.
• Risk of bias in included studies: we re-assessed risk of bias for studies that were in the previous version of the review, following
MECIR standards.
• We added a ’Summary of findings’ table for each comparison (organised by type of colloid).
I N D E X T E R M S
Medical Subject Headings (MeSH)
Albumins [therapeutic use]; Blood Proteins [therapeutic use]; Colloids [∗therapeutic use]; Critical Illness [mortality; ∗therapy];Dextrans
[therapeutic use]; Fluid Therapy [methods]; Gelatin [therapeutic use]; Hydroxyethyl Starch Derivatives [adverse effects; therapeutic
use]; Isotonic Solutions [∗therapeutic use]; Plasma Substitutes [adverse effects; therapeutic use]; Randomized Controlled Trials as Topic;
Rehydration Solutions [therapeutic use]; Resuscitation [∗methods]
MeSH check words
Humans
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